Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


BIOSPECIFIC LIGAND BINDING ASSAY

Subclass of:

436 - Chemistry: analytical and immunological testing

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
436503000 Utilizing isolate of tissue or organ as binding agent 3
20110097819MEMBRANE-COATED PARTICLES - A membrane-coated particle composition and methods comprising a particle surrounded by a native cell membrane are disclosed. The cell membrane may contain selected receptors or binding components. At least a portion of the receptors or binding components are oriented on the membrane-coated particle in the same or similar orientation as in the native cell membrane. The membrane-coated particle(s) finds use, for example, in contexts of basic research, proteomics, drug discovery, drug delivery, medical diagnostics, and aspects of patient care.04-28-2011
20100330700SUBSTRATE FOR ASSAYING BETA-GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD - An object of the present invention is to provide a peptide derivative for determining β-glucan or endotoxin which allows high sensitivity measurement, and a method for determining β-glucan and/or endotoxin using the same. The present invention relates to (1) a peptide derivative represented by the following general formula [1]:12-30-2010
20120129271LONGITUDINAL ASSAY - Embodiments of the invention relate generally to macro and small molecule detection and, more particularly, to methods for detecting macro and small molecules, including bio-molecules, in a liquid or gaseous sample. Methods according to embodiments of the invention are useful in the identification, discovery, and validation of biomarkers, as well as the screening of individuals for such biomarkers for diagnostic, therapeutic, and forensic purposes. In one embodiment, the invention provides a method of detecting an analyte in a fluid sample, the method comprising: passing a fluid sample containing a labeled analyte across at least one assay surface containing a capture agent for the analyte; detecting the labeled analyte; repeating the passing and detecting steps at least once; and creating a binding curve for the analyte based on the detecting of the labeled analyte.05-24-2012
Entries
DocumentTitleDate
20130040405METHODS FOR SENSITIVE AND RAPID DETECTION OF MOLECULES - In some embodiments, the present invention provides methods of detecting a molecule in a sample, such as an explosive. In some embodiments, the method comprises: associating the sample with an antigen/binding agent complex; measuring a rate of displacement of the binding agent from the antigen by the molecule in the sample; and correlating the measured rate of displacement to the presence of the molecule in the sample. In some embodiments, the measuring step comprises a determination of a change in frequency of the sample and a change in energy dissipation of the sample over a time interval. In some embodiments, the correlating step comprises a calculation of a ratio of a change in energy dissipation of the sample over a change in frequency of the sample over the time interval. In some embodiments, the method is used to determine the molecule concentration in the sample.02-14-2013
20130040407SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.02-14-2013
20130040406Device for Preparing And/Or Treating a Biological Sample - The present invention relates to a device for preparation and/or treatment of a biological sample comprising a set of storage chambers and/or reaction chambers intended for receiving a fluid, the chambers being separated by walls so as to constitute a set of adjacent chambers. It also relates to an analysis apparatus capable of using such a device and also a method of using this device.02-14-2013
20130045544VCJD CONFIRMATORY SCREENING ASSAY - The present invention related to an improved method for the detection of prion proteins, especially abnormal prion proteins (PrP02-21-2013
20130045542NEW FORMULATIONS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - A method of using at least one quantitative ratio of two different amyloid beta-peptides in a sample of a body fluid from a patient for determining the patient's probability of contracting Alzheimer's disease (AD) or for determining the patient's suffering from a precursor of Alzheimer's disease includes obtaining the sample of the body fluid from the patient. The at least one quantitative ratio is calculated from the two different amyloid beta-peptides from the sample. The patient's probability of contracting Alzheimer's disease (AD) or the patient's suffering from a precursor of Alzheimer's disease is calculated using the at least one quantitative ratio. The two different amyloid beta-peptides are selected from (a) Aβ(1-42), (b) Aβ(2-40) and (c) Aβ(2-42). The at least one quantitative ratio is selected from (a) Aβ(1-42)/(b) Aβ(2-40), (a) Aβ(1-42)/(c) Aβ(2-42), (b) Aβ(2-40)/(a) Aβ(1-42) and (c) Aβ(2-42)/(a) Aβ(1-42).02-21-2013
20110177614COMPOSITIONS AND METHODS FOR DETECTING CANCER - The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.07-21-2011
20110177610NOVEL MARKER FOR ARTERIOSCLEROTIC DISEASE - Disclosed is a novel marker for an arteriosclerotic disease. Also disclosed is a method for evaluating the presence or level of an arteriosclerotic disease in a mammal, or a method for evaluating the prophylactic or therapeutic effect on an arteriosclerotic disease in a mammal, which is characterized by detecting a soluble LR11 in a sample collected from the mammal.07-21-2011
20100129930Tyrosine Phosphorylation Sites - The invention discloses 351 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.05-27-2010
20090191646MOLYBDENUM COMPLEX & TEST KIT TO ENHANCE ACCURACY OF ANALYSIS OF ENDOGENOUS ANALYTES IN BIOLOGICAL FLUIDS - Methods for enhancement in accuracy of immunochemical analysis of heterogeneous biological fluids containing exogenous substances that can interfere in immunochemical analysis for endogenous analytes of interest. According to this method a heterogeneous biological fluid sample is pretreated with an interferant suppression effective amount of a molybdenum coordination complex, so as to reduce manifestation of the presence of said exogenous material under immunoassay conditions. This invention is suitable for the suppression of manifestation of exogenous substances, specifically metabolites of drugs of abuse, during the immunoassay of biological fluids of infants for detection of endogenous substances indicative of a wellness or disease state. This invention also has application for similar suppression exogenous substances in the biological fluid of adults that have been inadvertently exposed to such substances (e.g. secondhand smoke).07-30-2009
20100120172SUBSTANCE WITH ANTITHROMBOTIC ACTIVITY AND METHOD FOR DETECTING GLYCOKALLIDIN - A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.05-13-2010
20110207236SONICATION-ASSISTED METAL-ENHANCED FLUORESCENCE (SAMEF)-BASED BIOASSAYS - The present invention provides for sonication-assisted metal-enhanced fluorescence, luminescence, and/or chemiluminescence assay systems using low-intensity ultrasound waves to significantly reduce the assay time by increasing the kinetic movement of molecules within the system.08-25-2011
20120171779ANTIBODIES THAT SPECIFICALLY BIND HEDGEHOG-DERIVED POLYPEPTIDES - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′ CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.07-05-2012
20080261327Cell Free Assay for Determining a Substance of Interest and Molecular Complexes Used Therefore - The invention involves receptor complexes which include, inter alia, a receptor protein, and a reporter molecule. There is at least one unnatural, or non-naturally occurring amino acid in the receptor molecule. When a ligand interacts with the receptor, the interaction causes the reporter to generate a detectable signal. The complexes are useful in cell free, assay systems and may be used as part of micelles.10-23-2008
20110189790Methods of Predicting Antibody Solubility - The invention provides methods for testing and ranking therapeutic antibody candidates for biophysical properties related to solubility and the susceptibility of the antibody to aggregate in aqueous solutions. The methods are useful for selecting among antibody libraries or variants for candidates which can be formulated at high concentrations.08-04-2011
20120184051DEVICE AND METHOD FOR DETECTING AT LEAST ONE SUBSTANCE - A device for detecting at least one substance may include a resonator which, on its surface facing away from the carrier, is provided with a chemically sensitive layer for selectively binding a substance that is to be detected. An acoustic mirror is arranged between the carrier and the resonator. The acoustic mirror constitutes a band elimination filter having two closely adjacent notch frequencies, as a result of which the device is capable of oscillating in two resonant frequencies. The mass binding of the substance and the temperature can be determined computationally from the measured resonant frequencies.07-19-2012
20120184050MULTIPLEX SCREENING FOR LYSOSOMAL STORAGE DISORDERS (LSDS) - A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity. Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.07-19-2012
20120184049METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.07-19-2012
20100159614BIOCHIP AND APPARATUS FOR DETECTING BIOMATERIAL USING BIOCHIP - Provided is a biochip and an apparatus for detecting a biomaterial. The biochip includes a metal thin film on the surface of a substrate, restraining autofluorescence of the substrate, and a spacer on the metal thin film, having capture molecules immobilized on the surface of the spacer and specifically bound to target molecules. The spacer has a thickness controlled to enhance the strength of a fluorescence signal emitted from a fluorophore labeled with the target molecules and immobilized on the spacer by the specific binding between the capture molecule and the target molecule.06-24-2010
20100151589Glycoproteins Having Lipid Mobilising Properties and Therapeutic Applications Thereof - A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α06-17-2010
20100151591RAPID HOMOGENEOUS DIAGNOSTIC TESTING PLATFORM BASED ON LANTHANIDE FLUORESCENT RESONANCE ENERGY TRANSFER - The present invention provides compositions and methods for detecting the presence of an analyte in a sample. Exemplary compositions comprise macrocyclic lanthanide complexes that are useful for transferring energy to an energy transfer acceptor to indicate the presence of the analyte. The compositions and methods are particularly suited for detecting antibodies in a sample.06-17-2010
20110195523METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.08-11-2011
20110195522ASSAY FOR GENERATION OF A LIPID PROFILE USING FLUORESCENCE MEASUREMENT - The present invention relates to a method of generating a lipid profile for a sample solution. The method comprising: a first step of determining the concentration of total lipoprotein in a first aliquot of the sample using fluorescence analysis; a second step of determining the concentration of total cholesterol in a second aliquot of the sample using fluorescence analysis; and optionally a third step of determining the concentration of HDL in a third aliquot of the sample using fluorescence analysis. The concentrations of the total lipoprotein, and of total cholesterol may be used to calculate other lipid components and thereby generate a lipid profile. The invention also concerns apparatus that may be used to perform the method of the invention.08-11-2011
20110195520METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN - Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.08-11-2011
20100047926HYBRIDIZATION CHAIN REACTION - The present invention relates to the use of nucleic acid probes to identify analytes in a sample. In the preferred embodiments, metastable nucleic acid monomers are provided that associate in the presence of an initiator nucleic acid. Upon exposure to the initiator, the monomers self-assemble in a hybridization chain reaction. The initiator nucleic acid may be, for example, a portion of an analyte to be detected or may be part of an initiation trigger such that it is made available in the presence of a target analyte.02-25-2010
20120178180METHODS FOR THE IDENTIFICATION OF ZAP-70 INTERACTING MOLECULES AND FOR THE PURIFICATION OF ZAP-70 - The invention provides in a first aspect a method for the identification of an ZAP-70 interacting compound, comprising the steps of a) providing a protein preparation containing phosphorylated ZAP-70, b) contacting the protein preparation with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, c) incubating the aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex with a given compound, and d) determining whether the compound is able to separate phosphorylated ZAP-70 from the immobilized aminopyrido-pyrimidine ligand 24. In a second aspect, the present invention relates to A method for the identification of an ZAP-70 interacting compound, comprising the steps of a) providing a protein preparation containing phosphorylated ZAP-70, b) contacting the protein preparation with ligand aminopyrido-pyrimidine ligand 24 immobilized on a solid support and with a given compound under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and c) detecting the aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in step b). In a third aspect, the invention provides a method for the identification of an ZAP-70 interacting compound, comprising the steps of: a) providing two aliquots of a protein preparation containing phosphorylated ZAP-70, b) contacting one aliquot with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, c) contacting the other aliquot with aminopyrido-pyrimidine ligand 24 immobilized on a solid support and with a given compound under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and d) determining the amount of aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in steps b) and c). In a forth aspect, the invention relates to a method for the identification of an ZAP-70 interacting compound, comprising the steps of: a) providing two aliquots comprising each at least one cell containing phosphorylated ZAP-70, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, d) lysing the cells in order to obtain protein preparations, e) contacting the protein preparations with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and f) determining the amount of aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in each aliquot in step e).07-12-2012
20100112723MICROFLUIDIC APPARATUS AND METHODS FOR PERFORMING BLOOD TYPING AND CROSSMATCHING - Microfluidic cartridges for agglutination reactions are provided. The cartridges include a microfluidic reaction channel with at least two intake channels, one for an antigen-containing fluid and the other for an antibody-containing fluid, conjoined to a reaction channel modified by incorporation of a downstream flow control channel. At low Reynolds Number, the two input streams layer one on top of the other in the reaction channel and form a flowing, unmixed horizontally-stratified laminar fluid diffusion (HLFD) interface for an extended duration of reaction. Surprisingly, the design, surface properties, and flow regime of microfluidic circuits of the present invention potentiate detection of antibody mediated agglutination at the stratified interface. Antigen:antibody reactions involving agglutination potentiated by these devices are useful in blood typing, in crossmatching for blood transfusion, and in immunodiagnostic agglutination assays, for example.05-06-2010
20100112722Immunoassays and Characterization of Biomolecular Interactions Using Self-Assembled Monolayers - The present disclosure relates to methods of characterizing protein-protein interaction or conducting immunoassays in a biological sample using self-assembled monolayers (SAMs) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (SAMDI). The biological sample may be obtained from a living subject, such as a human or animal clinical sample containing multiple unknown proteins and/or antigens. Label-free methods of identifying protein-protein interactions, antigen-antibody binding and/or diagnosing a medical condition based on analysis of a biological sample using SAMDI are also provided, as well as biochips comprising surface bound proteins and/or antibodies and methods of making these biochips. The methods and biochips are useful, for example, for identifying protein-protein binding interactions and/or conducting immunoassays in samples such as humoral fluids or other clinical samples, cell lysates, tissue lysates, tumor lysates, and samples obtained, isolated or derived from animals or plants.05-06-2010
20130084649FLUORESCENCE MEASUREMENT - A sensor for fluorescence measurement comprising: a light source arranged for emitting light to a sample region, wherein the light source intensity is modulatable; an indicator system located at the sample region, said indicator system comprising: a receptor for an analyte; and a fluorophore associated with said receptor, wherein the fluorophore has a fluorescence lifetime that changes in response to the presence of analyte at the receptor; a single photon avalanche diode arranged to receive fluorescence light emitted from said sample region in response to the light incident on the sample region from the light source, and to generate an output signal; a driver arranged to modulate the light source intensity at a first frequency; a bias voltage source arranged to apply a bias voltage to the single photon avalanche diode, wherein the bias voltage is modulated at a second frequency, different from the first frequency, and wherein the bias voltage is above the breakdown voltage of the single photon avalanche diode; and a signal processor arranged to determine information related to a fluorescence lifetime of the fluorophore based on at least the output signal of the single photon avalanche diode.04-04-2013
20130084648POLYPEPTIDE SEPARATION METHODS - The present disclosure provides methods and compositions for separating polypeptide glycoforms using a medium that includes an Fc receptor. In certain embodiments, a medium includes an Fc receptor which comprises an extracellular portion of an Fc gamma RIII receptor.04-04-2013
20100075437Synthesis of highly luminescent colloidal particles - The present invention includes compositions and methods for their used wherein the compositions include clusters of coated fluorescent nanocrystals having a select size formed by controlled aggregation of individual coated nanocrystals.03-25-2010
20100075436METHODS FOR USE WITH NANOREACTORS - The invention relates to methods of using nanoreactor technology for sample analysis in microfluidic systems.03-25-2010
20100075438BIOCOMPATIBLE AND PHOTOCURABLE POLYMERS - The present invention relates to substrates for biological testing produced from photo-curable epoxy compositions which further include carboxyl-containing monomers such as acrylic acid, 2-carboxyethyl acrylic acid, 4-vinylbenzoic acid, or 3-Acrylamido-3-methyl-1-butanoic acid, or glycidyl methacrylate, etc. The photo-curable compositions may be used to cast films or fabricate beads, magnetic beads, or magnetic beads containing nickel barcodes. The resulting various kinds of films, beads, magnetic beads, or magnetic beads containing nickel barcodes may find use in clinical or biological applications.03-25-2010
20120244635NANOCHANNEL ARRAYS AND NEAR-FIELD ILLUMINATION DEVICES FOR POLYMER ANALYSIS AND RELATED METHODS - Provided are devices and methods for polymer analysis, in which labeled polymers are translocated along nanochannels that have illuminated detection regions within. As a labeled polymer translocates along the nanochannel and the labels pass over the illuminated detection regions, the labels become detectable (e.g., where different labels fluoresce in response to different wavelengths present at different illumination regions), and the user generates a spatial map of the location of the various labels along the length of the polymer. The location of the labels is then correlated to one or more structural characteristics of the polymer.09-27-2012
20120244632STEROL GLUCOSIDE TOXINS - The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).09-27-2012
20090298197SERS-BASED METHODS FOR DETECTION OF BIOAGENTS - An assay and method of assay for optical detection of bioagents, a target nucleic acid or a target protein using a surface enhanced Raman scattering (SERS) active biomolecule molecular beacon. The present invention also provides the assay and method in a multiplexed format.12-03-2009
20130078740PREPARATION OF MICROFLUIDIC DEVICE ON METAL NANOPARTICLE COATED SURFACE, AND USE THEREOF FOR NUCLEIC ACID DETECTION - The invention relates to a microfluidic device that utilizes nucleic acid-based detection and a detection system containing the same, as well as a process for preparing the micro fluidic device and for using the same to detect the presence of a target nucleic acid molecule in a sample.03-28-2013
20130078739CORTISOL IMMUNOASSAY USING FLUORESCENT PARTICLES - Provided are a base plate and a method for cortisol immunoassay, which enable immunoassay of cortisol with high sensitivity particularly in a clinically significant cortisol concentration range (that is, 1 μg/dL to 30 μg/dL). A base plate for cortisol immunoassay which has a cortisol albumin conjugate having a cortisol/albumin ratio of from 12 to 20 immobilized thereon is disclosed.03-28-2013
20130078738METHOD FOR MEASURING SUBSTANCE TO BE MEASURED USING FLUORESCENT PARTICLES, TEST SUBSANCE MEASUREMENT CHIP, AND TEST SUBSANCE MEASUREMENT KIT - A method for measuring a test substance including (1) reacting fluorescent particles and a test substance by bringing the test substance and the fluorescent particles into contact with a test area and a control area present on a substrate, (2) removing the unreacted fluorescent particles, (3) measuring the fluorescence of the fluorescent particles of the test area and the control area, and (4) correcting a fluorescence signal value in the test area using a fluorescence signal value in the control area, wherein the fluorescent particles are binding substance-labeling fluorescent particles in which one or more of a first binding substance which can bind to the test substance, and a third binding substance which can bind to a second binding substance and which does not bind to the test substance are bound, and the second binding substance which can bind to the first binding substance is immobilized on the control area.03-28-2013
20130078741IGA-BINDING PEPTIDE AND PURIFICATION OF IGA USING THE SAME - This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X03-28-2013
20130084651TEST INSTRUMENT FOR MEASURING ANALYTE IN SAMPLE, AND METHOD FOR MEASURING ANALYTE USING SAME - Disclosed is a test instrument for measuring an analyte in a liquid sample by a noble metal colloid aggregation measurement method. The test instrument involves a reaction chamber in which at least the liquid sample is to be reacted with a reagent, wherein the reagent is adhered on at least a part of a surface constituting the reaction chamber in a dried state, and the reagent enables the measurement of the analyte by a noble metal colloid aggregation measurement method. The test instrument additionally involves a supply section for supplying the liquid sample and a flow path for delivering the liquid sample that has been supplied to the supply section to the reaction chamber, wherein the liquid sample that has been supplied to the supply section is delivered to the reaction chamber through the flow path to cause the liquid sample to be brought into contact with the reagent that has been adhered in a dried state, thereby producing a difference in pressure between the supply section and the reaction chamber for the purpose of dispersing the reagent in the liquid sample. When the test instrument is used, the measurement based on an absorbance at a visible region can be achieved, the analyte can be measured accurately within a short time, and the measurement suitable for a POCT field can be achieved.04-04-2013
20130084650MOLECULAR MARKERS FOR URINARY TRACT INFECTIONS - The invention relates to an in vitro method for determining procalcitonin levels in plasma and urine as a diagnostic marker to identify patients with urinary tract infections, in vitro methods to perform said determination, a kit for the diagnosis of patients with urinary tract infections, and the usefulness of procalcitonin in the diagnosis urinary tract infections.04-04-2013
20130084652Homogeneous Chemiluminescence Assay Methods with Increased Sensitivity - Methods are disclosed for determining an analyte in a medium suspected of containing the analyte. One method comprises treating a medium suspected of containing an analyte under conditions such that the analyte, if present, causes a photosensitizer and a chemiluminescent compound to come into close proximity. The photosensitizer generates singlet oxygen and activates the chemiluminescent compound when it is in close proximity. Non-specific signal generated by singlet oxygen not in proximity is reduced or suppressed using a singlet oxygen quencher (SOQ). The activated chemiluminescent compound subsequently produces light. The amount of light produced is related to the amount of analyte in the medium. Use of Noise Modulation Agents significantly improves signal-to-noise ratios and assay sensitivity. Compositions and kits are also disclosed.04-04-2013
20130137188METHOD OF DETECTING RUPTURE OF MEMBRANES - The present invention relates to a method of detecting rupture of fetal membranes and to a device for implementing said method. In particular, a method of in-vitro detection of a rupture of fetal membranes comprising a step of simultaneously searching, within a specimen of vaginal or cervical secretions, for the alpha fetal protein (AFP) and for the insulinomimetic growth factor-binding protein 1 (IGFBP-1). The present invention finds, in particular, an application in the medical field, especially in the obstetric field.05-30-2013
20130034916FUNCTIONALIZED FLUORESCENT NANOCRYSTAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION - The present invention provides for functionalized fluorescent nanocrystal compositions and methods for making these compositions. The compositions are fluorescent nanocrystals coated with at least one material. The coating material has chemical compounds or ligands with functional groups or moieties with conjugated electrons and moieties for imparting solubility to coated fluorescent nanocrystals in aqueous solutions. The coating material provides for functionalized fluorescent nanocrystal compositions which are water soluble, chemically stable, and emit light with a high quantum yield and/or luminescence efficiency when excited with light. The coating material may also have chemical compounds or ligands with moieties for bonding to target molecules and cells as well as moieties for cross-linking the coating. In the presence of reagents suitable for reacting to form capping layers, the compounds in the coating may form a capping layer on the fluorescent nanocrystal with the coating compounds operably bonded to the capping layer.02-07-2013
20090017559Methods for diagnosing renal disorders - The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension.01-15-2009
20130040404BARRIER LAYER FOR GLUCOSE SENSOR - An optical glucose sensor comprising: a sensing region comprising a boronic acid receptor for binding to glucose and a fluorophore associated with said receptor; an optical waveguide for directing incident light onto the sensing region; and a hydrophilic, polymeric, glucose-permeable barrier layer which is provided on at least a part of the sensing region; wherein the sensor is adapted so that glucose enters the sensing region of the sensor through said barrier layer.02-14-2013
20130040403METHOD AND APPARATUS FOR AUTOMATED ANALYSIS - A method and apparatus for pretreatment of a desired sample in a discrete fluid analyzing instrument comprises automated means for handling and analyzing the sample and means for performing a pretreatment step on the sample or a sub-sample of the sample. The means for pretreatment are used for immobilizing at least one substance or analyte from the sample or sub-sample wherein the substance or analyte is reversibly immobilized. Usually, the apparatus further comprises means for eluting the substance or analyte from the capture means prior to analysis.02-14-2013
20090253217Method of Quickly Detecting Antigen Using Fluorescence Correlation Spectroscopy or Fluorescence Cross-Correlation Spectroscopy - The present invention is to provide a method of quickly detecting an antigen at an arbitrary concentration in an antigen sample, without a multi-stage examination of the concentration ratio between a detection reagent and an antigen to be detected, particularly when the concentration of the antigen in the sample is unknown, in the method of detecting an antigen using fluorescence correlation spectroscopy (FCS) or fluorescence cross-correlation spectroscopy (FCCS). By preparing (1) a series to which only a detection reagent is added and (2) a series to which an antigen and the detection reagent are added to achieve a maximum trimer concentration, and by performing a fluorescence spectroscopic analysis, the presence or absence of the antigen in the detection sample is quickly detected by the presence or absence of a trimer detection signal from a detector in the cases of (1) and (2), in a method of detecting an antigen by FCS or FCCS using as a detection reagent a fluorescent-labeled intact antibody or fluorescent-labeled antibody fragment targeted to an epitope of the antigen to be detected, and a non-fluorescent-labeled intact antibody or fluorescent-labeled intact antibody or fluorescent-labeled antibody fragment targeted to another epitope of the antigen.10-08-2009
20120208292FLUORESCENT MEASUREMENT IN A DISPOSABLE MICROFLUIDIC DEVICE, AND METHOD THEREOF - A device including a shallow chamber for analyzing a target analyte in a body fluid using the signal generated by fluorescent detector molecules specific for the target analyte and attenuating the signal emitted by fluorescent detector molecules non-specifically bound to the surfaces of the chamber by a signal attenuating dye; and method thereof.08-16-2012
20100099200DIRECT MASS SPECTROMETRIC ANALYSIS OF DRUG CANDIDATES TARGETING PROTEIN COMPLEXES - The invention relates to a method of using high mass matrix assisted laser desorption-ionization (MALDI) mass spectrometry for the qualitative and quantitative analysis of the effect of drug candidates on protein complexes such as protein-protein interactions in purified samples or complex biological matrices, as well as to the use of this method for lead compound optimization, drug characterization, drug manufacturing processes, and drug quality control processes, including automated high throughput applications.04-22-2010
20130034915Device and method for measuring analytes - The present invention is directed to a system, device and method for measuring the concentration of an analyte in a fluid or matrix. A thermodynamically stabilized analyte binding ligand for use in the system, device and method is disclosed. The thermodynamically stabilized analyte binding ligand is resistant to degradation at physiological temperatures and its use within the device provides a minimally invasive sensor for monitoring the concentration of an analyte in a fluid or matrix as are present in the body of an animal.02-07-2013
20130034914FLUORESCENCE-BASED APPROACH TO MONITOR RELEASE FACTOR-CATALYZED TERMINATION OF PROTEIN SYNTHESIS - Provided are probes comprising a class 1 release factor conjugated to a fluorescent label and methods of making the probes. Also provided are methods for detecting conformational changes in ribosomes and associated molecules, such as class 1 release factors. In addition, methods of identifying a compound for reducing nonsense-mediated decay of mRNA and/or for inhibiting termination of protein synthesis at a premature stop codon, are described. Methods of assaying RF3 activity are also included.02-07-2013
20090155930MONOCLONAL ANTIBODY DS6, TUMOR-ASSOCIATED ANTIGEN CA6, AND METHODS OF USE THEREOF - The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described.06-18-2009
20090155929METHODS FOR DETECTION OF HYDROPHOBIC DRUGS - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. For conducting an assay for the hydrophobic drug, the above pretreatment is performed and to the medium is added reagents for determining the presence and/or amount of the hydrophobic drug in the sample wherein the reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug, the presence and/or amount of the complex indicating the presence and/or amount of the hydrophobic drug in the sample.06-18-2009
20090155928Modulating robo: ligand interactions - Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.06-18-2009
20100105150ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL - A method of determining the presence, amount or concentration of at least one autoantibody that reacts with neutrophil gelatinase-associated lipocalin (NGAL), alone or in further combination with a method of determining the concentration of NGAL, which methods can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of a patient and, optionally, modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy; a kit comprising at least one component for assaying a test sample for at least one autoantibody that reacts with NGAL and instructions for assaying; a method of isolating an autoantibody that reacts with NGAL; an isolated autoantibody that reacts with NGAL; and a method for determining the reliability of an NGAL assay result.04-29-2010
20100105151Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same - The present invention relates to novel druggable regions discovered in dengue virus envelope glycoprotein, or dengue virus E protein, which is a class II viral E protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases caused by viruses having class II E proteins, e.g. viral fusion inhibitors.04-29-2010
20130045543NOVEL MUC1 ANTIBODY - An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.02-21-2013
20100041166Method and system for detecting a target within a polupation of molecules02-18-2010
20100041165PROBE-IMMOBILIZED CARRIER STORING MANUFACTURING CONDITION DATA AND MANUFACTURING METHOD AND APPARATUS THEREOF, DETECTING METHOD OF TARGET SUBSTANCE BY USE OF THE PROBE-IMMOBILIZED CARRIER, AND MEASURING APPARATUS, RECORDING MEDIUM, KIT AND SYSTEM FOR USE IN THE DETECTING METHOD - A target substance is more accurately detected by recording a manufacturing condition specific to a probe-immobilized carrier that influences a measurement result for the detection of the target substance, and correcting the measurement result obtained from the detection of the target substance by use of the probe-immobilized carrier on the basis of the recorded manufacturing condition. The influence of variations in the immobilization states of the probe onto the solid phase carrier on the measurement result of the target substance can be eliminated.02-18-2010
20090035874THERAPEUTIC AGENTS AND METHODS FOR CARDIOVASCULAR DISEASE - The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.02-05-2009
20130029429METHOD FOR AVOIDING INFLUENCE OF ENDOGENOUS LIPOPROTEIN AND REAGENT - To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component.01-31-2013
20130029428PREPARATION METHOD OF ANTIGEN-IMMOBILIZED IMMUNO- FLUORESCENCE SLIDE AND IMMUNO-FLUOROSCENCE SLIDE PREPARED THEREBY - A method of preparing an antigen-immobilized immuno-fluorescence slide, the method comprising: immobilizing a C-reactive protein on a slide to prepare a protein chip; mixing an antibody that specifically binds to a target protein, with streptavidin to label the antibody with a fluorescent nanoparticle; immuno-reacting the antibody by competitive mixing, assaying with a fluorescence camera, wherein the immobilizing of the C-reactive protein on the slide comprises: modifying the slide with 3-aminopropyltrimethoxysilane to prepare a modified slide; hydrating the slide modified with 3-aminopropyltrimethoxysilane; activating the modified slide by using a glutaraldehyde solution; dissolving a C-reactive protein at a concentration of 0.01-0.5 mg/ml in a 30-70 mM phosphate buffer solution (pH 6.5-7.8) to prepare an antigen solution for immobilization; placing a petri dish comprising the slide on a spotting guide and spotting 1-100 μl of the antigen solution on spotting points; and performing a reaction on the slide prepared as described above for 1-6 hours to immobilize the antigen, and an immune-fluorescence slide prepared by using the method.01-31-2013
20130029430PLASMON SENSOR, AND USAGE METHOD AND MANUFACTURING METHOD THEREOF - A plasmon sensor has a first metal layer and a second metal layer. The first metal layer has a bottom surface and a top surface configured to be supplied with an electromagnetic wave. The second metal layer has a top surface confronting the bottom surface of the first metal layer. Between the first metal layer and the second metal layer, there is provided a hollow region configured to be filled with a specimen containing a medium. Analyte capturing bodies are physically adsorbed at least one of below the first metal layer and above the second metal layer.01-31-2013
20100093107POLYMER-PROTEIN SUBSTRATES FOR IMMUNOSORBENT FLUORESCENCE ASSAYS - The present invention relates to antigen-capture substrates useful for orienting capture antibodies for immunosorbent antigen determination.04-15-2010
20120164756ASPIRIN ASSAY - The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.06-28-2012
20090124023Reagens for the Detection of Protein Acetylation Signaling Pathways - The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites/proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor/Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.05-14-2009
20130052750DIAGNOSTIC SYSTEM - The present invention provides, among other things, methods of creating an external marker for diagnosis and/or analysis of one or more diseases, disorders, or conditions, which may or may not otherwise have an external marker.02-28-2013
20130052749METHODS OF TRIGGERING ACTIVATION OF ENCAPSULATED SIGNAL-GENERATING SUBSTANCES AND APPARATUS UTILISING ACTIVATED SIGNAL-GENERATING SUBSTANCES - A method of performing a bioassay comprising activating capsules containing a signal precursor that is hydrolysable from a latent form in which substantially no signal is generated to a form in which it is able to generate a detectable signal, said activating comprising treating said capsules with heat and with an acid or a base catalysing solution, the combination of said heat and the pH of the catalysing solution being such as to hydrolyse said precursor to the form in which it is able to generate a detectable signal.02-28-2013
20130052748ASSAY DEVICE AND METHOD OF ASSAYING - A device for testing an analyte comprises a pathway allowing passage of analyte from an application zone to a waste zone. The device includes label material that emits or modifies light and which binds to the analyte. Between the application and waste zones there is a capture zone having capture material for binding any analyte traversing the pathway to the pathway. A first optical filter on one surface of the device allows transmission of light emitted or modified by the label and blocks light of at least one other wavelength range. This enables the device to be illuminated from one surface and light emitted or modified by the label to be detected from the opposite surface. The device may include a second filter allowing shorter wavelength light to reach the label. The device may be viewed using an illuminating reader or held up to a light source for viewing.02-28-2013
20100129928Tyrosine Phosphorylation Sites - The invention discloses 347 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.05-27-2010
20100136710RNA processing protein complexes and uses thereof - The invention provides human protein complexes with endonuclease activity. In particular, the invention provides human protein complexes with tRNA splicing endonuclease activity and/or 3′ end pre-mRNA endonuclease activity. The invention also provides a splice variant of human Sen2, namely human Sen2deltaEx8, and human protein complexes comprising human Sen2deltaEx8. The human Sen2deltaEx8 complexes have pre-tRNA cleavage activity and/or 3′ end pre-mRNA endonuclease activity. The invention also provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and methods of diagnosing, preventing, treating, managing or ameliorating a disorder utilizing such antibodies. The present invention also provides methods utilizing the complexes described herein, inter alia, in screening, diagnosis, and therapy. The invention further provides methods of preparing and purifying the complexes. The present invention further provides methods of identifying a compound that modulates the expression of a component of a complex described herein, the formation of a complex described herein or the activity of a complex described herein, and methods of preventing, treating, managing or ameliorating a disorder, such as a proliferative disorder, or a symptom thereof utilizing a compound identified in accordance with the methods.06-03-2010
20090325314N-Methyl Scanning Mutagenesis - The present invention relates to methods and compositions comprising the insertion of a single N-methyl amino acid into functional peptides. More specifically, the invention discloses methods referred to as N-methyl scanning mutagenesis, where one or more N-methyl amino acid substitutions into functional peptides enhances protease resistance while retaining binding affinity.12-31-2009
20090111195CHEMICAL REAGENTS AND METHODS FOR DETECTION AND QUANTIFICATION OF PROTEINS IN COMPLEX MIXTURES - The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention.04-30-2009
20090042316USE OF PERFLUOROPOLYMERS IN THE DETERMINATION OF THE RECEPTOR-LIGAND BINDING CONSTANT - Use of flat surfaces comprising perfluorinated polymers in the determination of the binding constant of two interacting molecular species by using measurements of reflected light intensity, said surface comprising at least one molecule with the receptor function adsorbed or immobilized on said surface, and at least one ligand which interacts with the receptor.02-12-2009
20090042314LANTHANIDE-DOPED NAYF4 NANOCRYSTALS, METHOD OF PREPARING AND USES THEREOF - The present invention relates to a method of preparing lanthanide-doped NaYF02-12-2009
20130089932FET Sensor and Methods for Detecting Melamine - The present invention provides a device and methods for the detection and quantification melamine in a sample by rapid and specific electrochemical detection. The present invention includes using a field-effect transistor (FET) biosensor having an open Si channel with a melamine antigen, or hapten, or an antibody, anchored via a linker molecule such as self assembled monolayer to the surface of the gate dielectric of the said open Si channel. The anchoring molecule having the capability of detecting melamine directly or indirectly by selectively binding melamine antibodies, which changes a field-effect on a Si channel, causing a change in conductivity of the FET. This change in conductivity can be measured and is used to determine the presence or absence of melamine in a sample compared to a standard signal or pre-measured database.04-11-2013
20110003400METHODS AND SYSTEMS FOR GROUND AND SURFACE WATER SAMPLING AND ANALYSIS - The invention provides devices, methods, and kits for collection of dry samples from fluid samples such as ground or surface water. Devices of the invention include a casing including a water intake zone wherein the casing encloses, a fluid reservoir, a pump, a non-aqueous collection matrix cartridge, and a waste water conduit, wherein the water intake zone, the fluid reservoir, the pump, the non-aqueous collection matrix cartridge, and the waste water conduit are all operably linked in sequence. Methods for using the device of the invention are provided. Kits including the device of the invention or for use with the invention are also provided.01-06-2011
20090305435METHOD OF CALIBRATING LIGAND SPECIFICITY - A method to determine specificity of ligand binding includes comparing a solid phase carrier first extract obtained by pre-treating a sample with a ligand-immobilized solid phase carrier and a solid phase carrier second extract obtained by treating the pretreated sample again with a ligand-immobilized solid phase carrier in terms of the proteins contained therein, and identifying a protein whose content is remarkably decreased in the second extract compared to the first extract, in order to solve 12-10-2009
20090305432Polypeptide Molecular Switch - A polypeptide can conduct electricity in a closed circuit. Conformational changes in the polypeptide due to posttranslational modifications or ligand binding can effect the conductive properties of the polypeptide which can be measured. In such a closed circuit, a polypeptide having at least one residue capable of reversible modification can be used as a molecular switch. Circuits comprising such molecular switches can be used, for example, in methods for assessing the modification state of a polypeptide, determining the activity of an enzyme of interest, identifying compounds that affect the activity of an enzyme of interest, storing data, detecting the presence of a compound and identifying inhibitors of protein-protein interactions.12-10-2009
20090305434METHOD OF DIAGNOSING NEUROPHSYCHIATRIC DISEASES, EATING DISORDERS OR METABOLIC DISEASES - The application relates to a method of diagnosing neuropsychiatric diseases, eating disorders and/or metabolic diseases, which comprises: (i) measuring the affinity and/or the avidity of antibodies, derived from a biological sample, directed against a biological molecule involved in homeostatic regulation and/or in motivational behavior and/or in emotion; (ii) comparing the affinity value obtained with a control value.12-10-2009
20090305433Water-Soluble Rhodamine Dye Conjugates - The present invention provides novel, water-soluble, red-emitting fluorescent rhodamine dyes and red-emitting fluorescent energy-transfer dye pairs, as well as labeled conjugates comprising the same and methods for their use. The dyes, energy-transfer dye pairs and labeled conjugates are useful in a variety of aqueous-based applications, particularly in assays involving staining of cells, protein binding, and/or analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing.12-10-2009
20130071953GDF-15 BASED MEANS AND METHODS FOR SURVIVAL AND RECOVERY PREDICTION IN ACUTE INFLAMMATION - A method for diagnosing whether a subject suffering from an acute inflammation and in some cases systemic inflammatory response syndrome (SIRS) is at increased risk for mortality. The method comprises determining the amount of the biomarker GDF-15 in a sample of said subject and comparing said amount to a reference. The method also relates to monitoring the development of acute inflammation in a subject by determining the amount of the biomarker GDF-15 in a first and a second sample of said subject wherein said first sample has been obtained prior to said second sample and comparing the amount of GDF-15 in said first and said second sample. Further encompassed are diagnostic devices and kits for carrying out the aforementioned methods.03-21-2013
20130071952LUMINESCENT POLYMER CYCLIC AMPLIFICATION - The present invention is directed to a luminescent immunoassay method for detecting an analyte in a liquid sample with high sensitivity. The invention provides a unique combination of (i) using a probe having a small sensing surface area for binding analyte molecules, (ii) using a high molecular weight branched polymer conjugated with multiple binding molecules and multiple luminescent labels, and (iii) cycling the probe having immunocomplex formed back to the reagent vessel and amplification vessel 1-10 times and repeating the reaction with the reagent and the amplification polymer, to improve the sensitivity of detection level. For each cycling, the luminescent signal is increased significantly over the noise.03-21-2013
20130071949IMMUNOASSAY FOR QUANTIFICATION OF AN UNSTABLE ANTIGEN SELECTED FROM BNP AND proBNP - The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.03-21-2013
20130071948PROCESS FOR PRODUCING SUPRAMOLECULAR FIBER - A method for preparing a linearly extended supramolecular fiber or a plurality of linearly aligned supramolecular fibers, which comprises the step of allowing supramolecular monomers to be self-assembled in a microfluidic channel.03-21-2013
20130071947CHIRALITY SENSOR AND METHOD FOR DETECTION OF AFLATOXIN BY USING THE SENSOR - A universal chirality sensor based on immuno-recognition-driven nanoparticle assembly has been fabricated. The design of smart 10 nm AuNP-antigen and 20 nmAuNP-antibody described for the detection of aflatoxin B1. 10 nm AuNP-antigen and 20 nmAuNP-antibody assemble to symmetric plasmonic nanoparticle dimers, which induced CD signal. The addition of aflatoxin B1 to the chirality sensor resulted in transverse CD signal compared to a blank control as shown by CD measurements. This process also allowed the rapid and facile determination of concentrations of aflatoxin B1 in drinking water (tap water). Good linearity for all calibration curves was obtained, and the limit of detection (LOD) for aflatoxin B1 was 0.02 ng/mL in tap water.03-21-2013
20130071951METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.03-21-2013
20130071950Agglutination Based Sample Testing Device - A sample testing device for testing for the presence of a component of interest in a liquid sample includes: (a) a capillary pathway having an upstream end and a downstream end and incorporating a reagent system capable of causing agglutination with the component; (b) optionally, a control capillary pathway; (c) a sampling region to which the liquid sample is applied and from which the sample is able to enter the upstream ends of the test and control capillaries; (d) a power source; (e) detection arrangements electrically associated with the power source for detecting the presence of liquid at a downstream region of the capillaries; (f) a display operated by the power source for indicating the result of the test; and (g) a signal processor associated with the power source, detection arrangement and display for evaluating the result of the test and providing the result on the display.03-21-2013
20130071946Suspension Container For Binding Particles For The Isolation Of Biological Material - A device, method and system is provided for binding particles for the separation and/or isolation of biological materials. In particular, a container is provided including a suspension of binding particles for the isolation of biological material, inner walls forming an elongate groove at the bottom of said container, and a cover having openings and/or being penetrable for a linear arrangement of multiple pipets or pipet tips, said openings being located above and parallel to said elongate groove.03-21-2013
20080299676METHODS FOR DIAGNOSING ENDOMETRIOSIS - Provided herein is a method for diagnosing and monitoring endometriosis in a subject by measuring levels of the 13-subunit of fibrinogen.12-04-2008
20130164858DIAGNOSTIC DETECTION DEVICE - The invention comprises a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion. In specific embodiments, the device is a pregnancy test device, which detects human chorionic gonadotropin (hCG) as an indicator of pregnancy. Devices with improved clinical sensitivity are provided which are capable of detecting all clinically relevant hCG isoforms.06-27-2013
20130164861BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A laser beam is emitted onto fluorescent molecules within a solution to orient the fluorescent molecules. The direction in which the laser beam is emitted is switched to switch the transition moment direction of the fluorescent particles to be parallel or perpendicular to the vibrating direction of linearly polarized excitation light. Thereby, the fluorescent molecules of free molecules and binding molecules can be switched between an excited and a non excited state. There is a difference in the speeds at which the orientation directions change for molecules which have undergone and molecules which have not undergone antigen antibody reactions. Therefore, the fluorescence contributed by fluorescent molecules associated with free molecules and the fluorescence contributed by fluorescent molecules associated with binding molecules can be calculated respectively, to measure the concentration of a detection target substance with high sensitivity.06-27-2013
20110059555BRANCHED AND MULTI-CHAIN NUCLEIC ACID SWITCHES FOR SENSING AND SCREENING - Embodiments of the invention relate to a branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding. The switch includes a probe strand, P, which includes the ligand binding domain; a switching framework which includes a cover strand (C), and a tether that holds P and C together and a signaling apparatus. Some embodiments include a toggle strand (T) where now the tether holds P, C, T, and the signaling apparatus together. As the switch changes between the first and second conformations; the signaling apparatus reports the state of the switch. The signaling entity is typically a lumiphore and a quencher located along the switching framework. Nucleic acid switches have applications in real time assays for diverse agents including infectious agents, environmental toxins, and terrorist agents, as well as screening methods for such agents. Further applications are found for nanoelectronics, nanofabrication and nanomachines.03-10-2011
20110014723COMPOSITIONS AND PROCESSES RELATING TO HUMAN BOCAVIRUS - Non-replicating, antigenic, human bocavirus virus-like particles (HBoV VLPs) are provided by the present invention along with assays using the HBoV VLPs to detect anti-HBoV antibodies in a biological sample. Pharmaceutical compositions including HBoV VLPs and/or anti-HBoV antibodies are described herein along with novel antibodies generated using HBoV VLPs as an antigen. A recombinant baculovirus is provided including a DNA sequence encoding an expressible human bocavirus VP2 with or without a DNA sequence encoding an expressible human bocavirus VP1 polypeptide, and/or a non-HBoV peptide or protein, and culturing the cells to form the VP1 and/or VP2 proteins that self assemble to form the HBoV VLPs which are then amenable to isolation.01-20-2011
20130059400Scanning Analyzer for Single Molecule Detection and Methods of Use - The invention encompasses analyzers and analyzer systems that include a single molecule analyzer, methods of using the analyzer and analyzer systems to analyze samples, either for single molecules or for molecular complexes. The single molecule uses electromagnetic radiation that is translated through the sample to detect the presence or absence of a single molecule. The single molecule analyzer provided herein is useful for diagnostics because the analyzer detects single molecules with zero carryover between samples.03-07-2013
20130059399Lateral Flow Test Kit and Method for Detecting an Analyte - A method and device for detecting analytes in a test sample. Embodiments include methods for quantitatively detecting analytes within a range of concentrations. In an embodiment the method includes a lateral flow test strip with multiple test areas for capturing a labeled receptor to provide a detectable signal.03-07-2013
20110065206Thrombospondin Fragments and Uses Thereof in Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents - The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.03-17-2011
20090197349ELECTROCHEMILUMINESCENCE OF RARE EARTH METAL CHELATES - Luminescent chemical reagents that include complexes of rare earth metals with ligands such as aromatic heterocyclic nitrogen-containing compounds and semi-aromatic oxygen-containing compounds are used to detect small quantities of complex substances such as pharmaceuticals, metabolites, and microorganisms in complex sample mixtures.08-06-2009
20090286329ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES - The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample.11-19-2009
20080311673Biomarkers for Breast Cancer - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.12-18-2008
20090117668Immune Agglutination Reagent Kit and Method of Measuring Antigen - In cases of poor reaction efficiency with the antibody due to inadequate number of epitopes or steric hindrance caused by epitopes being close to each other, this invention provides a direct method of efficiently measuring antigen in a given specimen without the need of pretreating it. Two types of monoclonal antibodies that recognize different epitopes are individually sensitized on separate latex. The specimen and one latex sensitized monoclonal antibody reagent are reacted to produce a reaction solution which is then reacted with the other latex sensitized monoclonal antibody reagent. The antigen can thus be directly measured in an efficient and highly sensitive way without pretreating it.05-07-2009
20120225495DEVICE FOR DISTRIBUTING PARTICLES IN A FLUID AND METHODS THEREOF - A vial and particles for distributing reagent bound particles in a fluid, a kit, and methods for distributing particles in a fluid.09-06-2012
20120225493Electronic-Chemometric Controlled System and Process for the Analysis of Analytes - A series of electronic-chemometric control processes to enhance the selectivity, concentration, analysis, and detec tion of chemical species (analytes) in the gas phase, such as when using SERS-based techniques. Controls consist variously of: 1) feedback of electronic signals corresponding to changes of static and variable parameters in targeted chemical species that vary according to a reduction, increase, maximization, linearization, or improved confidence in one or more chemometric output parameters; 2) methods for spatially locating the source of an analyte species; and, 3) variable duty cycling to save power and materials according to altered physical and environmental conditions within a monitored zone.09-06-2012
20120225491PORTABLE DETECTION DEVICES AND METHODS FOR DETECTION OF BIOMARKERS AND OTHER ANALYTES - A detection device and method for detecting one or more analytes of interest in a test sample are provided. Some embodiments use analyte-specific binding partners that are conjugated to quantum dots (Qdots) for use in detecting the presence and/or quantity of the analytes of interest in a test sample. FRET based methods may to used enhance the quantum dot (Qdot) signal through complexing of the quantum dots with lanthanide chelates, such as terbium. Some embodiments of the invention provide a novel disposable testing device that contains, all in one, the components necessary for carrying out the novel assay detection system of the invention. The disposable testing device may be used at home, for example, to detect and quantitate, at ultrasensitive levels, multiple analytes in a biological sample with no requirement for professional assistance.09-06-2012
20130065325ZWITTERIONIC REAGENTS - Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.03-14-2013
20130065322Radioimmunoassay with a 96-Welled Micro-plate - A method for using a multi-welled micro-plate in radioimmunoassay (“RIA”) is disclosed to improve the performance of RIA. At first, there is provided a multi-welled micro-plate that can be dismantled and divided into multiple wells. Then, samples are filled into the wells of the multi-welled micro-plate for incubation. Washing, tracer-adding, incubation, and washing are executed. At a final step, the multi-welled micro-plate is separated into wells, and each of to the wells is put into a test tube for gamma counting by a gamma counter.03-14-2013
20130065324IMMUNOASSAY APPARATUS INCORPORATING MICROFLUIDIC CHANNEL - An assay apparatus having an assay strip. The assay strip has a first area with a plurality of magnetic particles bonded thereto. The assay strip also has a microfluidic (or nanofluidic) channel or chamber, having a sensing area including one or more magnetic particle traps and a magnetic field source provided adjacent to the sensing area. Introduction of a fluid causes the magnetic particles to become attached to or displaced by a substance of interest, travel along the microfluidic channel to the sensing area and become concentrated in the one or more traps thus providing an indication of the presence or absence of a substance of interest in the fluid. There may be a plurality of traps.03-14-2013
20130065323Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.03-14-2013
20090209046Neutral Pharmaceuticals - The invention comprises neutral multi-functionality assemblies of pharmaceuticals comprising an active medicinal functionality, a transition metal functionality, and an ancillary ligand functionality. An exemplary series of mixed-ligand coordination complexes comprised of copper(II), a drug and an ancillary ligand were made and tested. It is demonstrated that the judicious choice of an ancillary ligand affords a large degree of control over die relative lipophilicity/hydrophilicity of the complex in relation to the uncomplexed drug molecule. The important factors to be considered in the design of such complexes, such as the additive-constitutive nature of the partition coefficient of the ancillary ligand and the relative size of the two types of ligands are disclosed, and methods of designing neutral multi-functionality assemblies of pharmaceuticals are disclosed.08-20-2009
20110020952METHOD FOR DETERMINING THE STAGE OF ULCERATIVE COLITIS OR INTERSTITIAL PNEUMONITIS AND REAGENT KIT THEREOF - The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body.01-27-2011
20110045605Characterization of Granulocytic Ehrlichia and Methods of Use - The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal.02-24-2011
20110045603Serine, Threonine, and Tyrosine Phosphorylation Sites - The invention discloses 990 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.02-24-2011
20090233379Taste Receptors Of The T1R Family From Domestic Dog - The present invention relates to the discovery of several genes of the domestic dog (09-17-2009
20080241961DROSOPHILA G PROTEIN COUPLED RECEPTORS, NUCLEIC ACIDS, AND MEHTODS RELATED TO THE SAME - The present invention provides a 10-02-2008
20090053825MOLECULAR RECOGNITION POLYMER ENABLING RECONSTRUCTION OF RECOGNITION FIELD FOR TARGET MOLECULE AND METHOD OF PRODUCING THE SAME - A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which is produced by applying the molecular imprinting method is disclosed. A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which has a molecule interacting with the target molecule in the polymer and in which the recognition field for a target molecule has been constructed and the above-described molecule interacting with the target molecule is detachable and replaceable. This molecular recognition polymer can be produced by synthesizing a complex of the target molecule with a molecule capable of specifically and reversibly binding to the target molecule, copolymerizing this complex with a molecule interacting with the target molecule and a crosslinking agent to give a polymer, and then detaching the target molecule and the molecule interacting with the target molecule from the polymer thus obtained.02-26-2009
20120115248METHODS OF DETERMINING THE PRESENCE AND/OR CONCENTRATION OF AN ANALYTE IN A SAMPLE - Compositions, methods, and systems for monitoring analyte levels are provided herein. The disclosure provides methods and systems for the real-time monitoring of analytes, such as citrate, calcium, phosphate and magnesium, in a biological fluid in a clinical setting.05-10-2012
20120115247DRUG MONITORING ASSAY - A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.05-10-2012
20090269856METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PROGNOSIS - Methods and compositions for evaluating the prognosis of a breast cancer patient, particularly an early-stage breast cancer patient, are provided. The methods of the invention comprise detecting expression of at least one, more particularly at least two, biomarker(s) in a body sample, wherein overexpression of the biomarker or a combination of biomarkers is indicative of breast cancer prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The biomarkers of the invention are proteins and/or genes whose overexpression is indicative of either a good or bad cancer prognosis. Biomarkers of interest include proteins and genes involved in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, invasion, proteolysis, or metastasis. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques.10-29-2009
20090325312Reagens for the detection of protein acetylation signaling pathways - The invention discloses 12-31-2009
20090142854SILANIZING AGENTS COMPRISING A SACCHARIDE END GROUP AND USES THEREOF, IN PARTICULAR FOR THE FUNCTIONALIZATION OF SOLID SUPPORTS - The invention relates to silanizing agents comprising a saccharide end group and to the use thereof for the functionalization of solid supports. The invention also relates to solid supports that have been functionalized by said silanizing agents (glycochips) and to the use of same, such for biological analysis and, in particular, for screening saccharide molecules or proteinaceous ligands of interest.06-04-2009
20090011521Streptavidin surface acoustic wave immunosensor apparatus - The invention, the manufacturing process and operation method for forming the streptavidin surface acoustic wave (SAW) immunosensor apparatus is disclosed. Firstly, the PZT film is formed on silicon substrate by using the micro-powder-sol-gel method. Then, the metal transducer electrodes are coated on the PZT film using semiconductor process technology to produce the SAW. Finally, the sensing area of the SAW element is modified by streptavidin to form the streptavidin SAW immunosensor. The invention could be used for examining the ligand decorated by biotin, also for examining antibody.01-08-2009
20090011520Stable D-dimer liquid preparation - The invention is in the field of coagulation diagnosis and relates to a liquid, buffer-based D-dimer composition, which additionally contains fibrinogen and which is suitable as a standard material for control or calibration purposes for D-dimer test procedures.01-08-2009
20100087011Detection and/or Characterisation of Oligomers - Disclosed is a method of detecting the presence of an oligomer analyte in a liquid sample, the method comprising the steps of: (a) contacting a sample comprising the oligomer or aggregate with an oscillating sensor surface, which surface may optionally be coated with a receptor that binds directly or indirectly to at least one component of the oligomer or aggregate, so as to cause direct or indirect binding of the oligomer or aggregate to the surface; (b) using a detection circuit to measure or calculate at least two of the following parameters: series resonance frequency (f04-08-2010
20080318337Method for Determining a Tissue Degradation Process by Detection of Comp Neoepitopes - The present invention relates to a method for determining a tissue degradation process by detection on COMP (Cartilage Oligomeric Matrix Protein) neoepitopes, where said COMP neoepitopes appear after cleavage of COMP at one or more site between position 530 and 660 of the amino acid sequence of COMP. Such as between position 550 (N12-25-2008
20120238038PEPTIDE BINDING TO METHYLATED DNA - The present invention aims to provide a tool etc. capable of detecting a methylated region of a DNA in a short time, in a labor-saving manner and without being limited by nucleotide sequences, and further capable of quantifying the methylation. The present invention provides a peptide containing a metal finger motif and a tyrosine derivative in a helix forming part of the motif, which recognizes and binds to a methylated region of a double stranded DNA.09-20-2012
20120238037IMMUNOLOGICAL ASSAY AND IMMUNOLOGICAL ASSAY KIT - An antibody enabling a rapid measurement of HMGB1, for example a combination of antibodies to HMGB1, is elucidated and an immunological assay and an immunological assay kit are provided. It is intended to provide an immunological assay kit for determining the presence or absence, or the concentration, or both of HMGB1, including a first antibody and a second antibody, wherein the first antibody is immobilized on a carrier and the second antibody is modified with a labeling substance, and the first antibody and the second antibody are any of the following antibody (A), antibody (B), antibody (C), and antibody (D), and a permutation combination of the first antibody and the second antibody is any one of antibody (A) and antibody (B), antibody (A) and antibody (C), antibody (B) and antibody (A), antibody (B) and antibody (C), antibody (B) and antibody (D), and antibody (C) and antibody (B).09-20-2012
20120238036METHOD FOR IMMOBILIZING PROTEIN A ON A SELF-ASSEMBLED MONOLAYER - The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented following formula (II) obviates the object.09-20-2012
20120238035MULTICOLOR MICROWAVE-ACCELERATED METAL-ENHANCED FLUORESCENCE (M-MAMEF) - The present invention relates to the use of multiple different light emitting molecules that emit different and detectable emission signals to provide systems and methods to detect different target products in a single assay sample, wherein the different light emitting molecules are positioned an optimal distance from metallic particles thereby enhancing emissions. Preferably, the systems and methods further comprise use of either microwave or sonic energy to increase binding reactions, timing of such reactions within the assay sample and reduce background non-specific biological absorption.09-20-2012
20130164862SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR - A sensing method for biopolymers by detecting the magnetic signal generated from a labeled biopolymer under AC magnetic field with thermo-responsive magnetic nano particles as label having a critical solution temperature across which the particles have the ability to aggregate or disperse with cooling or heating.06-27-2013
20120270338FLUOROIMMUNOASSAY METHOD - An object is to provide an immunoassay method requiring neither a solid-phase immobilization step nor a washing step, enabling quick and simple quantitative measurement of a target substance in a liquid phase and capable of visualizing an antigen. Such an object is attained by measuring the concentration of a target antigen present in a test substance by sequentially performing a step (a) of bringing an antibody light-chain variable region polypeptide and an antibody heavy-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; or bringing an antibody heavy-chain variable region polypeptide and an antibody light-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; a step (b) of measuring the fluorescence intensity of the fluorescent dye; and a step (c) of computationally obtaining the level of the antigen contained in the test substance with reference to a positive correlation between the concentration of the antigen in a liquid phase and the fluorescence intensity of the fluorescent dye.10-25-2012
20120270336AUTOMATIC ANALYZER - Using a microplate having wells for the dispensing and reaction of a sample including blood and a reagent, an automatic analyzer captures an image of whether reactions have occurred inside the wells and performs analysis, the automatic analyzer comprising: a section for, with captured images obtained by capturing images of the inside of the wells corresponding to categories, calculating photometric parameters of the images, evaluating whether a measurement result based on the images is negative for each test, and analyzing characteristic information of the sample; a section for matching and storing characteristic information of samples and measurement results; a section for extracting a photometric parameter of a measurement result judged as negative; and a section for calculating a difference between maximum and minimum values of an extracted photometric parameter, determining whether a measurement is valid using the difference, and adding a result of the determination to characteristic information.10-25-2012
20120244638METHOD AND SYSTEM FOR BINDING BEHAVIOR ANALYSIS - A method of evaluating an interaction parameter for the interaction between a plurality of analytes and a ligand using a biosensor, which comprises the steps of: 09-27-2012
20100068823Carrier Material, Method for the Production and Use Thereof - An embodiment of the present invention relates to a carrier material which is used in a method of diagnosis and which comprises a base material which is provided with a surface which is equipped with at least two different affinity ligands.03-18-2010
20080311675DYES HAVING RATIOMETRIC FLUORESCENCE RESPONSE FOR DETECTING METABOLITES - The presently disclosed subject matter provides thiol-reactive, environmentally sensitive fluorescent dyes, or fluorophores, which have an emission wavelength in the visible spectral region. When conjugated with a binding protein, the fluorophores exhibit a ratiometric response to one or more ligands or target analytes. The presently disclosed fluorophore-binding protein conjugates can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples.12-18-2008
20090017555DELTA-9-TETRAHYDROCANNABINOL DETECTION METHOD - The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (01-15-2009
20090317921ANTIBODY TO INHIBIN/ ACTIVIN BETA-B SUBUNIT - The present invention provides an improved antibody specific for the inhibin/activin beta-B subunit polypeptide. The antibody is highly specific for the beta-B subunit in a sample, and does not require processing of the sample with heat or oxidizing agents. Thus, discovery of the new antibody provides for simpler, more accurate immunoassays for a wider range of sample types.12-24-2009
20100210032SPECIFICITY AND SENSITIVITY ENHANCEMENT IN CANTILEVER SENSING - The invention is directed to a sensor system including at least one sensor and target specific receptors bound substrates for purposes of enhancing detection sensitivity. Optionally, the sensor system may include quantum dots for independently verifying the presence of a target molecule or compound. The sensor system may be particularly beneficial in the field of medical diagnostics, bio-defense, food safety, water safety and general chemical detection.08-19-2010
20120107957TEST REAGENT, AND METHOD FOR MEASURING ANALYTE IN TEST SAMPLE USING SAME - Object: To provide a test reagent for the analyte in a test sample, utilizing the level of agglutination of a particle suspension which suspend insoluble carrier particles carrying a substance for capturing the analyte as an indicator, which reagent does not undergo self-agglutination during storage, and which non-specific agglutination rarely occurs during measurement, as well as to provide a method for the analyte to be measured in a test sample. Means for Solution: The test reagent for the analyte comprises at least a Solution A which is a buffer solution having an electric conductivity of not less than 30 ms/cm; and a Solution B having an electric conductivity of not more than 6.5 ms/cm, the Solution B being a particle suspension which suspends particles which are insoluble carrier particles carrying a substance for capturing the analyte.05-03-2012
20100240148Method and Kit for Measurement of Acrolein Adduct in Sample Utilizing Agglutination Reaction of Immunological Microparticle - A method for measuring an acrolein adduct present in a sample comprising the steps of: (a) mixing a sample containing the acrolein adduct with a solution comprising an immunoglobulin that specifically recognizes the acrolein adduct; (b) adding to the mixture obtained in the step (a), a solution comprising microparticles to which a substance that specifically binds to the immunoglobulin that specifically recognizes the acrolein adduct and a blocking agent have been bound, and mixing them; and (c) measuring an extent of an agglutination reaction of the microparticles in the mixture obtained in the step (b), wherein the extent of the agglutination reaction being decreased relative to an amount of the acrolein adduct in the sample. The method enables a measurement of an acrolein adduct without requiring a complex operation.09-23-2010
20110117670MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.05-19-2011
20100291706DYE CONJUGATES AND METHODS OF USE - The present invention relates to cyanine compounds, compositions comprising them, articles of manufacture, and methods of making and using them. The cyanines usefully comprise one or more carboxyl groups or derivatives thereof that are indirectly attached to an aryl ring on an alkylaryl cyanine substituent. Also provided are conjugates of the disclosed cyanines and one or more other substances. Solvates, solutions, and derivatized forms of the cyanines are also provided. The cyanines find use in a variety of bioassays, both in direct single-label applications and in energy transfer formats. Methods utilizing the disclosed cyanines for analyzing a sample for a target are provided. Also disclosed are detection complexes comprising the disclosed cyanines, as well as compositions and articles comprising the cyanines in an excited state, for example formed by direct excitation or by energy transfer. The cyanines may be used as alternatives to other known optically active species in a variety of settings. Other embodiments are described further herein.11-18-2010
20120288962METHOD OF DETECTING RAW PORK AND DETECTION KIT THEREFOR - [Object] To provide preparation of a detection antibody optimal for detecting by immunoassay raw pork in non-heated food with high performance and high sensitivity without causing non-specific reaction, a convenient and high-accuracy detection process using the detection antibody, and a detection kit therefor.11-15-2012
20100311190DEVICES AND METHODS FOR DETECTING AMNIOTIC FLUID IN VAGINAL SECRETIONS - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.12-09-2010
20110129942FLUORESCENCE DETECTING METHOD - An amount of fluorescent labels corresponding to an amount of a detection target substance are caused to bind on a detecting portion. The fluorescent labels are excited, and the amount of the detection target substance is detected based on the intensity of fluorescence emitted due to the excitation. Fine inorganic fluorescent particles which do not become discolored are employed as the fluorescent labels.06-02-2011
20110003399Tumor Necrosis Factor-Gamma - Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.01-06-2011
20080213918Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof - The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.09-04-2008
20100159613Method for assaying the antioxidant capacity of a skin care product - A method for assaying the antioxidant capacity of a skin care product, the method including preparing an emulsion base, dissolving a sample of a skin care product into the emulsion base to form a homogeneous emulsion mixture, adding a detection probe to the homogeneous emulsion mixture, adding reactive oxygen species generator and/or reactive nitrogen species generator to the homogeneous emulsion mixture, measuring the fluorescence intensity change of the detection probe in the presence of the sample over time, in the presence of the standard over time, and in the presence of a blank over time, and calculating the initial rate of oxidation of the detection probe to determine the antioxidant capacity of the sample of the skin care product.06-24-2010
20080206888Screening using polarization anisotropy in FRET emissions - Methods and apparatus are described for detecting specific binding between first and second chemical entities. The first chemical entity in association with a first fluorophore is immobilized. The second chemical entity is allowed to bind with the immobilized first chemical entity. The second chemical entity is or becomes coupled to a second fluorophore, which forms a FRET pair with the first fluorophore. The bound chemical entities are exposed to radiation at an excitation frequency for either the first or the second fluorophore, and polarization anisotropy of a FRET fluorescent signal from the bound chemical entities is measured to detect specific binding between the first and second chemical entities. Techniques are also disclosed for detecting whether a FRET interaction is occurring between a first chemical entity including a donor fluorophore and a second chemical entity including an acceptor fluorophore, using simultaneous anisotropy measurements at the wavelengths of the donor and acceptor fluorophores.08-28-2008
20110300642METHODS FOR DIFFERENTIATING AND MONITORING PARATHYROID AND BONE STATUS RELATED DISEASES - The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values, one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.12-08-2011
20110300641PROTEIN ISOFORMS FOR DIAGNOSIS - Several aspects of this invention relate to diagnosis of diabetic states in a mammal using protein isoforms. In some aspects, it relates to a method for determining the diabetic state of a mammal. This method can include, for example, (a) measuring the serum concentration of one or more protein isoforms, (b) analyzing the serum concentration of the one or more protein isoforms, and (c) determining the diabetic state of the mammal. Other aspects include kits used to perform the method. Further aspects are the isolated protein isoforms themselves, and their methods of isolation.12-08-2011
20110300640METHOD AND DEVICE FOR AUTHENTICATING OBJECTS PROVIDED WITH A MARKER, THE SPECIFICATION OF WHICH: - The invention relates to a method for authenticating objects provided with a marker that contains nucleic acid.12-08-2011
20110081730ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.04-07-2011
20110136253Irinotecan Immunoassay - Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.06-09-2011
20120178181DEVICE AND METHOD FOR LABEL-FREE DETECTION OF DNA HYBRIDIZATION - A device and method for detecting the hybridization of an unmodified target deoxyribonucleic acid (DNA) molecule including exposing a Raman substrate to the unmodified target DNA molecule, where the unmodified target DNA molecule is a complementary DNA molecule to a thiol-terminated probe DNA molecule covalently linked to the Raman substrate. Also, the thiol-terminated probe DNA molecule includes an adenine analog substituted for adenine. The hybridization of the unmodified target DNA molecule to the thiol-terminated probe DNA molecule is detected by measuring a Raman spectroscopic response of the Raman substrate.07-12-2012
20110281374BIOMARKER - A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1α (IL-1α) in a serum or plasma sample.11-17-2011
20120107958MICROBEAD OPTICAL SENSOR WITH LAYERED PLASMON STRUCTURE FOR ENHANCED DETECTION OF CHEMICAL GROUPS BY SERS - An optical sensor and method for use with a visible-light laser excitation beam and a Raman spectroscopy detector, for detecting the presence chemical groups in an analyte applied to the sensor are disclosed. The sensor includes a substrate, a plasmon resonance mirror formed on a sensor surface of the substrate, a plasmon resonance particle layer disposed over the mirror, and an optically transparent dielectric layer about 2-40 nm thick separating the mirror and particle layer. The particle layer is composed of a periodic array of plasmon resonance particles having (i) a coating effective to binding analyte molecules, (ii) substantially uniform particle sizes and shapes in a selected size range between 50-200 nm (ii) a regular periodic particle-to-particle spacing less than the wavelength of the laser excitation beam. The device is capable of detecting analyte with an amplification factor of up to 1005-03-2012
20120107952MICROWAVE-ACCELERATED PLASMONICS - The present invention relates to systems and methods using microwave accelerated surface plasmonics for the detection of target species, wherein the system has a metallic surface and the system is exposed to microwave energy for increasing detection time and/or the reaction kinetics of the target species and other interacting participants in the system and wherein plasmonic emissions from the metallic surface alone or coupled with emissions from a luminescing entity are detected.05-03-2012
20120003752Prognostic biomarkers for the progression of primary chronic kidney disease - Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof.01-05-2012
20100190266METHOD FOR MEASURING BONDING ACTIVITY OF ANTIBODY WHICH MIMICS ANTIBODY-DEPENDENT CELL MEDICATED CYTOTOXIC ACTIVIY - The present invention provides a simple method which is capable of evaluating the binding activities of an antibody to both an antigen and an Fc receptor.07-29-2010
20110143457CYSTATIN C ADSORPTION INHIBITOR - Disclosed is a method by which the adsorption of cystatin C to a container can be inhibited in a simple manner to improve the accuracy of the measurement of cystatin C. Provided are: a cystatin C adsorption inhibitor comprising a non-ionic surfactant; a cystatin C measurement reagent comprising the adsorption inhibitor; and a cystatin C measurement kit. Also provided is a method of inhibiting the adsorption of cystatin C, the method comprising bringing a cystatin C-containing sample into contact with a measurement instrument in the presence of a non-ionic surfactant. The aforementioned non-ionic surfactant is preferably a polyoxyethylene-type surfactant. Alternatively, the aforementioned non-ionic surfactant has preferably a phenoxy structure, more preferably a benzylphenoxy structure.06-16-2011
20110143455NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma.06-16-2011
20110143454METHOD FOR DETECTION OF SPECIFIC IMMUNOGLOBULIN CLASS G ANTIBODIES - The invention relates to a method for determining an analyte in a sample by means of an assay that can be carried out in a one-step format without performing washing steps. The method includes a first analyte-specific receptor that contains at least one bonding point for the analyte, e.g., several antibodies on a particle, as well as a second analyte-specific receptor that can selectively bond to an arrangement comprising at least two analyte molecules which are bound to the first receptor. An antibody sandwich immune assay is described in which the detection is based on electrochemiluminescence.06-16-2011
20110287557SINGLE QUANTUM-DOT BASED APTAMERIC NANOSENSORS - A signal-off-quantum-dot-based sensor for detecting the presence of a target molecule comprising: an aptamer probe having a nucleotide sequence which specifically interacts with the target molecule by sequence-dependent interaction, wherein the aptamer probe is sandwiched between (a) an oligonucleotide which is immobilized on the surface of a quantum dot (QD), and (b) a fluorophore-labeled oligonucleotide, wherein when the sensor is excited by an energy source: (i) in the absence of specific interaction between the target molecule and the aptamer probe, a baseline signal is emitted, and (ii) in the presence of specific interaction between the target molecule and the aptamer probe, a detection signal is emitted, wherein the baseline signal is greater than the detection signal, whereby the presence of the target molecule is detected.11-24-2011
20110287558RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES - A compound of formula (I) is provided:11-24-2011
20110287556BLOOD GROUP ANTIGENS OF DIFFERENT TYPES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.11-24-2011
20090111194Methods and device for the detection of occult blood - The present invention relates generally to detection of occult blood. In particular, the present invention provides a device and methods for the simultaneous detection of hemoglobin and transferrin in fecal samples, which permit a more sensitive diagnosis of occult blood in fecal sample and a differential diagnosis of bleeding of the upper GI tract versus the lower GI tract.04-30-2009
20110124120ASSAY FOR EVALUATING AFFINITY AND SPECIFICITY OF LIGAND-ALBUMIN BINDING - A method for identifying a ligand or compound which binds to albumin comprises the steps of contacting a reaction mixture comprising a site-specific probe and albumin in the presence and the absence of the ligand or compound and measuring either dissociation constant K05-26-2011
20110294227METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS - The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably P1GF-2 and P1GF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.12-01-2011
20110294229COLORIMETRIC AND FLUORIMETRIC FLUORIDE SENSING - The present invention generally relates to fluoride receptor reagent compounds comprising one or more N-aryl or heteroaryl substituted 1,4,5,8-naphthalenetetracarboxydiimide (NDI) units and an associated method for the detection of fluoride in a composition. π-electron orbitals present in the NDI unit of the reagents form a complex with fluoride anions. It is believed that the anion-π interaction results in a charge transfer process between the fluoride anion and the NDI unit, resulting in a number of measurable effects (e.g., colorimetric response).12-01-2011
20110294226Survival motor Neurons (SMN) gene: a gene for spinal muscular atrophy - The present invention relates to the discovery of the human survival motor-neuron gene or SMD gene, which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene.12-01-2011
20110171749NANOPARTICLE TRACER-BASED ELECTROCHEMICAL DNA SENSOR FOR DETECTION OF PATHOGENS-AMPLIFICATION BY A UNIVERSAL NANO-TRACER (AUNT) - The present invention relates to methods and compositions for identifying a pathogen. The inventions provide an antibody-based biosensor probe comprising (AUNT) in combination with a polymer-coated magnetic nanoparticle. In particular, a nanoparticle-based biosensor was developed for detection of 07-14-2011
20100015723Antagonists of Interleukin-15 - Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or γ-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.01-21-2010
20110189795USE OF PERFLUOROPOLYMER SUBMICROMETRIC LATEXES IN THE DETERMINATION OF MOLECULAR INTERACTIONS BY LASER LIGHT SCATTERING (LLS) - Use of a latex of perfluorinated polymers having particles with an average diameter between 5 and 200 nm for determining the binding constant of two interacting molecular species by Laser Light Scattering (LLS), said polymeric particles comprising on the surface an amphiphilic non ionic surfactant, the same or a different surfactant ended with a receptor and a ligand interacting with the receptor.08-04-2011
20090298195SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS - Method for engineering an immunoglobulin comprising at least one modification in a structural loop region of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of:—providing a nucleic acid encoding an immunoglobulin comprising at least one structural loop region,—modifying at least one nucleotide residue of at least one of said structural loop regions,—transferring said modified nucleic acid in an expression system,—expressing said modified immunoglobulin,—contacting the expressed modified immunoglobulin with an epitope, and—determining whether said modified immunoglobulin binds to said epitope, as well as modified immunoglobulins.12-03-2009
20100035361TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of 02-11-2010
20090053828DETECTION OF GLYCOPEPTIDES AND GLYCOPROTEINS FOR MEDICAL DIAGNOSTICS - A diagnostic method for determining the absence or presence of a disease is provided. The method includes assaying the amount and/or types of glycopeptides in a sample from a subject, and comparing these to the amount and types of reference glycopeptides. The method may include the use of a stable isotope label, affinity selection, immunoaffinity chromatography, and glycoproteomics techniques, to identify and quantify changes in glycosylated peptides or glycosylated proteins associated with cancers such as malignant lymphoma or breast cancer, to monitor patient's response to therapy, and to monitor disease recurrence.02-26-2009
20090221095Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes - Methods are provided to identify and characterize compounds that bind with duplex and triplex polynucleotides.09-03-2009
20090186422SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES - Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.07-23-2009
20080311674METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS - Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.12-18-2008
20100112719ELECTRONIC SIGNAL AMPLIFICATION IN FIELD EFFECT DEVICE BASED CHEMICAL SENSORS - Briefly, disclosed is a method and apparatus for detecting an analyte wherein an enhanced charge marker may enhance steric, electrostatic, optic and/or mechanical changes associated with a recognition event between an analyte and a probe.05-06-2010
20090317919Method for Assaying Antigens - A method for assaying an antigen adsorbed on a solid support is provided. The method comprises: a) contacting a suspension of the antigen adsorbed on the solid support with a solution or suspension of an optionally detectably-labelled primary antibody to the antigen to form a solid-supported antigen-antibody complex; b) where the primary antibody is detectably labelled, optionally measuring the detectable label thereby to determine the quantity of the antigen; or c) contacting the solid-supported antigen-antibody complex with a detectably-labelled probe for the solid-supported antigen-antibody complex; and d) measuring the detectable label on the probe, thereby to determine the quantity of antigen. The antigen is preferably a component of a sub-unit vaccine, and most preferably anthrax protective antigen.12-24-2009
20100035363Homogeneous Time Resolved Fluorescence Based Test System for Paramyxoviridae - The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the RSV F1 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN57 (SEQ ID NO: 1); a second helical polypeptide consisting essentially of the sequence of C45 (SEQ ID NO: 2) wherein said IQN57 is labeled with a light emitting fluorophore and said C45 is labeled with an ultra-violet excitable fluorophore.02-11-2010
20100035362BIO-SILICA CHIP COMPRISING SILICA BINDING PROTEIN AND METHOD FOR FABRICATING THE SAME - The present invention relates to a bio-silica chip comprising a silica-binding protein and a fabrication method thereof, and more particularly to a bio-silica chip in which a fusion protein of a silica-binding protein and a probe protein is immobilized on a chip comprising a silica layer, a fabrication method thereof and a method of using the bio-silica chip to detect interactions with biomaterials. The bio-silica chip will be very useful in biosensors, etc., because the bio-silica chip is advantageous in that it does not cause non-specific protein binding in the detection of protein-DNA, protein-ligand, protein-antibody, protein-peptide, protein-carbohydrate, protein-protein and cell-biomaterial interactions. Also, in the method for fabricating the bio-silica chip, a probe chip can be selectively immobilized on a silica device chip, which is widely used in biosensors, without a chemical surface treatment process. Thus, a chip fabricating process is simplified and a complicated process for purifying the probe protein becomes unnecessary, thus providing great improvements in productivity and economic efficiency02-11-2010
20100112721BLOOD BIOMARKERS FOR BONE FRACTURE AND CARTILAGE INJURY - Blood biomarkers are described for use in methods and compositions to determine whether an individual has sustained a bone fracture or a cartilage injury.05-06-2010
20100112720CONTINUOUSLY REPEATABLE METHOD OF DETECTING ANTIGENS IN TEST VOLUME - A continuously repeatable method of detecting possible presence of one or several different selected target antigen(s), such as explosives and/or narcotics, in a predetermined test volume with a flow-through analysis device, such as a Piezoelectric Quartz Crystal Microbalance device (QCM), an Ellipsometer device or a Surface Plasmon Resonance biosensor device, is described. The device is equipped with one or several fluidly connected, individually operated, flow-through testing cells, each cell containing a sensing surface, each sensing surface comprising a selected modified target antigen immobilized thereon, which modified antigen has weaker affinity than the target antigen for a selected antibody specific for the selected target antigen. One testing cell is for analyzing a target antigen by the competition mode, whereas optional other testing cells are individually selected for analysis by the competition mode or the displacement mode.05-06-2010
20120107956INDIRECT LATERAL FLOW SANDWICH ASSAY - Disclosed herein are indirect lateral flow sandwich assays, in which the target analyte binds an analyte-specific reagent comprising a first member of a conjugate pair, forming a complex which contacts and binds a colored particulate label comprising a complementary member of said conjugate pair, forming a second complex. Capture of this analyte-comprising, second complex by an immobilized analyte specific capture reagent results in the formation of an immobilized labeled sandwich complex that can be detected.05-03-2012
20120107954PHYSIOLOGIC SAMPLE PREPARATION FOR NANOSENSORS - The present invention provides a microfluidic purification chip for capturing a biomarker from a physiological solution. The present invention also provides a method of capturing and releasing a biomarker, wherein the biomarker is originally in a physiological solution. The present invention further provides a method of pre-purifying and measuring the concentration of a biomarker in a physiological solution.05-03-2012
20120107953STABILIZATION OF INTERLEUKIN 6 IN SERUM BASED SOLUTIONS - Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C05-03-2012
20090148958NUCLEOTIDE-TRANSITION METAL COMPLEX CATALYST - This invention is to provide a catalyst (an artificial enzyme) which can be used as an alternative to a protein enzyme in the field relating to medicine, pharmaceuticals, biochemistry or chemical engineering. Such a catalyst comprises a complex of a transition metal and a monomeric or polymeric nucleotide or an analogue thereof.06-11-2009
20090148959METHOD OF QUANTITATIVELY MEASURING SMALL PARTICLE LOW DENSITY LIPOPROTEINS - The object of the present invention is to provide a fast and simple method for fractional measurement of a small particle LDL.06-11-2009
20110269246MEASURING LEVELS OF FRATAXIN - This document relates to methods and materials involved in measuring levels of a frataxin polypeptide present in a biological sample. For example, methods and materials related to the use of anti-frataxin antibody-bound microspheres and biotinylated anti-frataxin antibodies to measure the levels of a frataxin polypeptide in a biological sample from a mammal (e.g., a newborn human) are provided.11-03-2011
20100267165MICROELECTRONIC SENSOR DEVICE FOR THE DETECTION OF TARGET PARTICLES - The invention relates to a microelectronic sensor device for the examination of target particles (10-21-2010
20130189795BLAST, BALLISTIC AND BLUNT TRAUMA SENSOR - A molecular biosensor is provided including a lipid vesicle and a housing wherein the vesicle is contained on or within the housing and where the housing has a portion capable of transmitting a force generated, external to the housing to the vesicle. The biosensor is used in processes of detecting the presence or absence of an event force such as a blast or blunt force sufficient to produce a medical complication such as traumatic brain injury.07-25-2013
20100279433ASSAY METHOD FOR ALZHEIMER'S DISEASE - A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of Aβ11-04-2010
20110195521METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN - Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.08-11-2011
20120190130CARTRIDGE FOR DETECTING TARGET ANTIGEN AND METHOD FOR DETECTING TARGET ANTIGEN USING THE SAME - There are provided a cartridge for detecting a target antigen and a method for detecting a target antigen existing in a biological sample using the cartridge. In the cartridge, multiple detections of various antigens can be rapidly and conveniently performed, and a plurality of target antigens can be quantitatively analyzed using one cartridge, thereby reducing time and cost.07-26-2012
20120190132Device and method of monitoring a patient - A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients.07-26-2012
20120190131Biosensor Electronics - The electrostatic resonators of bridge, cantilever and comb type or piezoelectric resonators with detection electronics are key components of chemical, biological, biochemical and biomedical sensors with sensitivity down to the single molecule detection of ligands. The detection electronics relies on measurement of frequency changes of resonators using phase or signal comparator. The large arrays of these sensors with individual or common sensing circuitry improve detection sensitivity, selectivity and lower incidence of false positives and negatives.07-26-2012
20120088313METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE - The present invention provides a method for detecting a substance in a biological sample, a carrier for using in the method, and a kit. The method of the present invention includes 1) providing a carrier on which a biotin-binding protein is bound and providing a biotinylated protein by biotinylating a protein that specifically binds to a substance to be detected; 2) binding the biotinylated protein to the carrier provided in step 1) to produce a biotinylated protein-bound carrier; 3) mixing (a) a biological sample, and (b-i) a cell homogenate extract prepared from cells of the same species as that of the host cells used for expressing, for example, the biotin-binding protein in step 1), and a biotin-binding protein, or (b-ii) a cell homogenate extract prepared from cells of the same species as that of the host cells used for expressing, for example, the biotin-binding protein in step 1) and genetically engineered to express a biotin-binding protein, and adding the mixture to the biotinylated protein-bound carrier produced in step 2); and 4) detecting the substance specifically bound to the biotinylated protein.04-12-2012
20110151580METHOD FOR THE DETECTION OF BREAST CANCER BY DETERMINING ALCAM AND/OR BCAM LEVELS IN A PATIENT - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting the presence and severity of breast cancer in a subject. The present application also provides methods for determining the prognosis of a subject with breast cancer as well as methods for monitoring the therapeutic response to a breast cancer treatment or therapy.06-23-2011
20100120170DETECTION AND MEASUREMENT OF THYROID HORMONE AUTOANTIBODIES - A non-radioisotopic method detects T3AA and T4M thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antibody or antigen-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antibody or antigen-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.05-13-2010
20090239312Chromosome 6 and 9 Genes Involved in Premature Canities - The invention provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 9 selected from the group consisting of the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARBLI, DDX31, GTF3C4 and Q96MA6 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 6 selected from the HLAG, NT_007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPA1 B, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, and diagnostic methods employing same.09-24-2009
20090239311Method of Differentially Diagnosing Dementias - In an ex vivo method of differentially diagnosing dementias selected from a group of demetias, which includes vascular dementias and frontotemporal lobe degenerations, a concentration of at least one carboxy-terminally truncated amyloid β peptide species as a biomarker is determined in a body fluid obtained from a patient, the at least one carboxy-terminally truncated amyloid β peptide species being selected from the group of species consisting of Aβ1-38, Aβ1-37 and Aβ1-39; and the concentration of the at least one carboxy-terminally truncated amyloid β peptide species is compared to a threshold concentration value for the respective one carboxy-terminally truncated amyloid β peptide species.09-24-2009
20100081212ANTIBODIES FOR DETERMINING THE PROTHROMBIN FRAGMENT F2/F1+2 IN A HOMOGENEOUS IMMUNOASSAY - The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.04-01-2010
20090087922SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES - Methods and probes are provided for the analysis of target sequences having two or more polymorphisms wherein one of the polymorphisms is to be distinguished and another polymorphism is to be masked.04-02-2009
20120142119Novel gold nanoparticle aggregates and their applications - The invention is drawn to a method of using nanoparticle aggregates to form sensors and optical filters. Properly sized (60 and 200 nm) nanoparticle aggregates with cores having a sulfur-oxygen molecular species and a shell with a surface in contact with the core are obtained. Those nanoparticle aggregates have a first resonance profile to wavelengths between 350 nm and 1075 nm. A modified resonance profile for those nanoparticle aggregates is determined. The nanoparticle aggregates are then selectively sized by irradiating them with electromagnetic energy at sufficient intensity and spectral content to modify the first resonance profile towards the modified resonance profile. The resulting nanoparticle aggregates can be used as sensors or optical filters at a selected wavelength.06-07-2012
20100081211LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE - The invention relates to a detectable molecule comprising a biospecific binding reactant attached to a luminescent lanthanide chelate comprising a lanthanide ion and a chelating ligand of the formula (I)04-01-2010
20120107961MAGNETIC SENSOR DEVICE, METHOD OF OPERATING SUCH A DEVICE AND SAMPLE - A sensor device (05-03-2012
20120107960NONLINEAR LUMINESCENT MOLECULE, FLUORESCENT STAIN, AND OBSERVATION METHOD(AS AMENDED) - The present invention relates to a nonlinear fluorescent molecule that generates a nonlinear fluorescence reaction by incidence of excitation light. This nonlinear fluorescence molecule includes donors and, and an acceptor that is coupled to the donors and. As the donor is excited by the incidence of the excitation light, electric charge moves from the donor to the acceptor. Then, the donor and the acceptor form a charge separated state. In a state in which the charge separated state is maintained, the donor fluoresces when transiting from an excited state to a ground state.05-03-2012
20120107959BAIT CHEMISTRIES IN HYDROGEL PARTICLES FOR SERUM BIOMARKER ANALYSIS - This invention describes the identification of novel organic dye chemistries that can be used as affinity baits to capture proteins and other biomolecules useful in the fields of medical diagnostics, environmental science, toxicology, and infectious disease. Incorporation of unique affinity dye compounds within hydrogel capture particles improves analyte yield and preanalytical precision, and stabilizes the analyte against degradation, while increasing measurement sensitivity. The particles in this invention can be used for routine clinical testing as well as for discovery of low abundance disease biomarkers. Example hydrogel particles containing new high affinity bait chemistries were used to identify a new set of human serum biomarkers.05-03-2012
20110195524SEMI-SEQUENTIAL ASSAY FOR DETECTION OF AN ANALYTE IN A SAMPLE - The invention is related to a method for detection of an analyte in a sample, wherein the method is a semi-sequential assay procedure.08-11-2011
20090263916Antagonists of HMG1 for treating inflammatory conditions - There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG 1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.10-22-2009
20090263915AGGLUTINATION INHIBITION ASSAY METHOD AND REAGENT - Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form.10-22-2009
20090263914BIOANALYTICAL ASSAY - A nanoparticle having a detectible feature and whose diameter is less than 200 nm, and which is coated with multiple specific binding reactants such that the affinity constant of the nanoparticle towards an analyte exceeds that of free binding reactant towards the analyte and/or the association rate constant between the nanoparticle and the analyte exceeds the association rate constant between the free binding reactant and the analyte. Also disclosed is a homogenous assay based on a first group labeled with a luminescent energy donor nanoparticle and a second group labeled with an energy acceptor compound, where the donor has a long excited state lifetime, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between these groups, is measured.10-22-2009
20090162943Reagents and Methods for the Detection of Transmissible Spongiform Encephalopathy - This invention relates to the detection of transmissible spongiform encephalopathy (TSE) in samples using agents, such as antibodies, that bind to the extreme N-terminal region of mature full-length PrP. These allow the development of sensitive immunoassays for PrP06-25-2009
20130217149COMPETITION ASSAY - The application provides competition assays used to detect free-light chains or intact immunoglobulins comprising incubating the sample with anti-FLC antibody, or heavy chain class-light chain type-specific antibodies, or fragments of such antibodies, and a known amount of FLC or intact immunoglobulin and detecting the binding of the antibody to the known amount of FLC or immunoglobulin. Assay kits and methods of producing particles coated with FLC are also provided.08-22-2013
20110201130HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure provides among other things assays, methods and kits for assessing the presence or amount of human B-type natriuretic peptide in a test sample wherein the assay exhibits reduced cross-reactivity with other forms of the peptide.08-18-2011
20110201129METHOD FOR THE DETECTION OF ENDOMETRIOSIS USING AN ME-2 ANTIGEN - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO: 6 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 6 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.08-18-2011
20090258438Method for universal biodetection of antigens and biomolecules - A universal signal molecule is generated in response to the presence within a biological fluid sample of a target agent. Two probes that bind to the target agent are provided within the sample and the target agent is captured, purified, and concentrated on a bead. One of the probes is attached to a signal nucleic acid that does not bind to the target agent. The signal nucleic acid is caused to be released from the probe, thereby generating a universal signal molecule. The presence of the universal signal molecule in the sample is detected, thereby providing for detection of the target agent within the sample.10-15-2009
20090221094Anthrax Polypeptide Binding - Methods are disclosed for detecting anthrax protective antigen polypeptides and inhibiting their binding to β2 integrin α. A domain polypeptides, for example β2 integrin receptors. The disclosed methods are useful, for example, in diagnosing the presence of an anthrax toxin in the environment or in a subject and also for reducing anthrax intoxication in a subject. The methods can also be used to identify compounds that inhibit binding of an anthrax toxin to a β2 integrin.09-03-2009
20120295368KITS FOR DETECTING TARGET MATERIAL AND METHODS OF DETECTING TARGET MATERIAL USING THE KITS - Kits for detecting a target material and methods of detecting a target material by using the kits are provided, the kits include a target material binding portion including a first molecule and a probe linked to the first molecule, and a target material detection portion including a plurality of nanoparticles each having a surface to which a compound having a zwitterion and a second molecule are linked. The first molecule is specifically bound to the second molecule in a pair.11-22-2012
20120295367COMPOSITION AND METHOD FOR ANALYSIS OF TARGET ANALYTES - A method of detecting first and second analytes includes providing a mixture containing first analytes and second analytes; adding microparticles of a first size coated with first competitive inhibitors that compete with the first analytes for binding to first antibodies to the first analytes, and adding microparticles of a second size coated with second competitive inhibitors that compete with the second analytes for binding to first antibodies to the second analytes, adding second antibodies specific to the first antibodies to the first analytes and second antibodies specific to the first antibodies to the second analytes, wherein the second antibodies specific to the first antibodies to the first analytes are labeled with a first fluorescent moiety, and the second antibodies specific to the first antibodies to the second analytes are labeled with a second fluorescent moiety11-22-2012
20110171752Methods and Systems for Detecting MHC Class I binding peptides - The present invention is based on the discovery that MHC heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measurement for the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention.07-14-2011
20090142855Polynucleotides and Polypeptides of the IL-12 Family of Cytokines - The present invention relates to the primate family of cytokines. Provided herein are polynucleotides encoding such polypeptides, and reagents useful for producing the encoded polypeptides in a host source, and for identifying compounds which bind and modulate the activity of the encoded polypeptides. Also provided are reagents useful for the diagnosis or treatment of inflammatory and/or autoimmune related diseases in primates.06-04-2009
20090093067METHODS FOR MAKING AND USING SPR MICROARRAYS - An article, process, and method for surface plasmon resonance plates are described. A substrate is covered with a thin metal film onto which a second thin metal film is deposited. The surface of the second thin metal film is converted to the metal oxide which is used to covalently bond organosilanes to the surface. Reactive organosilanes containing terminal bonding groups are arranged in a plurality of spots that are surrounded by inert organosilanes. Biomolecule attachment to the binding group is detected or measured from surface plasmon signals from the first thin metal film.04-09-2009
20090093068IMMUNOSENSOR AND MEASURING METHOD USING THE SAME - An immunosensor includes a base body (04-09-2009
20110269248BIO-MARKERS FOR DIAGNOSING DIABETIC RETINOPATHY - Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.11-03-2011
20090104713Phenobarbital derivatives useful in immunoassay - Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (“an antibody specific for phenobarbital”).04-23-2009
20090104712HEPATITIS B PRE-S2 NUCLEIC ACID - This invention relates to a nucleic acid molecule encoding a middle Hepatitis B virus (HBV) surface protein, a vector comprising the nucleic acid molecule, a host cell comprising the vector, and a composition comprising the expression products of this vector, which may comprise middle HBV surface protein, or a mixture of middle HBV surface protein and small HBV surface protein. The compositions of the invention may be useful for expressing a middle HBV surface protein, or a mixture of small and middle HBV surface proteins in defined ratios, determining the binding of an antibody to a middle or small HBV surface protein, determining the quality of an anti-middle or an anti-small HBV surface protein antibody, or determining the quality of a kit containing anti-middle or anti-small HBV surface protein antibodies.04-23-2009
20100279432INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.11-04-2010
20090291507FLUIDICS DEVICES - The invention relates to fluidics as used in medical and diagnostic equipment and relates further to means for purifying, abstracting, filtering, detecting and/or measuring analytes in liquid samples.11-26-2009
20110171753MODIFIED ANTI-HEPARIN/PF4 COMPLEX ANTIBODY AND HIT ANTIBODY STANDARD - Provided is a modified antibody which enables the quantitative measurement of the amount of a heparin/PF4 complex, an onset factor of heparin-induced trombocytopenia (HIT), without the influence of the presence of PF4, and which can be used as an HIT antibody standard specific for the heparin/PF4 complex. The modified antibody is prepared by linking a human IgG, or an antibody fragment derived from a human IgG, to a monoclonal antibody obtained by immunizing an animal (excluding a human) with the heparin/PF4 complex.07-14-2011
20110171751RECOMBINANT POLYPEPTIDES FOR DIAGNOSING INFECTION WITH TRYPANOSOMA CRUZI - Recombinant polypeptides are disclosed that are useful for diagnosing American trypanosomiasis, or Chagas disease, a disease caused by the infectious agent 07-14-2011
20110171750 MARKER FOR GRAFT FAILURE AND MORTALITY - Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.07-14-2011
20130217147DETECTION OF COMPLEXES OF TAU AND AMYLOID - The invention relates to methods for detecting complexes of Tau, Tau variants, including phosphorylated variants, and amyloid containing molecules, as well as autoantibodies to those complexes or components of those complexes, in physiological fluid samples.08-22-2013
20100279431USE OF BNP-TYPE PEPTIDES FOR PREDICTING DIALYSIS NEED - The present invention relates to diagnosing the risk of developing a need for dialysis and/or predicting a need for dialysis, particularly in patients suffering from renal disorders, comprising the steps of measuring the level of a BNP-type peptide or a variant thereof in a sample from the patient, diagnosing the risk by comparing the measured level of the BNP-type peptide or a variant thereof to at least one reference level. The BNP-type peptide may, for example, be brain natriuretic peptide (BNP), proBNP, NT-proBNP, a variant of BNP, a variant of proBNP, or a variant of NT-proBNP.11-04-2010
20110207233METHOD FOR MEASURING INHIBITORY ACTIVITY ON LIGAND-RECEPTOR BINDING - A method for measuring the presence or absence and/or strength of the inhibitory activity of a test substance on binding between a ligand and a receptor thereof, which comprises the following steps (1) to (3):08-25-2011
20120288959RAPID DETECTION OF CEREBROSPINAL FLUID, METHODS AND SYSTEMS THEREFORE - Methods and systems are disclosed for rapid detection of cerebrospinal fluid (CSF) in a sample. In some embodiments, the methods comprise depleting a biological sample of beta-1 transferrin by contacting the sample with a sialic acid-specific lectin bound to a solid support, followed by subjecting the beta-1 transferrin-depleted sample to a lateral flow immunoassay. The methods can be used to detect CSF comprised by a sample in under one hour. Furthermore, the methods can detect CSF in a biological sample such as a plasma sample of a volume as small as about 10 μl.11-15-2012
20080241960INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN - Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided.10-02-2008
20080241958Method for Determining HCG Levels in Fluid Samples - The subject invention is an immunoassay for the semi-quantitative test kit for determination of human chrionic gonadtropin (hCG) in fluid sample (such as urine) as an aid in the diagnosis of a certain stage of pregnancy. The test device includes five strips having each having a dipping end or sample ends where sample can be applied. Results are indicated by coloration of two bands across a clear area of the strips, one band being coated with a reagent such as hCG antigens and the other with a reagent such as goat/rabbit polyclonal antibody gold conjugate. The combination of color indications on the bands provides the test results.10-02-2008
20080280376Method of Evaluation of the Relative Risk of Developing Atherosclerosis in Patients - The present invention relates to a method for determining the amount of circulating CD36 protein or a fraction thereof which is present in cell-free plasma, preferably in a high molecular weight plasma fraction, such as a lipoprotein fraction selected from Low Density Lipoprotein, Intermediate Density Lipoprotein, and Very Low Density Lipoprotein using an immunological method which comprises the steps of (i) providing a plasma sample to be investigated, (ii) providing an anti-CD36 antibody, (iii) exposing the sample to be investigated to the antibody, and (iv) detecting and quantifying the amount of CD36 which binds to the antibody.11-13-2008
20080280377HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure provides among other things assays, methods and kits for assessing the presence or amount of human B-type natriuretic peptide in a test sample wherein the assay exhibits reduced cross-reactivity with other forms of the peptide.11-13-2008
20080293162Methods and compositions for diagnosing neoplastic disease - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.11-27-2008
20080293160DNA AND RNA CONFORMATIONAL SWITCHES AS SENSITIVE ELECTRONIC SENSORS OF ANALYTES - The electrical conductivity of DNA and other oligonucleotide constructs is dependent on its conformational state. Such a dependence may be harnessed for the electronic sensing of external analytes, for instance, adenosine or thrombin. Such a DNA sensor incorporates an analyte receptor, whose altered conformation in the presence of bound analyte switches the conformation, and hence, the conductive path between two oligonucleotide stems, such as double-helical DNA. Two distinct designs for such sensors are described that permit significant electrical conduction through a first or “detector” double-helical stem only in the presence of the bound analyte. In the first design, current flows through the analyte receptor itself whereas, in the second, current flows in a path adjacent to the receptor. The former design may be especially suitable for certain categories of analytes, including heterocycle-containing compounds such as adenosine, whereas the latter design should be generally applicable to the detection of any molecular analyte, large or small, such as the protein thrombin. Since analyte detection in these DNA sensors is electronic, the sensors may be used in rapid and automated chip-based detection of small molecules as well as of proteins and other macromolecules.11-27-2008
20080305557Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.12-11-2008
20080293159Validation Process - The present invention provides a process for validating the efficacy of a sample having a known activity determined using a biological assay. The process includes subjecting the sample to a biological assay capable of testing for the activity. The process may optionally include an initial step of determining a biological assay for the desired activity. The present invention is particularly applicable to samples from milk.11-27-2008
20100144057Fluidic Force Discrimination - This invention describes a method of using controlled fluidic forces to improve the performance of a biochemical binding assay where a target molecule is captured by specific molecular recognition onto a substrate surface with an affinity coating, and then labeled with a detectable micrometer-scale particle using a second specific molecular recognition reaction with the target. By using specific ranges of label sizes and laminar flow conditions, controlled fluidic forces can be applied to the label particles in order to selectively remove molecules bound to a surface according to their binding strength, and thereby increase the ratio of specifically bound labels to more weakly attached non-specifically bound labels. This method can be used with a wide variety of label types and associated detection methods, improving the sensitivity and selectivity of a broad range of binding assays.06-10-2010
20110269245METHODS AND KITS FOR DETECTION OF TOXEMIA - Various embodiments of methods and kits are disclosed for prognosis, detection, and/or diagnosis of toxemia in a subject patient by analyzing an aliquot of the subject patient's extracellular fluid (e.g., blood serum) that contains carrier proteins.11-03-2011
20100144058B-LYMPHOCYTE STIMULATOR BINDING POLYPEPTIDES AND METHODS BASED THEREON - Binding polypeptides that specifically bind B lymphocyte stimulator protein or B lymphocyte stimulator-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate function of B lymphocyte stimulator or B lymphocyte stimulator receptor, comprising B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate B lymphocyte stimulator function or B lymphocyte stimulator receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator.06-10-2010
20100144055Assays For Clinical Assessments of Disease-Associated Autoantibodies - The disclosure provides methods of detecting autoantibodies (AAs) in biological samples. The methods use capture probes that can bind to an disease-associated antigen/AA complex and a detection probe that can bind to the AAs. The presence, absence, and/or amount of the complex may be measured, wherein the presence of the complex may be diagnostic or prognostic of a disease or medical condition. The disclosure also provides methods of simultaneously detecting AAs and antigens in biological samples. The presence, absence, and/or amount of AAs and antigens may be measured, wherein the amount of antigen present and/or the amount of autoantibody present may be diagnostic or prognostic of a particular disease or medical condition.06-10-2010
20100144056PARTICLES CONTAINING DETECTABLE ELEMENTAL CODE - The invention relates to a new type of element encoded particles suitable for the attachment of bio molecules to enable massively multiplex bio-analytical methods, and to calibrate and tune the elemental flow cytometer mass spectrometer (FC-MS).06-10-2010
20090181469METHOD OF ENHANCING SIGNAL DETECTION OF CELL-WALL COMPONENTS OF CELLS - The invention relates to methods of enhancing signal detection of components of cell walls, wherein the methods involve lysing cells to form cell-wall fragments and analyzing the cell-wall fragments.07-16-2009
20110207235USE OF PERFLUOROPOLYMERS IN THE DETERMINATION OF THE RECEPTOR-LIGAND BINDING CONSTANT - A method for determining the binding constant of interacting molecular species comprises the use of flat surfaces comprising perfluorinated polymers and measurements of reflected light intensity. The surfaces comprise at least one molecule with the receptor function absorbed or immobilized on the surface and at least one ligand that interacts with the receptor.08-25-2011
20110207234Synthesis and Use of Cross-Linked Hydrophilic Hollow Spheres for Encapsulating Hydrophilic Cargo - Cross-linked hydrophilic nanocapsules and various compositions and methods for their preparation and use are provided.08-25-2011
20090298198DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING COMPLEMENT COMPONENTS ON WHITE BLOOD CELLS - The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.12-03-2009
20090298196QUANTITATIVE MEASUREMENT METHOD FOR RECOMBINANT PROTEIN - The present invention is intended to provide a method of rapidly, simply and accurately measuring a recombinant protein. As means for resolution, the protein quantity is measured by causing the expression of a fusion protein with the target protein and epitope tags containing two types of epitopes, bringing them into contact with detection antibodies which specifically recognize each epitope, and detecting a phenomenon caused by both detection antibodies coming close to each other.12-03-2009
20090162944Method of Measuring Biomolecular Reaction at Ultrahigh Speed - According to the present invention, a method for ultrafast and precise measurement and analysis of biomolecules using a small sample was established, and moreover, a compact and simple micro fluid device for implementing the method was provided. Using the method and the micro fluid device of the present invention, the ultrafast, instant, and precise analysis of biomolecules is possible, and there is a great deal of potential for application in the research field, manufacturing field or medical field, environmental monitoring and the like.06-25-2009
20090137063METHOD FOR DETERMINING THE QUALITY OF A BIOLOGICAL SAMPLE - The present invention relates to a method of determining the quality of a biological sample. A method according to the invention may be used to determine if a biological sample is suitable to use in a further biological assay demanding samples of good quality to render an accurate result. The method comprises detecting the presence of protein fragments in the biological sample by using appropriate means. The invention also relates to a kit for determining the quality of a biological sample.05-28-2009
20090004755METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES - The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.01-01-2009
20120094394HOMOGENEOUS AGGLUTINATION IMMUNOASSAY METHOD AND KIT FOR SUCH METHOD - A homogeneous agglutination immunoassay method wherein a sample possibly containing the analyte to be measured is mixed with a binding partner for the analyte and with at least one chaotropic agent, monovalent ions in form of at least one salt, or with a combination of at least one chaotropic agent and monovalent ions in form of at least one salt, measuring at least one signal related to interactions of the binding partner with the analyte over a reaction time and calculating from at least one of the signals measured the concentration of analyte in the sample.04-19-2012
20090029481Method for separating target component using magnetic nanoparticles - An object to be achieved by the present invention is to provide a method for determining the amount of a component contained in a specific lipoprotein fraction in a biological sample using an automatic analyzer, without the requirement of a step of fractionating a sample by centrifugation. The present invention provides a method for separating a target component in a biological sample, which comprises the steps of: (1) causing a biological sample to come into contact with independently dispersed magnetic nanoparticles having a particle size of 50 nm or less, which have anionic functional groups on their surfaces, so as to form an agglutinate of the magnetic nanoparticles and biomolecules capable of interacting with the magnetic nanoparticles; and (2) collecting the agglutinate by an external magnetic field.01-29-2009
20090258437COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS - The present invention provides compounds and methods for rapid labeling of N-glycans, for example, rapid fluorescent labeling of N-glycans. In one aspect, the present invention provides fluorescent carbamate or thiocarbamate compounds. Upon contacting with N-glycans, the compounds undergo facile reactions with N-glycans to form fluorescent-labeled N-glycans.10-15-2009
20090004757Analyte Assay Using Particulate Labels - Method for specific detection of one or more analytes in a sample. The method includes specifically associating any one or more analytes in the sample with a scattered-light detectable particle, illuminating any particle associated with the analytes with light under conditions which produce scattered light from the particle and in which light scattered from one or more particles can be detected by a human eye with less than 500 times magnification and without electronic amplification. The method also includes detecting the light scattered by any such particles under those conditions as a measure of the presence of the analytes.01-01-2009
20080318338Assays and Implements for Determining and Modulating HSP90 Binding Activity - Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby.12-25-2008
20090017557FVII Specific Antibodies and Use Thereof - The present invention relates to novel antibodies against FVII, use for determining amount of correctly folded and intact FVII in a sample, as well as for purification and process optimization.01-15-2009
20090221100METHODS FOR DIFFERENTIATING PLASMA-DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE - The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.09-03-2009
20090325313TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of an un-natural amino acid in the polypeptide is provided here. Also provided are methods of using the two-helix binders.12-31-2009
20090325311Measurement methods - The invention relates to methods for measuring unconjugated molecules, e.g. antibodies, in a mixture that also includes conjugated molecules, e.g. antibodies.12-31-2009
20130217148Methods Of Determining Skeletal Maturity - The present invention provides methods to determine skeletal maturity.08-22-2013
20130217150ASSAY APPARATUS AND ITS CONTROL METHOD AND REACTION CONTAINER FOR ASSAY - In an assay apparatus for performing an assay related to a specimen received from the outside thereof based on a reaction between the specimen and a reagent by using a reaction container that holds the reagent, the apparatus includes a detection means that detects a state in which an assay has ended before completion, and a mark providing means that provides a predetermined mark for the reaction container when the state in which the assay has ended before completion is detected by the detection means.08-22-2013
20090081808DEVICE AND METHOD FOR IDENTIFYING MYCOTOXINS - The invention relates to an apparatus and a process for detection of mycotoxins and to kits suitable for carrying out said process.03-26-2009
20110143453ALBUMIN-BOUND PROTEIN/PEPTIDE COMPLEX AS A BIOMARKER FOR DISEASE - Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC).06-16-2011
20100248389ELECTROCHEMICAL DEPOSITION OF POLYMERS ON METAL SUBSTRATES - Described herein are methods for electrodepositing a variety of different polymers on metal substrates. The polymers are strongly adhered to the substrates. The substrates produced herein can be used in a number of different applications such as, for example, medical devices and biosensors. For example, the biosensors can be composed of one or more electrodes, where the electrodes have the same or different polymers electrochemically deposited on them. Finally, the methods described herein permit the evaluation of the electrodeposition process as well as monitor the ability of biomolecules to bind to the electrodeposited polymers.09-30-2010
20110143456METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.06-16-2011
20100003766CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I:01-07-2010
20110229983MARKING FUEL FOR AUTHENTICATION - A first fuel and a second fuel are marked with a marker that can be detected quantitatively in a predetermined concentration range. The second fuel is marked with a binary marker. Decreased concentration of the quantitative marker, presence of a binary marker, or both may be indicative of a fuel that is altered (e.g., mixed, laundered, diluted, or adulterated). Testing a fuel includes testing the fuel for a presence of a first marker in the fuel in a predetermined concentration range, and testing the fuel for a presence of a second marker. The presence of the first marker in the predetermined concentration range and an absence of the second marker may be indicative that the fuel is unaltered. The presence of the first marker in the fuel in a concentration less than the predetermined concentration range or the presence of the second marker may be indicative that the fuel is altered.09-22-2011
20110229979RISPERIDONE IMMUNOASSAY - Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.09-22-2011
20090053826Electropolymerisable monomers that are soluble in aqueous solution and electroactive probes that can be obtained with such monomers - The invention relates to an electropolymerizable monomer, intended to be polymerized in aqueous solution, comprising a single electropolymerizable unit and an electron-donating group, characterized in that it also comprises at least one arm ionizable in aqueous solution. The invention also relates to the polymerization process, to the electroactive probe thus obtained and to the method for the detection of a target ligand in a biological sample.02-26-2009
20110229984MATERIALS AND METHODS DIRECTED TO ASPARAGINE SYNTHETASE AND ASPARAGINASE THERAPIES - Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.09-22-2011
20110229980OLIGONUCLEOTIDE PROBE AND USE THEREOF - The present teaching provides a fluorescent oligonucleotide probe having a high degree of design flexibility and wide applicability, as well as the use thereof. This is an oligonucleotide probe capable of forming a stem and loop, comprising at least one fluorophore located between adjacent nucleotides in the stem and is linked to a unit represented by Formula (1) and at least one quencher located at a site capable of pairing up with the at least one fluorophore located between the adjacent nucleotides in the stem and is linked to a unit represented by Formula (2). (In the formulae, X represents the fluorophore, Y represents the quencher, R1 represents an optionally substituted C09-22-2011
20090081809Monoclonal antibody specific to dentin-derived heparan sulfate - The present invention provides a monoclonal antibody displaying excellent specificity against heparan sulfate saccharide chains for the analysis of heparan sulfate saccharide chains specific to dentin. The invention also provides a method of evaluating reproductive dentin using the monoclonal antibody. The anti-heparan sulfate monoclonal antibody reacts against dentin-derived heparan sulfate and in particular the anti-heparan sulfate monoclonal antibody reacts strongly and specifically with uncalcified predentin regions. In the method of evaluating dentin, the antibody is reacted against an isolated dentin-derived sample and the reaction is used in order to evaluate the development of dentin.03-26-2009
20110223688GRATING-BASED EVANESCENT FIELD MOLECULAR SENSOR USING A THIN SILICON WAVEGUIDE LAYER - A technique for high sensitivity evanescent field molecular sensing employs a detection scheme that simultaneously couples a polarized beam to a single mode of a waveguide, and couples the polarized beam out of the waveguide to specularly reflect the beam by the same grating. Strong interaction with the single (preferably TM) mode is provided by using a silicon on insulator (SOI) wafer having a waveguide thickness chosen between 10-400 nm so that the majority of the mode field strength spans the evanescent field. Well known, robust techniques for producing a grating on the waveguide are provided. Interrogation from a backside of the SOI wafer is taught.09-15-2011
20110223687METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER - Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.09-15-2011
20110223684DETECTION OF SPECIFIC NITRATED MARKERS - Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.09-15-2011
20090191644Imprinted polymer for binding of organic molecules or metal ions - The invention relates to an imprinted polymer imprinted with an organic molecule or a metal ion wherein the matrix of the polymer has been prepared from one or more monomers including bilirubin or an analogue thereof. The imprinted polymers may be prepared by polymerising one or more monomers including bilirubin or an analogue or derivative thereof in the presence of the molecule or metal ion to be imprinted or an analogue or derivative thereof, and subsequently at least partly removing the molecule or ion to be imprinted or its analogue or derivative. The polymers may be used in a method for detection and/or assay of the imprinting molecule or metal ion.07-30-2009
20090191645COMPOUNDS AND METHODS FOR MODULATING INTEGRIN ACTIVITY - The present invention provides methods and compositions for modulating integrin activity. In particular, the present invention encompasses methods and compositions for altering the interaction between the α and β chain extracellular clasp regions.07-30-2009
20090053827Assay device and method - An assay device includes a first reagent including a magnetic particle and a second reagent including detectable component. The first and second reagent can each independently bind to an analyte in a sample. A time-varying magnetic field can be used to distinguish detectable components that are associated with analyte from detectable components not associated with analyte.02-26-2009
20090117667METHODS FOR MEASURING AFFINITY SUBSTANCES IN SAMPLES COMPRISING STEP OF DISRUPTING BLOOD CELL COMPONENTS - The present invention provides methods for measuring an affinity substance using pearl chain formation of carrier particles, in which the methods include the step of electrically disrupting blood cell components. Blood cell components which interfere with the counting of carrier particles are electrically disrupted. Furthermore, blood cell components can be disrupted without addition of hemolytic agents which interfere with immunological reactions. Whole blood samples can be directly used as measurement samples without separating serum or plasma. Therefore, it is unnecessary to separate serum or plasma when analyzing blood components.05-07-2009
20110229981DETECTION OF SHED CD31, DIAGNOSIS OF ATHEROTHROMBOSIS AND AUTOIMMUNE DISORDERS, AND METHODS FOR ANALYZING SIGNALING PATHWAYS - The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.09-22-2011
20090004756METHODS FOR IDENTIFYING AGENTS THAT TARGET LEAKS IN RYANODINE RECEPTORS - The present invention provides screening methods for identifying agents that enhance binding of a ryanodine receptor and its corresponding FKBP protein, such agents to be used in treating diseases associated with ryanodine receptors.01-01-2009
20090221099Methods and compositions for protein detection using fluorescent polymer sensors - Compositions, methods and related apparatus, as can be used for selective protein detection and identification.09-03-2009
20110223685OXIDIZED APOA1 DETERMINATION BY MASS SPECTROMETRY - Methods are provided for the detection and quantitation of proteins generally and apolipoprotein A-I and oxidized derivatives thereof in particular. Further provided are methods for the assessment of the risk cardiovascular disease in a subject, wherein the assessment is based on the amount of oxidized and unoxidized apolipoprotein A-I in a biological sample obtained from a subject.09-15-2011
20090209045SCREENING ASSAY - The present invention relates to agents that modulate the interaction of a dopamine receptor interacting polypeptide (DRIP) as represented by FIGS. 08-20-2009
20090209047BIOMARKERS AND ASSAYS FOR MYOCARDIAL INFARCTION - Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included.08-20-2009
20090117666System and Method for Quantifying Analytes in Immuno or Enzymatic Assays - The present invention provides apparatus and methods for performing assays for determining the presence of and/or quantifying an analyte in a sample. The analyte and a label preferably immobilized on a particle are mixed to provide a homogenous solution. The homogeneous solution can be optionally made to flow through a filter. The homogenous solution or the filtrate can be metered through the read zone at a controlled flow rate and the presence of the label or the presence of the particle can be detected. The methods and apparatus of the invention do not require the use of a capture zone.05-07-2009
20090117665Rapid sample collection and analysis device and methods of use - The present invention is directed to devices and methods for determining the presence of analyte in a fluid sample. The devices utilize a sample collection well, an expression plate for expressing sample into the sample collection well, a plunger that drives a lance, and a test compartment containing test elements. The devices also preserve an aliquot of fluid sample in a reservoir for later confirmation testing. When the plunger is lowered into the sample collection well, a lance on the device punctures a frangible material that covers a sample outlet. When the sample outlet is thus opened, fluid sample flows from the sample collection cup to the test compartment. In one embodiment the plunger is lowered as a cap is applied to the device. The devices are useful for detecting the presence of analyte in a wide variety of fluid samples, such as saliva, oral fluids, and more. The invention also provides methods of using the devices, and kits containing the devices.05-07-2009
20090215198Immunological Latex Turbidimetry Method and Reagent Therefor - An immunological latex turbidimetry method for analyzing an antigen or antibody in a sample, comprising steps of: 08-27-2009
20090246886LATERAL FLOW TEST STRIP WITH MIGRATING LABEL - A lateral flow test strip is disclosed that includes a path of flow from a sample receiving zone through a mobilization zone to a primary capture zone and a secondary capture zone. A mobilizable conjugate is present in the mobilization zone, and a mobilizable label is present on the test strip upstream of the conjugate. An immobilized first specific binding partner is present in the primary capture zone and an immobilized second specific binding partner is present in the secondary capture zone. The conjugate includes a primary specific binding partner for the first specific binding partner in the primary capture zone, and a secondary specific binding partner that binds the label and the second specific binding partner. Application of liquid sample to the sample receiving zone results in movement of the liquid sample along the path of flow to move the label and conjugate distally along the test device. The label binds the conjugate after the conjugate binds the analyte, the first specific binding partner or second specific binding partner, so that labeling of the conjugate is delayed.10-01-2009
20090246887Diamond Crystallites For Biotechnological Applications - A diamond-based composition that contains (1) a diamond crystallite having chemically derivatized surface groups, and (2) a polymer having functional groups, in which a portion of the functional groups bind to the chemically derivatized surface groups non-covalently. Also disclosed are methods of using such composition for analyzing a biological sample by determining the identity of biomolecules bound to the composition.10-01-2009
20090246885Media for affinity chromatography - The invention relates generally to solid supports for chromatography. In specific embodiments the invention provides for solid supports suitable for affinity chromatography along with methods, systems and kits which use the same.10-01-2009
20090239309METHOD OF STABILIZING PULMONARY SURFACTANT PROTEIN - The present invention relates to a method for long-term stabilizing a pulmonary surfactant protein, to a stabilized aqueous solution containing a pulmonary surfactant protein, and to a kit for assaying a pulmonary surfactant protein which kit contains, as a component reagent, a stabilized aqueous solution containing a pulmonary surfactant protein.09-24-2009
20090258435BIOTIN-RECEPTOR REAGENTS FOR SENSITIVITY MODULATION IN ASSAYS - Methods are disclosed for designing an antibody reagent for use in an assay for the detection of an analyte to obtain an optimum assay sensitivity and/or dynamic range. The antibody reagent is a conjugate of a small molecule attached by a spacer group to an antibody for the analyte. The method comprises controlling, in the preparation of the conjugate, reaction parameters comprising the hydrophobicity or hydrophilicity of the spacer group, the length of the spacer group, the number of molecules of the small molecule attached to the antibody and the point of attachment of the small molecule to the antibody to obtain an optimum assay sensitivity and/or dynamic range. In some embodiments the method comprises preparing two or more conjugates by selecting a set of parameters for each conjugate wherein the set of parameters is different for each conjugate, conducting an assay for the analyte employing each conjugate and selecting for use in the assay the conjugate that provides the optimum assay sensitivity and/or dynamic range.10-15-2009
20080318339Sensing Device and Method For Determination of Teh Amount of Target Molecule in an Analyte - A sensing device is provided which has a universal sensor surface. This allows easy modification of the detection properties without the need for investigation of the binding properties of a new target to the sensor surface. The device comprises a sensor surface, which has attached thereto a primary capture molecule. The invention further relates to a method for measurement of a target wherein this device is used.12-25-2008
20100273275Methods of determining levels of steroid fractions utilizing SHBG calculations - There are provided methods for assaying biological specimens for steroids (androgens and estrogens), Sex Hormone-Binding Globulin (SHBG) and Albumin in order to calculate the free and bioavailable steroid concentration based on the laws of mass action and association constants predicated on the identification that one molar equivalent of SHBG contains two molar equivalents of steroid binding sites.10-28-2010
20120034707ATOMICALLY PRECISE NANORIBBONS AND RELATED METHODS - Disclosed are atomically precise nanoribbons formed by gradient-driven catalytic etching of crystalline substrates to produce edges formed along specific crystallographic axes by thermally-activated particles. Also provided are related methods for fabrication of these nanoribbon structures. Further provided are devices and related methods for power generation and for detection of specific targets using the disclosed structures.02-09-2012
20130122607DETECTION DEVICE AND DETECTION METHOD FOR INTERMOLECULAR INTERACTION - In order to improve the detection accuracy of a reflection spectrum, a detection device for intermolecular interaction is provided with a detector (05-16-2013
20100184236GUANOSINE TRIPHOSPHATE (GTP)-BINDING PROTEIN-COUPLED RECEPTOR PROTEIN, BG37 - The present inventors conducted a similarity search of the amino acid sequence of known G protein-coupled receptor proteins in GenBank, and obtained a novel human GPCR gene “BG37”, cDNA containing the ORF of the gene was cloned and its nucleotide sequence was determined. Moreover, novel GPCR “BG37” genes from mouse and rat were isolated. Use of the novel GPCR of the present invention enables screening of ligands, compounds inhibiting the binding to a ligand, and candidate compounds of pharmaceuticals which can regulate signal transduction from the “BG37” receptor.07-22-2010
20110111522NON-VISIBLE DETECTABLE MARKING FOR MEDICAL DIAGNOSTICS - Sample media for the analysis of analytes in a fluid test sample includes a carrier, at least one test field on the surface of the carrier including at least one reagent reactive with the analytes and capable of providing a detectable response. A non-visible bar code formed by at least two distinct non-visible marker fields is located on the carrier. The marker fields are configured to reflect electro-magnetic (EM) radiation within one or more ranges of non-visible wavelengths to form a coded sequence of reflectances correlated to identification of the sample media.05-12-2011
20100261291Nucleic acids specifically binding bioactive ghrelin - The present invention is related to a nucleic acid specifically binding bioactive ghrelin, more preferably n-octanoyl ghrelin, and its use for the diagnosis of ghrelin mediated diseases and disorders.10-14-2010
20100167419Capillary Flow Solid Phase Assay - Methods, materials, apparatus and systems are described for performing capillary flow assay. In one aspect, a system includes a sample collection unit to collect a sample liquid and a sample testing and storing unit to interface with the sample collection unit to test and store the collected sample liquid. The sample testing and storing unit includes a sample inlet shaped to receive the collected sample from the sample collection unit, and a sample well positioned below the sample inlet to retain at least a portion of the sample liquid. The sample testing and storing unit includes a sample housing unit to store a remainder of the sample liquid not retained in the sample well, and an analyte testing unit housing shaped to receive an analyte detecting unit to test a presence of a target analyte in the sample liquid.07-01-2010
20100151588MEANS AND METHODS FOR DIAGNOSING AND TREATING CANCER BASED ON THE FRMD3 GENE - The present invention relates to pharmaceutical compositions comprising a FRMD3 polynucleotide or polypeptide as well as diagnostic compositions, devices or kits comprising a FRMD3 polynucleotide or polypeptide as well as antibodies or oligonucleotides derived therefrom. Moreover, the present invention relates to methods and uses for diagnosing or treating a hyperproliferative disorder based on the aforementioned FRMD3 polynucleotides or polypeptides.06-17-2010
20100216253Organic Material-Immobiling Structure and Method for Production of the Same, and Peptide and DNA Therefor - The invention provides an organic material-immobilizing structure employing new immobilization means, characterized in that at least a part of the surface of the substrate is comprised of one or more members containing silicon oxide, the organic material is bound to the surface of the substrate through a binding domain bound to the organic material and containing an amino acid sequence capable of binding to silicon oxide, selected from the group consisting of amino acid sequences of SEQ ID NOS: 1 and 2: Val-Ser-Pro-Met-Arg-Ser-Ala-Thr-Thr-His-Thr-Val; and Ile-Pro-Met-His-Val-His-His-Lys-His-Pro-His-Val, and derivatives thereof.08-26-2010
20100197040ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.08-05-2010
20080213917LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.09-04-2008
20100227417Methods and Kits for Detection of Thromboxane A2 Metabolites - Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.09-09-2010
20110059554DETERMINING AN EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN A BIOLOGICAL SAMPLE - A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.03-10-2011
20110059553METHODS AND COMPOSITIONS FOR DETECTING HERPES SIMPLEX VIRUS TYPE 2 - The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.03-10-2011
20110059552RUBELLA E1 ENVELOPE PROTEIN VARIANTS AND THEIR USE IN DETECTION OF ANTI-RUBELLA ANTIBODIES - The invention relates to soluble rubella E1 antigens and variants of these antigens. The antigens contain amino acids 201 to 432 or 169 to 432 and are lacking amino acids 453 to 481 as well as at least the amino acids 143 to 164. They further contain a region spanning two disulfide-bridges. The invention also relates to a recombinant DNA molecule encoding the rubella E1 antigens, the expression of rubella E1 antigens as chaperone fusion proteins and their use in a method of detecting antibodies against rubella in a sample.03-10-2011
20110059551Assay Device - Disclosed is an assay device to determine the presence of at least one analyte of interest in a liquid sample, the device comprising means for generating a first signal (the ‘test’ signal) which indicates the presence and/or amount of analyte of interest in the sample; and means for generating a second signal, the generation of which second signal indicates both (a) the test has been successfully conducted, and that (b) sufficient time has elapsed following contact of the assay device with the liquid sample for the test to be read and the first signal to have been properly generated.03-10-2011
20110059549METHODS AND SYSTEMS FOR PRODUCING NANOLIPOPROTEIN PARTICLES - Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein.03-10-2011
20120196383INTEGRATED OPTOFLUIDIC SYSTEM USING MICROSPHERES - An integrated optofluidic system for trapping and transporting particles for analysis is provided comprising a planar substrate; a microfluidic channel; and a waveguide integrated with the channel. A microsphere particle in the integrated optofluidic system can act as a cavity, allowing light to circulate many thousands of times around the circumference of the microsphere. Optical trapping and transport is used for nanoscale positioning to excite the microsphere resonances. Sensitive measurements on molecules can be accomplished by monitoring changes in whispering gallery modes (WGMs) that propagate around the circumference of the microsphere. By using a broadband or supercontinuum light source, a microsphere can be trapped and many WGM resonances can be excited through the visible and near-infrared wavelengths simultaneously. After the resonances are measured using the waveguide transmission, the microsphere can be freed by decreasing the optical power and the process repeated with a different microsphere.08-02-2012
20120196382Multicoded Analytical Nanostrips - Analytical nanostrips for clinical analysis are improved by using multifunctional coding (“multicoding”) to allow simultaneous identification of the particular assay, the value of the assayed analyte, and a calibration of the analyte. The multicoding layout on the nanostrip minimizes the number of zones that are required for a given assay. Moreover, the nanostrip can be scanned in real time during flow of the nanostrip through a detection beam. This both simplifies the assay and allows for alternative means of coding.08-02-2012
20100197041NUCLEIC ACID BINDING ASSAYS - This invention relates to methods for screening compounds for the ability to interact with a nucleic acid target, assay kits useful thereof and compositions regarding same. In a particular aspect, the invention relates to specific binding assays employing fluorescent label(s). The methods involve assessing the conformation of nuclei acid targets in the presence and absence of test compounds, and identifying as a ligand any test ligand that causes a measurable conformation change in nuclei acid targets. The effect of compounds on target nuclei acids conformation is assessed by measuring the fluorescence changes of a fluorescently label(s) attached hereto.08-05-2010
20100221845BIOSENSOR - One object of the present invention is to provide a biosensor and a production method therefor, by which hydrogel that enables immobilization of a physiologically active substance can be conveniently produced using safe raw materials. The present invention provides a biosensor which comprises a substrate having a metal layer on its surface, wherein a hydrophilic polymer having a reactive functional group capable of reacting with a hydroxyl group or an amino group of a physiologically active substance is bound to the metal layer directly or indirectly via an intermediate layer.09-02-2010
20090191647Antibody Pair Screening Methods - The invention provides methods for identifying antibody preparations that can form a pair of antibodies that optimally detect a target antigen, for example, in a sandwich immunoassay. These methods provide high affinity and epitope-specific antibodies.07-30-2009
20100227416Nano-Scale Bridge Biosensors - Devices, systems, and methods for detecting nucleic acid hybridization, including single nucleic base mutations at low concentrations, are disclosed, using capture units having nanoparticles with attached single-stranded oligonucleotides that are capable of hybridizing target oligonucleotides and reporter molecules having nanoparticles with attached single-stranded oligonucleotides, without the use of labeling or target modification.09-09-2010
20100240147HIGH SENSITIVITY NANOTECHNOLOGY-BASED MULTIPLEXED BIOASSAY METHOD AND DEVICE - In a method and device for high sensitivity analysis of multiple bioassays plurality of nanoparticles (N) is dispersed in a fluid sample, at least one probe (C) of a first type having affinity for at least one analyte being attached to each nanoparticle; a plurality of probes of at least a second type having affinity for the analyte is attached to the internal surface (S) of the container; means are provided for detecting the signal generated by the adhesion of the nanoparticles to the internal surface of the reactor, brought about by the interaction of the analyte with the nanoparticle-bound probes and that of the analyte with the probes attached to the internal surface. The method and the device are particularly effective for detecting different genotypes of human papilloma virus (HPV).09-23-2010
20100216255METHODS OF DETERMINING ACTIVE LEVELS OF DRUGS IN FLUID SAMPLES - Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided.08-26-2010
20100227415METHOD AND MEANS FOR PREDICTION OF SYSTEMIC LUPUS ERYTHEMATOSUS SUSCEPTIBILITY - A method of predicting the risk of a person developing systemic Lupus erythematosus susceptibility comprises the detection of autoantibody to class A scavenger receptors, in particular to MARCO and SR-A autoantibody. Also disclosed is a support coated with the autoantibody and a kit comprising the support and a secondary antibody capable of binding to a serum component bound to the autoantibody on the support.09-09-2010
20110111530HOMOGENEOUS IMMUNOASSAYS FOR MULTIPLE ALLERGENS - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.05-12-2011
20110111524Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.05-12-2011
20100240146FLUORESCENT PROTEIN PARTICLES - A fluorescent protein particle comprising: a particle forming component capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; a fluorescent component; and a functional component capable of binding to, or being bound by, a target.09-23-2010
20100240145Novel hemopoietin receptor protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.09-23-2010
20130217145ANTIBODIES WHICH DETECT PIVKAII AND METHODS OF USE THEREOF - The present invention relates to antibodies or binding proteins which bind to PIVKA II and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.08-22-2013
20130217146VIRTUAL SEPARATION OF BOUND AND FREE LABEL IN A LIGAND ASSAY FOR PERFORMING IMMUNOASSAYS OF BIOLOGICAL FLUIDS, INCLUDING WHOLE BLOOD - Detection and characterization of immunologically detected substances are performed electronically on human and animal biological fluids such as whole blood, serum, plasma, urine, milk, pleural and peritoneal fluids, and semen, which fluids are contained in a thin chamber forming a quiescent fluid sample, which chamber has at least two parallel planar walls, at least one of which is transparent.08-22-2013
20100129927Peptides for Use in Diagnosing the Presence of Ruptured Atherosclerotic Lesions in a Individual - The present invention relates to peptides that are able to interact with ruptured atherosclerotic plaque-associated antibodies, which peptides comprise an immunoreactive part of one of the amino acid sequences according to SEQ ID NOS: 1-25. The invention further relates to a diagnostic reagent comprising the peptides, to the use of the method and to a method and test kit for the diagnosis of a sample from an individual for the presence therein of antibodies that are indicative of the presence of ruptured atherosclerotic plaques in the individual.05-27-2010
20100136711IMMUNOASSAY METHOD FOR PRO-GASTRIN-RELEASING PEPTIDE - To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample.06-03-2010
20090042315COMPOSITIONS OF SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR - Compositions comprising nonpolar amino acids and specific binding agents to hepatocyte growth factor (HGF) are provided. Methods of making and using such compositions are also provided.02-12-2009
20120196384BIOSENSOR UTILIZING A RESONATOR HAVING A FUNCTIONALIZED SURFACE - Systems and methods for detecting the presence of biomolecules in a sample using biosensors that incorporate resonators which have functionalized surfaces for reacting with target biomolecules. In one embodiment, a device includes a piezoelectric resonator having a functionalized surface configured to react with target molecules, thereby changing the mass and/or charge of the resonator which consequently changes the frequency response of the resonator. The resonator's frequency response after exposure to a sample is compared to a reference, such as the frequency response before exposure to the sample, a stored baseline frequency response or a control resonator's frequency response.08-02-2012
20120196381Miniaturized Microparticles - An encoded microparticle having a spatial code is provided; and a set of encoded microparticles possessing subsets each provided with a distinguishable spatial code, wherein the codes comply with a pre-determined coding scheme. Presented are also methods of using the encoded microparticles in various biological assays, such as various multiplex assays and visualizing them by creating a digital image of the encoded microparticles and determining whether false positives are present. Further are provided methods of manufacture of the encoded microparticles which employ ferromagnetic nanoparticles applied using spin-on-glass techniques.08-02-2012
20090075393Integrated Affinity Microcolumns and Affinity Capillary Electrophoresis - Device and method for detecting the presence of known or unknown toxic agents in a fluid sample. Targets in the sample are bound to releasable receptors immobilized in a reaction region of a micro- or nano-fluidic device. The receptors are selected based on their affinity for classes of known toxic agents. The receptors are freed and the bound and unbound receptors separated based on differential electrokinetic mobilities while they travel to a detection device.03-19-2009
20090075392AGENTS FOR AND METHOD OF QUANITIFYING MULTIPLE RELATED COMPONENTS IN A BIOLOGICAL SYSTEM - The present invention relates to agents comprising non-natural protein sequences with at least two protein or polypeptide epitopes that are relationally linked by a common or shared functional relationship such as being components in a series of components of the same metabolic or signal transduction pathway or a pathway associated with interaction between two systems such as host-parasite or host-pathogen. The invention further includes a method of simultaneously calibrating and investigating the quantitative relationships between the at least two protein or polypeptide epitopes.03-19-2009
20120034710Detection of Degradation Products of NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.02-09-2012
20120034709 SURFACE MODIFIED SUBSTRATE, BIOTIP AND A METHOD FOR PRODUCING THEREOF - A surface modified substrate is produced by a method including reacting a substrate having a reactive functional group on a surface thereof with a functional group being reactive to the reactive functional group, and reacting the substrate with a compound represented by the general formula,02-09-2012
20120142120VASOACTIVE HORMONE-BASED STRATIFICATION OF PATIENTS SUFFERING FROM DISEASES RELATED TO ENDOTHELIAL FUNCTION/DYSFUNCTION - The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from said subject; (ii) determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying said subjects into either of the categories: (a) responder to a medication for treatment of said disease, (b) non-responder to a medication for treatment of said disease not showing an unfavourable effect after having received said medication; (c) subjects showing an unfavourable effect after having received said medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention.06-07-2012
20100035365Fluorescent Silica-Based Nanoparticles - The present invention provides nanoparticle compositions comprising, for example, a core comprising a fluorescent silane compound; and a silica shell on the core. Also provided are methods for the preparation of nanoparticle compositions including fluorescent nanoparticles, ligated-fluorescent nanoparticles, ligated-fluorescent nanoparticles having therapeutic agents, and ligated-fluorescent nanoparticles coupled or associated with an analyte. Also provided are methods: for the detection of the ligated-fluorescent nanoparticles; for associating the linked-fluorescent nanoparticles with a cellular component of interest and recording or monitoring the movement of the cellular component; for improving the therapeutic properties of the therapeutic agent by combining the therapeutic agent with linked-fluorescent nanoparticles and contacting or administering the combination to a cell or organism; for making and using the fluorescent nanoparticles in, for example, diagnostic agents for the detection of various analytes, and like applications.02-11-2010
20090253218METHOD FOR SEROLOGIC AGGLUTINATION AND OTHER IMMUNOASSAYS PERFORMED IN A THIN FILM FLUID SAMPLE - A method and system for performing a serological agglutination assay in a liquid sample. The system provides a simple method for creating an in-situ sample/reagent admixture within a sample analysis chamber without the use of any precision fluid-handling components.10-08-2009
20110027912PURIFIED SERUM ALBUMIN, AND IMMUNOLOGICAL MEASUREMENT METHOD - An object of the present invention is to provide: a purified serum albumin having less lot-to-lot variation; and an immunoassay method utilizing the purified serum albumin, in which high reactivity and less non-specific reactions are achieved.02-03-2011
20110027911SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS - Provided are methods for solubilizing a membrane protein in order to provide substantially homogeneous membrane proteins that are solubilized within reverse micelle systems at concentrations that are suitable for analytical study of such membrane proteins, including nuclear magnetic resonance spectroscopy. Also provided are substantially homogeneous membrane proteins that are solubilized within a reverse micelle system, as well as methods for the study of solubilized membrane proteins, and for the screening of drug candidates that target such membrane proteins.02-03-2011
20090209048Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same - Disclosed are a luminescence biotin-transition metal complex conjugate and a method of amplifying signals using the same. More particularly, disclosed herein are a luminescence biotin-transition metal complex conjugate comprising an energy acceptor and biotin, and optionally an energy donor and a method of amplifying signals using the biotin-transition metal complex conjugate using intramolecular energy transfer. The luminescence biotin-transition metal complex conjugate using a transition metal probe provides a phosphorescence detection system capable of improved sensitivity.08-20-2009
20090170219Nucleic acid capable of binding to immunoglobulin G and use thereof - The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.07-02-2009
20090170218METHODS FOR DETECTION OF CYCLOSPORIN A - Methods and reagents are disclosed for determining the presence and/or amount of cyclosporin A in a medium suspected of containing cyclosporin A. In the method a combination is provided in a medium. The combination comprises (i) the sample, (ii) a first member of a signal producing system (sps) associated with a first support wherein the first sps member is capable of activating a second member of the sps and wherein the first support is associated with a first member of a specific binding pair, and (iii) the second sps member associated with a second support wherein the second sps member is activatable by the first sps member. The second support comprises either (I) cyclosporin C or cyclosporin A and the combination further comprises a conjugate of an antibody for cyclosporin A and a second member of the specific binding pair or (II) antibody for cyclosporin A and the combination further comprises a conjugate of cyclosporin A and a second member of the specific binding pair. The combination is subjected to conditions for binding of cyclosporin A to the antibody for cyclosporin A. The first sps member is activated and the amount of signal generated by the second sps member is detected. The amount of signal is related to the presence and/or amount of cyclosporin A in the sample.07-02-2009
20110117671Method for Stabilizing Microparticles Having Reactive Substance Bound Thereto, and Reagent Containing the Microparticles - Provided is a method for maintaining the reactivity of microparticles having a reactive substance bound thereto in a dispersion liquid of the microparticles over a long period of time by stabilizing the microparticles in the dispersion liquid. The method for stabilizing microparticles having a reactive substance bound thereto includes the step of allowing a sulfur-containing amino acid or a derivative thereof to coexist in a dispersion liquid of the microparticles. The sulfur-containing amino acid includes one or more of cysteine, cystine, and methionine. The method is particularly useful when a precipitation preventing substance, such as a polyanion, dextran, or the like, is allowed to coexist in the dispersion liquid.05-19-2011
20110117669MATERIALS AND METHODS FOR DETECTING TOXINS, PATHOGENS AND OTHER BIOLOGICAL MATERIALS - Embodiments of the present invention provide binding molecule-functionalized high electron mobility transistors (HEMTs) that can be used to detect toxins, pathogens and other biological materials. In a specific embodiment, an antibody-functionalized HEMT can be used to detect botulinum toxin. The antibody can be anchored to a gold-layered gate area of the HEMT through immobilized thioglycolic acid. Embodiments of the subject detectors can be used in field-deployable electronic biological applications based on AlGaN/GaN HEMTs.05-19-2011
20100297778Conjugate Having Cleavable Linking Agent - A method and reagent that can be used to eliminate the signal caused by non-specific binding of a labeled conjugate, e.g., a specific binding member attached to a label, to a solid phase, e.g., a magnetic microparticle. The method and the reagent involve the use of a cleavable linking agent to link the label to the specific binding member that specifically binds to the analyte. The use of a cleavable linking agent would allow the release of the label from the specific binding member from the complex comprising the magnetic microparticle, analyte, and labeled conjugate into solution. After the release of the label, the magnetic microparticles having any label non-specifically bound thereto, are removed from the reaction mixture. Only the label, e.g., acridinium, from the labeled conjugate would remain in the elution well. The conjugate that is non-specifically bound through interaction between the label and the solid phase, e.g., a magnetic particle, would remain bound to the solid phase, and would subsequently be removed from the elution well when the solid phase is removed from the elution well and transferred to another well the introduction of additional reagent(s).11-25-2010
20090221097METHOD OR AGENT FOR INHIBITING THE FUNCTION OF EFFLUX PUMP OF PSEUDOMONAS AERUGINOSA - The purpose of the present invention is to provide a method and an agent to efficiently inhibit the function of the drug efflux pump of 09-03-2009
20100304499METHOD OF EXTRACTING FOOD COMPONENT, FOOD INSPECTION METHOD AND FOOD INSPECTION KIT - Provided is a technique of extracting a component in a food from the food by using a reducing agent that is inexpensive and has a mild reducing action. A component in a food is extracted by mixing the food with an extractant containing a sulfite. In addition, the resultant food extract is brought into contact with a specific antibody that specifically recognizes a substance included in a specified ingredient of interest for inspection, to thereby inspect the presence or absence and/or the amount of a specified ingredient in a food by utilizing an immunological measurement method. Further provided is a food inspection kit for inspection of the presence or absence and/or the amount of a specified ingredient in a food, including: (1) an extractant and a sulfite to be added to the extractant, or an extractant including a sulfite added; and (2) an antibody that specifically recognizes a substance included in a specified ingredient of interest for inspection.12-02-2010
20110236997Methods and Reagents for Shortening Incubation Times in Hybridization Assays - The methods and reagents described herein can be used to shorten incubation times in hybridization assays. As demonstrated in the examples, we have identified specific sulfonic acid polymers and hybridization conditions that lead to significantly shorter incubation times (e.g., signals after three hours that are comparable to signals that could traditionally only be obtained after overnight incubation). In some embodiments, shorter incubation times are achieved by adding the sulfonic acid polymer(s) during the hybridization process. Alternatively or additionally, in some embodiments, shorter incubation times are achieved via changes to the hybridizing conditions, e.g., by reducing the hybridization volume, increasing the salt concentration, and/or increasing the probe concentration (capture extender probe and/or label extender probe).09-29-2011
20100304498MICROCHIP REACTION DETECTION SYSTEM AND METHOD OF REACTION OF MICROCHIP IN FLOW PATH - Disclosed is a microchip reaction detection system comprising: a microchip comprising a driving liquid injection unit into which a driving liquid for driving a solution is injected and a detection unit on which a substance to be reacted is supported and where the reaction between the substance and the solution is detected; a driving liquid pump for injecting the driving liquid into the driving liquid injection unit; an air pump for injecting a gas into the detection unit; and a control unit for controlling the driving liquid pump so that the driving liquid can be injected into the driving liquid injection unit and also controlling the air pump so that the gas can be injected into the detection unit intermittently in an amount at least effective for pushing away the solution injected in the detection unit while feeding the solution to the detection unit.12-02-2010
20100304500NANO-BIOSENSOR FOR BIOMOLECULAR RECOGNITION AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a nano-biosensor for detecting avidin bio-conjugated antibodies and a method of manufacturing the same. The nano-biosensor comprises a core made up of Zns: Mn nanoparticles. The core is surrounded by mercaptoelthanol molecules. Biotin is attached to the mercaptoethanol molecules surrounding the core. The ZnS:Mn nano particles with a size of 5-10 nm are prepared by quaternary W/O micro-emulsion method. According to one embodiment, a nano-biosensor comprises a nano particle of ZnS:Mn wherein the nano particle of ZnS:Mn includes ZnSO12-02-2010
20110236991Aptamer-Based Colorimetric Sensor Systems - The present invention provides an aptamer-based colorimetric sensor system for determining the presence and optionally the concentration of an analyte in a sample. Methods of utilizing the sensor system and kits that include the sensor also are provided. The sensor utilizes a linker and oligonucleotide functionalized particles to form an aggregate, which disaggregates in response to the analyte.09-29-2011
20100311185DETECTION METHODS - The invention relates to a method for quantitatively or qualitatively detecting an analyte in a sample, with the sample being incubated, for the purpose of avoiding, diminishing and/or detecting the high-dose hook effect, with an analyte-specific binding partner R12-09-2010
20100311188FEMALE FERTILITY TEST - The present invention is related to a diagnostic test kit that assesses ovarian reserve by measuring Follicle Stimulating Hormone (FSH) in a liquid sample. The sample can be deposited on a first portion of the device for transport to a second portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a test site, in fluid communication with the release medium and formed of a second, different material.12-09-2010
20100311186DEVICES AND METHODS FOR PERFORMING RECEPTOR BINDING ASSAYS USING MAGNETIC PARTICLES - The present invention provides methods, devices, and systems for performing receptor binding assays. In particular, magnetically responsive particles configured to form a complex with a labeled conjugate corresponding to one or more analytes of interest can be moved within an assay device to one or more discrete detection regions through the application of one or more magnetic fields. By positioning the detection region such that the direction of this movement is, for at least a portion of the movement, counter to the direction of fluid flow within the device, detection of assay signals can be performed without the need for separate wash steps. Moreover, contamination of the signals resulting from labeled conjugate being carried in the direction of fluid flow substantially reduced.12-09-2010
20130137189METHOD AND APPARATUS FOR PERFORMING A LATERAL FLOW ASSAY - An embodiment of the present invention provides a method for performing a lateral flow assay. The method includes depositing a sample on a test strip at an application region, detecting a first detection signal arising from the test strip in the first detection zone, and generating a baseline for the first measurement zone by interpolating between values of the detection signal outside of the first measurement zone and inside of the first detection zone. The method may include locating a beginning boundary and an ending boundary for the first measurement zone on the test strip. Additional detection zones having measurement zones may also be incorporated with the embodiment.05-30-2013
20130137190IMMUNOCHROMATOGRAPHIC DEVICE - The present invention provides an immunochromatographic device, which contains the following (a) and (b): (a) a first device part holding a first insoluble carrier used for developing a complex formed with an analyte and a labeling substance comprising a metal labeled with a first binding substance that can bind to the analyte and capturing the analyte and the labeling substance at a reaction portion containing a second binding substance that can bind to the analyte, and (b) a second device part holding a second insoluble carrier used for developing a liquid and a third insoluble carrier used for absorbing a liquid, in such a way that the first insoluble carrier does not come into contact with the second insoluble carrier and the third insoluble carrier.05-30-2013
20130137191METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker, NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule ceil injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.05-30-2013
20100311187ANTIBODY RECOGNIZING C-DOMAIN OF MIDKINE - It is intended to provide an antibody which inhibits the function of midkine. An antibody which recognizes an epitope consisting of amino acid residues 62 to 104 of midkine or a fragment thereof; DNA encoding the antibody or a fragment thereof; a recombinant vector which contains the DNA; a transformant which has the vector or a hybridoma which produces the antibody; a method for producing the antibody by allowing the transformant or hybridoma to produce the antibody or a fragment thereof and collecting the resulting antibody or fragment thereof; a pharmaceutical composition containing the antibody or a fragment thereof as an active ingredient; and a diagnostic agent containing the antibody or a fragment thereof as an active ingredient.12-09-2010
20110111525PRO-ENDOTHELIN-1 LEVELS FOR THE PREDICTION OF RISK OF TACHYARRHYTMIC EVENTS - The invention relates to in vitro methods for prognosis and risk-stratification for a patient having a cardiac disease as heart failure. The invention further relates to the use of such a method.05-12-2011
20130164860AFFINITY METHODS AND COMPOSITIONS EMPLOYING ELECTRONIC CONTROL OF PH - Methods and apparatuses for detection of target molecules are provided.06-27-2013
20110111529METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE - Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE. Specifically disclosed is a method for quantifying an antigen-specific canine IgE, which comprises the following steps (A) to (D): (A) contacting a biological sample collected from a subject with an antigen to conjugate IgE contained in the sample with the antigen; (B) measuring the quantity of IgE in a standard sample collected from an experimental animal which is different from the subject and has been sensitized with the same antigen as that used in step (A) by using a substance capable of recognizing both IgE from the subject and IgE from the experimental animal, thereby producing a standard curve; (C) detecting a conjugate formed in step (A) by using the same substance capable of recognizing both IgE from the subject and IgE from the experimental animal as that used in step (B); and (D) determining the quantity of IgE in the biological sample collected from the subject by utilizing the quantity of the conjugate detected in step (C) and the standard curve produced in step (B). Also specifically disclosed is a method for quantifying an antigen-specific human IgE.05-12-2011
20110111526PRO-ENDOTHELIN-1 FOR THE PREDICTION OF IMPAIRED PEAK OXYGEN CONSUMPTION - Subject of the present invention is an in vitro method for the alternative assessment of peak oxygen consumption (VO05-12-2011
20130164859DNA-DECORATED GRAPHENE CHEMICAL SENSORS - The present invention provides a broad response single-stranded DNA-graphene chemical sensor device. The present invention also provides methods for improving the ability of graphene to work as a chemical sensor by using single-stranded DNA as a sensitizing agent.06-27-2013
20090068758SYNTHETIC RECEPTOR - A polymer capable of selectively binding alfentanil is prepared from one or more suitable monomers (e.g. ethylene glycol methacrylate phosphate) and a cross-linker. It may be a molecularly imprinted polymer. An element (03-12-2009
20120270335REACTIVE POLYMERS FOR SOLID-PHASE EXTRACTION - Apparatus, methods and polymers for solid phase extraction by binding an analyte containing a primary amino group. The polymer is a reactive polymer, wherein binding of the analyte to the polymer causes fluorescent isoindole complex formation. A method of binding comprises use of an SPE carrier, such as an SPE cartridge, loaded with a reactive polymer. Binding of an analyte is detected by observing changes in fluorescence after applying the analyte to the polymer. Fluorescence can be detected using a fluorometer or transilluminator, for example. In a preferred embodiment, the reactive polymer is prepared from a monomer mixture comprising acetonitrile and triethylamine.10-25-2012
20110008911DIAGNOSTIC METHOD FOR DISORDERS USING COPEPTIN - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.01-13-2011
20090017556METHODS AND COMPLEXES INVOLVING IMMUNOGLOBULIN MOLECULE - A device that includes a proteinaceous factor is disclosed. The proteinaceous factor is encoded by the nucleotide sequence of any one of SEQ ID NO.: 1, a degenerate variant of SEQ ID NO.: 1, and a complement of SEQ ID NO.: 1. The proteinaceous factor may be a recombinant. In addition, the device may include any one of (i) Immunoglobulin G (IgG) bound non-specifically to the proteinaceous factor, (ii) at least one diagnostic label bound to the proteinaceous factor, (iii) Immunoglobulin G bound non-specifically to the proteinaceous factor and at least one diagnostic label bound to the proteinaceous factor, and (iv) at least one base supporting the proteinaceous factor.01-15-2009
20110033950TURBIDIMETRIC IMMUNOASSAY FOR ASSESSING HUMAN CYSTATIN C - There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved.02-10-2011
20110033951ASSAY METHOD AND KIT FOR NUCLEIC ACID BINDING PROTEIN - An object of the present invention is to provide a method of detecting a nucleic acid binding protein and a method of screening for a binding inhibitor or promoter for a nucleic acid binding protein. According to the present invention, there is provided a method of detecting binding between a nucleic acid and a nucleic acid binding protein, comprising determining the degree of structural change in a nucleic acid complex having at least two nucleic acid duplex moieties.02-10-2011
20100159615IMMUNOLOGICAL DETECTION METHOD USING AVIAN ANTIBODY - An object of the present invention is to provide an immunological detection method using an avian antibody, comprising suppressing a non-specific reaction caused by using an avian antibody. According to the present invention, there is provided an immunological detection method comprising detecting a target substance in a sample from a mammal using an avian antibody, characterized in that a non-specific reaction induced by the use of the avian antibody is suppressed.06-24-2010
20110111528MODIFIED POLYPEPTIDES STABILIZED IN A DESIRED CONFORMATION AND METHODS FOR PRODUCING SAME - The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation.05-12-2011
20110129943Method for Analyzing Proteins - A method for analyzing proteins makes use of an array of first capture molecules which are specific for peptide epitopes. The proteins to be analyzed or a protein mixture containing the proteins to be analyzed is degraded to peptide fragments corresponding to the peptide epitopes, after which the array of capture molecules is incubated with the peptide fragments. The peptide fragments bound to the capture molecules are then detected.06-02-2011
20100151590DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES THROUGH INDEL-DIFFERENTIATED PROTEINS - A compound capable of specifically binding to pathogen EF-1α but not host EF-1α, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.06-17-2010
20100151587Method of Assaying Antigen and Kit to be Used therein - By using an antibody which is covalently bonded to a water soluble polymer as an antibody to be used in a competitive immunoagglutination assay in a homogeneous system, a protein antigen at a high concentration can be accurately assayed in an undiluted system without resorting to dilution.06-17-2010
20120034708Sample Carrier for Effecting Chemical Assays - There is disclosed apparatus and a system for effecting testing on a sample, such as for medical testing. The apparatus includes a sample chip (02-09-2012
20110244595BIOMEDICAL CHIP FOR BLOOD COAGULATION TEST, METHOD OF PRODUCTION AND USE THEREOF - In a biomedical chip for blood coagulation tests and its manufacturing method and use, the biomedical chip comprises a substrate layer, a middle layer, and a cap layer, engaged and stacked with each other to define a microfluidic channel which has a first inlet and an outlet of the microfluidic channel respectively. A mixing interval is expanded outward from the microfluidic channel and interconnected to a second inlet, and has an interconnect portion and a capillary portion disposed between the substrate layer and the cap layer, and more specifically disposed around the periphery of the interconnect portion. With the biomedical chip having the substrate layer and cap layer made of a hydrophilic material, the blood and the reagent can be driven automatically by the capillary force of the microfluidic channel to flow and mix with each other, and the hydrophilic capillary force can be permanently maintained.10-06-2011
20110244594TARGET SUBSTANCE DETECTING METHOD AND TARGET SUBSTANCE DETECTING APPARATUS - A target substance detecting method employs a detecting chip equipped with a fine flow channel. Examinations, in which clogging of the flow channel and inhibition of immune reactions can be easily and expediently prevented without preliminary processes, are enabled to be performed without fluctuations in hemolysis rates. The detecting chip having a flow channel base having the flow channel and a detecting portion formed in the flow channel is employed. A liquid sample that may contain a target substance and contains cellular non target substances is caused to flow into the flow channel. An ultrasonic wave emitting section provided upstream of the detecting portion emits ultrasonic waves into the liquid sample from a direction perpendicular to the longitudinal direction of the flow channel such that a standing wave is generated within the flow channel.10-06-2011
20090258436Reagents for the Detection of Protein Phosphorylation in Signaling Pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.10-15-2009
20090325315DETECTION METHOD OF TARGET SUBSTANCE, DETECTION REAGENT USED FOR THE SAME, AND THE USES THEREOF - A new detection method, for detecting a target substance using formation of an aggregate due to binding of a target substance and a binding substance that binds thereto, that is excellent in detection accuracy, and sensitivity, and a new detection reagent used for the same are provided. Modifying substances having a maximum diameter of about 50 nm or less bind to a binding substance that binds to a target substance, and a modified binding substance is prepared as a binding reagent. A target substance in a sample is detected by bringing this modified binding reagent into contact with the sample, and optically detecting an aggregate that is formed by binding of the modified binding substance and the target substance in the sample. Preferably, the modifying substance includes biotin or a biotin derivative and further includes avidin or an avidin derivative, and the avidin or the avidin derivative binds to the biotin or the biotin derivative. Further, preferably, the biotin or the biotin derivative binds to the binding substance via a spacer.12-31-2009
20110212543METHOD FOR PREPARING AGGLUTINATABLE PLATELET FRAGMENTS AND THE USE THEREOF - The present invention relates to a method for preparing agglutinatable platelet fragments, in which native platelets are treated with ultrasound and a fixative. The platelet fragments are suitable for use in diagnostic assay methods which include an agglutination reaction, such as, for example, in a method for determining WWF activity.09-01-2011
20090311802Isolated Soluble IL-TIF/IL-22 Receptor or Binding Protein Which Binds to IL-TIF/IL-22 and Uses Thereof - The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.12-17-2009
20110124117SERS NANOTAG ASSAYS WITH ENHANCED ASSAY KINETICS - Methods and systems for the use of surface-enhanced Raman scattering nanotags (SERS nanotags) in various assay platforms which feature accelerated reaction kinetics. One embodiment includes a method detecting a substance of interest by associating a SERS nanotag with the substance of interest while accelerating the reaction kinetics of the association steps. This method also includes detecting a Raman spectrum of a reporter molecule associated with the SERS nanotag. The reaction kinetics of the assay may be accelerated by applying microwave radiation to the sample, heating the sample, agitating the sample, mixing the sample, vibrating the sample or other methods.05-26-2011
20100227414Affinity capture mass spectroscopy with a porous silicon biosensor - Affinity Capture-Mass Spectroscopy (AC-MS), an analytical technique which couples the sensitivity of a label-free binding detected biosensor, and the information richness of mass spectroscopy is described. A 3-dimensional porous silicon bio-surface is used to capture proteins, DNA, or small molecules while acquiring a label-free, time resolved signal linearly proportional to the amount of binding. A switch to dissociative buffer conditions then frees the captured molecule for analysis by mass spectroscopy. In particular, techniques for use with electrospray mass spectroscopy are described.09-09-2010
20110086437METHODS TO INHIBIT CELL GROWTH - A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization.04-14-2011
20110136258Multiplanar Lateral Flow Assay with Sample Compressor - A sample compressor applies pressure to a sample collector and a sample application zone of a test strip to transfer a sample from the sample collector and a binding partner of an analyte to the sample application zone in a lateral flow device. At least one of the binding partners of the analyte is not located on the test strip prior to use of the lateral flow device. The test strip may be a universal test strip with no molecule that specifically binds the analyte is located on the test strip. The sample compressor may be a universal sample compressor also with no molecule that specifically binds the analyte on the sample compressor. The lateral flow device may also include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone.06-09-2011
20110086434MICROFLUIDIC DEVICE AND METHOD FOR CONTROLLING FLUID FLOW USING THE SAME - A microfluidic device includes: a lower plate having a first channel; a first upper plate fixedly stacked on the lower plate and having grooves on an upper portion thereof, a fluid inlet and a fluid outlet formed at positions corresponding to both ends of the first channel; and a second upper plate movably inserted into the grooves of the first upper plate and including a second channel, a hole connected to a right end of the second channel, and a third channel connected to the right side of the hole.04-14-2011
20110091995Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - antigens that can be used to differentiate 04-21-2011
20100035360REAGENT FOR DETECTION OF AUTOANTIBODY AND KIT FOR DIAGNOSIS OF AUTOIMMUNE DISEASE - This invention is intended to discover a novel autoantibody that can be used as a marker for an autoimmune disease and to provide an effective means for diagnosing an autoimmune disease. Disclosed is a reagent for detecting an autoantibody comprising an inositol 1,4,5-trisphosphate receptor (IP02-11-2010
20090311803Treatment Of Tumors Expressing Mutant EGF Receptors - The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII.12-17-2009
20090311801Diagnostic Test to Exclude Significant Renal Injury - Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.12-17-2009
20090311800Ultrasound method - The present invention provides methods and apparatus for detecting the product of a reaction on a particle held at the pressure node of a standing wave. The methods and apparatus are particularly concerned with blood typing and the Coombs method.12-17-2009
20120244637METHOD AND SYSTEM FOR INTERACTION ANALYSIS - A method of determining one or more interaction parameters for the interaction between an analyte and a ligand using a biosensor, which comprises the steps of: A: providing a sensor surface having the ligand immobilized thereto, B: contacting the sensor surface with a control analyte, C: registering the sensor response from binding of the control analyte to binding sites of the ligand, D: determining the control saturation response (R09-27-2012
20120244636INCORPORATION OF METHYL LYSINE INTO POLYPEPTIDES - The invention relates to A method of making a polypeptide comprising at least one N09-27-2012
20120244634METHOD FOR DETECTION OF BASIC PEPTIDE AND REAGENT FOR DETECTION OF BASIC PEPTIDE - The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.09-27-2012
20120244633LIGHT-EMITTING INTRA-CAVITY INTERFEROMETRIC SENSORS - Light-emitting intra-cavity interferometric (ICI) optical sensors based on channel waveguide structures which include an internal light emitting material and a functionalized region. In some embodiments, the waveguides are made of a sol-gel which incorporates the light emitting material. In some embodiments, the waveguide structure includes an ICI resonator backbone and the ICI sensor is a laser sensor. In some embodiments, the resonator backbone has an interferometric Y-branch shape. In some embodiments, the resonator backbone has a Mach Zehnder interferometer shape. In some embodiments, an ICI laser sensor has an interferometric arrayed waveguide grating shape. In some embodiments, an ICI sensor may be remotely optically pumped and remotely read.09-27-2012
20120244631Apparatus and Method for Determining Microscale Interactions Based on Compressive Sensors such as Crystal Structures - Techniques for determining values for a metric of microscale interactions include determining a mesoscale metric for a plurality of mesoscale interaction types, wherein a value of the mesoscale metric for each mesoscale interaction type is based on a corresponding function of values of the microscale metric for the plurality of the microscale interaction types. A plurality of observations that indicate the values of the mesoscale metric are determined for the plurality of mesoscale interaction types. Values of the microscale metric are determined for the plurality of microscale interaction types based on the plurality of observations and the corresponding functions and compressed sensing.09-27-2012
20120244630MULTIPLEXED ANALYTE CONCENTRATION MEASUREMENT - Disclosed is a method of multiplexed concentration measurement of one or more analytes in a sample by means of electrical impedance measurements, the method comprises the steps of : providing the sample; providing a plurality of subsets of particles with capture molecules specific for at least one of the analytes, where the particles in each subset are distinguishable from the particles in the other subsets; mixing the sample with the subsets of particles, wherein the method further comprises the steps of: measure the change in the electrical impedance measurement, when the particles pass one or more sets of electrodes; determining the concentration of the one or more analytes by analyzing the electrical measurement change associated with the particles passing by the electrodes, where the concentration of the one or more analytes are determined based on a change in a property of the respective particles.09-27-2012
20120244629METHOD FOR PREDICTING HIGH-GRADE VESICOURETERAL REFLUX IN CHILDREN WITH A FIRST FEBRILE URINARY TRACT INFECTION - A method for predicting a high-grade vesicoureteral reflux in a patient includes the steps of measuring the serum concentration of procalcitonin in a biological sample, assigning a procalcitonin value, looking for a dilation of one or two ureters shown on an echographic image of a kidney, assigning an echographic value, and combining the values by two mathematical equations with the definition of a threshold above which the patient is considered at risk for vesicoureteral reflux. A kit including a device for measuring the procalcitonin concentration and device for measuring the cross-section of the ureter is described.09-27-2012
20100015725LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES - The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.01-21-2010
20100062540Method for Detecting Aggregate-Forming Circulating Protein Forms Using an Agent for Aggregating Said Forms and an Agent for Capturing Formed Aggregates - The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.03-11-2010
20110177617CROSS-LINKING REAGENTS FOR MOLECULAR INTERACTIONS ANALYSIS - The invention describes the use of particular cross-linking reagents containing 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole groups as reactive groups for cross-linking reactions of supramolecular target-ligand-complexes. The resulting cross-linked products may be directly analyzed using mass spectrometry, gel or fluorescence based technologies, X-ray crystallography, NMR or other analytical technologies. The method using High-Mass MALDI mass spectrometry provides various biological applications such as characterization of antibodies, drug discovery, and protein complex analysis including automated or higher throughput applications.07-21-2011
20100062541Adiponectin receptor and gene encoding the same - The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.03-11-2010
20110250702ISOLATED PEPTIDES OF RABBIT FACTOR VII - The present disclosure relates to peptides isolated from rabbit factor VII and to the use of thereof for the generation of antibodies specifically directed against the latter. The disclosure also relates to the use of antibodies directed against rabbit factor VII for the detection or purification of rabbit factor VII, specifically when said rabbit factor VII is in a biological sample which also contains human factor VII.10-13-2011
20110097818DEVELOPING SOLUTION FOR IMMUNOCHROMATOGRAPHY, AND MEASUREMENT METHOD USING SAME - Provided is a developing solution for immunochromatography that is precise and highly sensitive and is able to sufficiently detect even a low-concentration substance to be detected while controlling false positive reactions caused by non-specific adsorption of components other than the substance to be detected contained in a sample. The invention relates to a developing solution that contains a non-ionic surfactant and a vinyl-based water-soluble polymer having oxygen atom- and nitrogen atom-containing polar groups, for immunochromatography using a detection reagent labeled with an insoluble carrier.04-28-2011
20090215197TARGET SUBSTANCE CAPTURING MOLECULE - A capturing molecule having not less than two domains specifically binding to different sites of a target substance, wherein the not less than two domains comprise (1) a first domain having a hypervariable loop structure at a binding site to the target substance, and (2) a second domain having no hypervariable loop structure at a binding site to the target substance.08-27-2009
20090215195Set1 proteins and uses thereof - The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.08-27-2009
20100068824SENSING METHOD, SENSING DEVICE, INSPECTION CHIP, AND INSPECTION KIT - A sensing method comprises the steps of: allowing a liquid sample containing an analyte to flow through a channel, applying a force oriented in a given direction normal to a direction in which the liquid sample flows in the channel upon the analyte in a given position of the channel to move the analyte in the given direction so that the analyte is concentrated, causing the liquid sample to flow to a sensing surface forming a part of a wall surface of the channel located downstream of the given position and in the given direction against the channel, the sensing surface securing thereon a binding substance specifically reacting with the analyte, to allow the concentrated analyte to bind to the binding substance, and detecting a quantity of the analyte bound to the binding substance.03-18-2010
20100248391BIOSENSOR DEVICE AND METHOD OF DETECTING BIOLOGICAL PARTICLES - A biosensor device (09-30-2010
20110097817REACTION DEVICE FOR ANALYZING BIOLOGICAL SAMPLES AND RELATIVE METHOD - A reaction device and method provided with a reaction cell in which, in sequence, a plurality of biological samples, liquid, semi-liquid or mixed, of analogous or different type, are subjected to a reaction for a determinate analysis. The device comprises a first dispenser element which introduces a predetermined quantity of the biological sample inside the cell; a plurality of microvalve dispensers, each of which nebulizes a determinate microvolume of a desired reagent inside the cell, wherein the type of reagent and the amount of the microvolume of reagent are chosen as a function of the specific reaction to be carried out, selected from a group comprising reactions for analyses of a chemical-biological type, such as immunological or coagulative reactions, or of a chemical-physical type; a mixer element which mixes the biological sample with the selected reagent; a second dispenser element which sends to analytical measurement a determinate quantity of the biological sample after reaction with the selected reagent; washing members and discharge members, able respectively to wash the inside of the cell and to discharge the content of the cell, so as to prepare the cell for a subsequent reaction; an electronic processor which commands and controls, in the desired times and modes, the functioning of both the first dispenser element which dispenses the sample, of the microvalve dispensers which dispense the reagents, and of the mixer element, and also of the second dispenser element which sends the reacted sample for measurement, and of the washing members and discharge members, as a function of the type of reaction to be performed and the type of biological sample to be analyzed, so that their functioning is synchronized and automated according to pre-determined memorized reaction programs, selectable by an operator.04-28-2011
20110250704Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification - The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.10-13-2011
20110250700Methods for Sequencing Individual Nucleic Acids Under Tension - The invention provides apparatuses and methods of use thereof for sequencing nucleic acids subjected to a force, and thus considered under tension. The methods may employ but are not dependent upon incorporation of extrinsically detectably labeled nucleotides.10-13-2011
20110081731Method of Assaying Antigen and Reagent Therefor - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured.04-07-2011
20090023226Variant Integrin Polypeptides and Uses Thereof - Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the impaired form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in the high affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit that could be used therapeutically.01-22-2009
20100062542ANTIBODY AGAINST AFLATOXINS, SUPPORT USING THE ANTIBODY, METHOD OF IMMUNOLOGICALLY DETECTING AFLATOXINS AND METHOD OF CONCENTRATING AND PURIFYING AFLATOXINS - It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.03-11-2010
20110076782READ-AFTER-WRITE DETECTION OF ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES - Embodiments of the invention relate to magnetizing and detecting nanoparticle-labeled antigens on biosample tracks deposited on a tape media. An aspect of the invention comprises apparatus and methods for labeling antigens with demagnetized nanoparticles, magnetizing the nanoparticles with an electromagnetic write head, and detecting the antigens via the magnetized nanoparticles by reading the tape media with a read sensor in a read-after-write operation. The write head and read sensor are part of a head-module of magnetic tape drive. Target antigens are attached to the biosample tracks by antibodies. Nanoparticles of differing magnetic properties may be selectively paired with antibodies associated with different antigens to allow multiple antigens to be detected upon a single scan by the read sensor.03-31-2011
20110076781EXPANDING THE DYNAMIC RANGE OF A TEST STRIP - The present invention provides a test strip with an expanded dynamic range for performing an assay to determine the presence of, or measure the quantity of, an analyte in a sample. It also provides methods for determining the presence of, or measuring the quantity of, an analyte in a sample, and for detecting a prozone sample.03-31-2011
20110076783MULTI-DIMENSIONAL FLUID SENSORS AND RELATED DETECTORS AND METHODS - The present invention provides multi-dimensional sensors with fluidic flow channels for processing fluid samples.03-31-2011
20110151583METHOD FOR EVALUATING MYOCARDIAL ISCHEMIC STATE USING BLOOD SAMPLE - The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method. A method for determining myocardial ischemia comprising subjecting a blood sample which is derived from a test subject and which contains a BNP molecular group containing at least two selected from the group consisting of BNP 1-32 molecule, BNP 3-32 molecule, BNP 4-32 molecule, BNP 5-32 molecule, and a molecule having a mass number larger than that of BNP 5-32 molecule by 16 Da to a detection process capable of distinguishing and quantifying the individual BNP molecules different in mass number to detect the BNP molecular group, wherein myocardial ischemia in the test subject is determined using, as an index, a ratio between a detected intensity of at least one molecule selected from the BNP molecular group and a detected intensity of at least one other molecule selected from the BNP molecular group.06-23-2011
20120202299ILLUMINATION DETECTION SYSTEM AND METHOD - An optical analysis apparatus and method in which a detector provides two different signals, based on responses to incident light absorbed within the detector over different depths. These signals are processed to discriminate between incident light of two different frequencies and thereby determine the intensity of the light of one desired frequency.08-09-2012
20120149129LOW COST, PORTABLE SENSOR FOR MOLECULAR ASSAYS - An integrated sensor that is capable of discriminating the distance of a label from the sensor without using an optical signal. The label is attached to a single probe molecule or a group of probe molecules that interacts with a single or group of target molecules. As a consequence of this interaction, the probe molecule and/or the target molecule undergo a conformal change. This conformal change leads to perturbations in the distance of the label from the sensor. Thus, measurements and properties such as the concentration and the identity of one or more target molecules can be discerned from signals generated by the sensor (or by a plurality of sensors in a sensor array) and subjected to analysis using general purpose programmable computers programmed with suitable software that controls the analytical process, and such measurements and properties can be provided as a result of the analysis.06-14-2012
20110059550MINIMALLY INVASIVE ASSESSMENT OF IgE MEDIATED ALLERGY - A system and method for determining the presence and level of allergy indicators in a human fluid sample such as, but not limited to, blood serum and saliva, is disclosed. In another embodiment, the method may assess a level of allergens in a consumable product. The system and method may make use of functionalized magnetic nanoparticles that have modified surfaces suitable for attracting allergy indicators from human fluid sample and allergens from consumable products. The system and method may provide a minimally invasive assessment of allergy indicators to determine whether one is allergic to a substance.03-10-2011
20110008912Polymer-coated substrates for binding biomolecules and methods of making and using Thereof - Described herein are polymer-coated substrates for binding biomolecules and methods of making and using thereof.01-13-2011
20110250701NOVEL APPLICATION OF AIMP1 POLYPEPTIDE - The present invention relates to a novel use of AIMP1 polypeptide, more particularly to a composition for diagnosis of arthritis comprising an antibody against AIMP1, a kit for diagnosis comprising the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The present invention provides a composition for diagnosis of arthritis including an antibody against AIMP1 polypeptide as a novel diagnosis marker of arthritis, a kit for diagnosis including the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The composition, kit for diagnosis, method for diagnosis and antibody against the AIMP1 polypeptide may be used to diagnose arthritis early since they allow easy diagnosis of arthritis using a specimen from the patient.10-13-2011
20110045606METHOD FOR DETECTING A TARGET MOLECULE IN A BIOLOGICAL SAMPLE - A method is provided for detecting a target molecule in a biological sample. One step of the method includes immobilizing the biological sample on a membrane. Next, the membrane-bound biological sample is contacted with at least one detection moiety. The membrane-bound biological sample is then separately mated with a substrate and the target molecule detected. At least one step of the method is performed under positive pressure or a vacuum.02-24-2011
20100311189Novel Receptor Nucleic Acids and Polypeptides - Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.12-09-2010
20120231552DEVICE FOR A TEST STRIP HOLDER, METHOD AND ARRANGEMENT - For the simplified use of a test strip holder, a device having a holding or positioning device is provided, comprising a mixing chamber, a lid for closing the mixing chamber, and an obvious fluid opening for a fluid passage from the mixing chamber to the test strip holder. This allows for the test strip holder to be inserted into the device in a simple way and a sample can be prepared in the mixing chamber of the device. The device is provided with a mixing chamber that can be closed, wherein a reaction partner, for example a gold conjugate, can be dissolved in the sample for increasing the sensitivity of the test strip.09-13-2012
20100112724METHOD OF DETERMINATION OF PROTEIN LIGAND BINDING AND OF THE MOST PROBABLE LIGAND POSE IN PROTEIN BINDING SITE - The present invention proposes a method of structural design, search and selection of potential medicinal compounds—ligands, comprising prognostication of the value of the protein ligand binding in terms of the score calculated with the help of the scoring function developed for scoring, and prognostication of the most probable ligand pose in the protein binding site in terms of the score calculated with the help of the scoring function developed for docking (the docking function). It is proposed to use two absolutely different scoring functions for docking and scoring. A special procedure is proposed for the development of docking function. Use of two absolutely different functions in the process of docking and scoring principally distinguishes the proposed method of predicting the binding affinity of ligand-protein interaction from all the known methods and makes it possible to substantially improve the quality of said prediction.05-06-2010
20090023228Dual-acting Imidazole antihypertensive agents - The invention is directed to compounds having the formula:01-22-2009
20090023225Methods and devices for analyte detection - Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.01-22-2009
20090023224Vascular endothelial growth factor 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.01-22-2009
20110250703IL1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.10-13-2011
20080248588SHRIMP ALLERGEN, ANTI-SHRIMP ALLERGEN ANTIBODY, AND USE THEREOF - Provided is a novel shrimp allergen. The shrimp allergen of the present invention includes an isolated shrimp collagen or a polypeptide fragment thereof. According to the present invention, there is provided the novel shrimp allergen, and there are provided, using the allergen, an anti-shrimp allergen antibody, a method of detecting contamination of a shrimp allergen, an agent for detecting contamination of a shrimp allergen, a method of measuring sensitivity to a shrimp allergen, and an agent for measuring sensitivity to a shrimp allergen.10-09-2008
20120202297GENDER DETERMINATION METHOD - A non-invasive gender determination method and kits for accomplishing the same are disclosed herein. The present invention is based on difference in testosterone levels in the maternal body fluids of females carrying male fetuses relative to that of females carrying a female fetus. The present invention does not need specialized equipment and can quickly and rapidly detect the presence of testosterone in maternal urine or serum and thus indicate fetal gender. The kits and methods disclosed herein are useful for breeders of single-fetus mammals, veterinarians, and interested parents.08-09-2012
20110151579Secreted Epithelial Stromal-1 Molecules and Uses Thereof - The present invention provides novel Secreted Epithelial Colon Stromal-1 (Secs-1) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing Secs-1 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with Secs-1 polypeptides.06-23-2011
20120171781HIGHLY SENSITIVE IMMUNOASSAY WITH LARGE PARTICLE LABELS - The present invention is related to an immunoassay for the detection of an analyte in a sample, said assay comprising a plurality of moieties capable of binding to said analyte, wherein capture moieties which are not specific for the same epitope are bound to a solid substrate, and at least one epitope-specific detection moiety is bound to a detectable marker, and wherein the detectable marker to which the epitope-specific detection moiety is bound is a large particle marker having a particle size of ≧50 nm and ≦5000 nm.07-05-2012
20120171778FUNCTIONALIZATION OF NANOFLUIDIC CHANNELS - A functionalized nanofluidic channel and method for functionalization that provides control over the ionic environment and geometry of the nanofluidic channel with the immobilization of biomolecules on the inner surface of the channel and use of high ionic concentration solutions. In one embodiment, the surface charge of the nanochannel is controlled with the immobilization of a protein such as streptavidin in the nanochannel. In another embodiment, the biomolecules are receptors and changes in nanochannel conductance indicates ligand binding events. The functionalized nanofluidic channel can be easily adapted for use with microchannel arrays.07-05-2012
20090317920HAPTEN COMPOUND AND ANTIBODY - The present invention is a compound having a structure represented by the following formula (1):12-24-2009
20110151582METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES - Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.06-23-2011
20110151581TRIGGER ASSAY FOR DIFFERENTIATING BETWEEN RHEUMATIC AND NON-RHEUMATIC DISORDERS - The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject including determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of the autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject—either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit.06-23-2011
20120202296SYSTEM, METHOD, AND APPARATUS FOR MEASURING AFFINITY CONSTANTS - Nonlinear spectroscopic systems, methods, and apparatuses for measuring affinity constants of molecule-molecule reactions and/or for determining a maximum number of molecule-molecule complexes. Second harmonic generation (“SHG”) or sum-frequency generation is used to probe a sample. A magnitude of a net electric charge at a solid/water interface can be detected and used to determine characteristics of the molecule-molecule complex.08-09-2012
20110177611LIGAND BINDING DOMAINS OF NUCLEAR RECEPTORS IN CONTROLLABLE FORM AND METHODS INVOLVING THE SAME - The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.07-21-2011
20110177616Diagnostic Test Kits Employing an Internal Calibration System - A diagnostic test kit that employs a lateral flow assay device and a plurality of assay reagents for detecting a test analyte within a test sample is disclosed. The assay reagents include detection probes that are capable of producing a detection signal representing the presence or quantity of the test analyte in the test sample. To further enhance detection accuracy, calibration probes are also used that are capable of producing a calibration signal representing the presence or quantity of a calibration analyte. The calibration signal may be utilized to calibrate the detection signal.07-21-2011
20110212540Probe and method for DNA detection - A hybridization probe containing two linear strands of DNA lights up upon hybridization to a target DNA using silver nanoclusters that have been templated onto one of the DNA strands. Hybridization induces proximity between the nanoclusters on one strand and an overhang on the other strand, which results in enhanced fluorescence emission from the nanoclusters.09-01-2011
20110177615PROTEIN EXPRESSION - The present invention is concerned with improved expression of recombinant proteins, in particular fusion proteins, and methods for their expression. The present invention is also concerned with proteins for use in detection assays, and especially for directed surface immobilisation.07-21-2011
20110177612Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders - The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.07-21-2011
20110256640ASSAY FOR TROPONIN I USING MAGNETIC LABELS - The present invention relates to a method for measuring Troponin I in a sample comprising the steps of providing a sample, contacting the sample with a monoclonal anti-Troponin I antibody coupled to a magnetic label, contacting the sample with a polyclonal anti-Troponin I antibody coupled to a sensor surface and detecting the magnetic label on the sensor surface. The invention further relates to a device and a cartridge for measuring Troponin I in a sample.10-20-2011
20110256637Target Detection Using a Single-Stranded, Self-Complementary, Triple-Stem DNA Probe - Provided are novel single-stranded oligonucleotide probes that have a triple-stem configuration in the absence of target binding to the target binding sequence. The probes also have a fluorophore and a quencher. In the absence of target binding to the target binding sequence, these single-stranded oligonucleotide probes are capable of forming self-complementary duplexes such that the probe is in the triple-stem configuration and the fluorophore is positioned adjacent the quencher. In the presence of target binding to the target binding sequence, formation of the self-complementary duplexes is inhibited such that the probe is configured to position the fluorophore away from the quencher such that a signal of the fluorophore is detectable. Also provided are methods of using the probes.10-20-2011
20110256635SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.10-20-2011
20110256633Secretory Granules and Granulogenic Factors as a Target for Cancer Treatment - The present invention relates to a method for screening a cancer therapeutic agent, comprising the steps of: (a) contacting a test substance of interest with a cell containing a granulogenic factor-encoding nucleotide sequence; and (b) analyzing expression of the granulogenic factor or production of secretory granules, wherein the test substance is determined as the cancer therapeutic agent where it inhibits the expression of the granulogenic factor or the production of secretory granules. In the present invention, the expression of the granulogenic factor contributes to induction of secretory granule formation in non-secretory cells, and inhibition of the granulogenic factor expression leads to inhibition of secretory granule formation in secretory cells. In addition, the secretory granules produced by the present granulogenic factor change cell activities via the IP10-20-2011
20120276655DETECTION OF ANTIBODIES - The present invention relates to a method of detecting a target antibody, particularly a target autoantibody, in a sample, using a small molecule fluorophore-labelled target antigen, or a functional fragment, functional variant or functional derivative thereof that specifically binds to the target antibody. Detection is typically carried out using immunodiffusion or immunoelectrophoresis. The invention also relates to methods of diagnosing disease, particularly autoimmune disease, using small molecule fluorophore labelled target antigens and autoantigens. Small molecule fluorophore labelled target antigens, including autoantigens, are also disclosed, as are uses such.11-01-2012
20120276656Multiplexed Assay Methods - The present invention is directed to methods for conducting multiplexed assays. The methods are particularly well suited for measuring a plurality of analytes that may be present in very different abundances. The invention also relates to systems, devices, equipment, kits and reagents for use in such methods.11-01-2012
20120202298HTS Fluorescence Polarization Assay for Inhibitors of Keap1-Nrf2 Interaction - Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.08-09-2012
20120202295MATERIALS AND METHODS FOR ASSAY OF ANTI-HEPATITIS C VIRUS (HCV) ANTIBODIES - A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.08-09-2012
20080213916Allosterically Catalyzed Signal Amplification in Chemical and Biological Sensing - Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to the presence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed.09-04-2008
20110008908APPARATUS AND METHOD FOR SEPARATING AND ANALYZING BLOOD - An apparatus, comprising at least separating means (01-13-2011
20110008909Assay Device - Disclosed is an assay device for the determination of the presence and/or amount of a species in a liquid sample, the assay device comprising one or more reagents for providing an analyte of interest wherein the assay device further comprises a control species which is capable of interacting with the one or more reagents to provide a detectable control antigen.01-13-2011
20110263047PEPTIDE TAG AND USES THEREOF - The present invention provides a novel peptide tag, uses of the same and methods and systems for the purification of proteins. In particular, the invention provides the use of a beta-lactam (β-lactam) binding protein or fragment, analogue, homologue, variant or derivative thereof, as a tag or label.10-27-2011
20110256634SENSOR MEASURING METHOD AND SENSING APPARATUS - A method of performing a measurement with a sensor having a sensing surface and at least one capture molecule attached to the sensing surface for forming a binding pair with an analyte of interest, the binding pair having a flexible spatial orientation, the method comprising capturing the analyte of interest with the capture molecule, thereby forming the binding pair in an initial spatial orientation; applying a first electromagnetic force to the sensing surface to alter the spatial orientation of the binding pair; and performing a sensor measurement with the binding pair in the altered spatial orientation. A sensor apparatus implementing this method is also disclosed.10-20-2011
20110020950SCAFFOLD FOR COMPOSITE BIOMIMETIC MEMBRANE - Disclosed herein is a membrane scaffold comprising a planar material having a hydrophobic surface and a functional area comprising a plurality of apertures. The apertures have a diameter of from about 80 μm to about 3000 μm and the rims of the apertures comprise bulges extending above and/or below the surface level of the planar material. The membrane scaffold is useful in the preparation of a composite biomimetic membrane wherein functional channel forming molecules have been incorporated in said membrane.01-27-2011
20110053290LIGHT ADDRESSING BIOSENSOR CHIP AND METHOD OF DRIVING THE SAME - Provided is a biosensor chip. The biosensor chip includes a plurality of biosensor cells that are arranged in a matrix and selectively generate and output a sensed signal by addressing of external light, at least one sensing line that is simultaneously connected with the plurality of biosensor cells and transmits the sensed signal from one selected from the biosensor cells, and an output terminal that receives the sensed signal from the sensing line and outputs the sensed signal to an external reader. Thus, the biosensor cells are set in array in the biosensor chip without a separate driving unit, so that a process of manufacturing the biosensor chip is simplified. The biosensor cell to be sensed is selectively addressed through the external light, so that it is possible to reduce a price of the biosensor chip used as a disposable chip.03-03-2011
20110053289Assay Device and Method - An assay method and device can perform at least one (e.g., at least two) assays on a single aliquot of a sample liquid. The device can mix a sample liquid with assay reagents including magnetically susceptible particles. The device is configured to create a sample liquid-air interface with the sample liquid. The magnetically susceptible particles can be located (via an applied magnetic field) at the liquid-air interface when a second liquid contacts the interface to form a liquid-liquid interface. The magnetic particles travel across the liquid-liquid interface to the second liquid. The magnetically susceptible particles are configured to trans-port an analyte across the interface into the second liquid. An assay for the analyte is performed in the second liquid. An assay for another analyte can also be performed in the sample liquid.03-03-2011
20110027908DEVICE FOR DETECTION OF ANTIGENS AND USES THEREOF - Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.02-03-2011
20110027907SSL7 MUTANTS AND USES THEREFOR - The invention relates to SSL7 mutants which have no, or at least reduced, ability to bind to IgA. The mutants have significant application in the purification or isolation of C5 from samples and in the identification or detection, including quantitation, of C5 in samples. Use of the mutants has the benefit of minimising or preventing simultaneous isolation and/or detection of IgA in a sample, simplifying and improving methods relying on wild type SSL7.02-03-2011
20110027909Chimera Compositions and Methods of Use - This invention is directed to novel compositions, process methods, research tools, and use of these in the identification and development of novel therapeutic and/or diagnostic products. The compositions of the invention are chimera proteins that in essence recreate and/or potentiate one or more protein complex interactions that occur in vivo in the modulation of biological processes.02-03-2011
20110263045Method of Detection of Nucleic Acids With a Specific Sequence Composition - This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the use of nucleic acid Target Binding Assemblies to detect and localize specific Target Nucleic Acids. The detection and localization of the Target Nucleic Acid is accomplished even in the presence of nucleic acids which have similar sequences. The method provides for a high degree of amplification of the signal produced by each specific binding event. In particular, methods and compositions are presented for the detection of HIV and HPV nucleic acid in samples. These methods and compositions find use in diagnosis of disease, genetic monitoring, forensics, and analysis of nucleic acid mixtures. Some of the novel compositions used in the detection method are useful in preventing or treating pathogenic conditions.10-27-2011
20110263044DEVICE AND METHOD FOR THE AUTOMATIC DETECTION OF BIOLOGICAL PARTICLES - An apparatus and a method for automatic detection of particles, in particular, biological particles such as micro-organisms. The apparatus has a device for binding the particles to separating particles which can be bound selectively to the particles. The apparatus further includes a separating device for extraction of the separating particles with bound particles from a collecting fluid, and a detection unit for detecting a number and/or concentration of the particles separated in this manner. The device for binding the particles to the separating particles includes a collecting device for collecting a collecting fluid including the separating particles and the particles that are provided by a particle-fluid mixture.10-27-2011
20110263046Methods of identification of novel ligands for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (NR1F3) activity - The invention relates to modulators for the orphan nuclear receptor RORgamma and methods for identification and screening of novel modulators for RORgamma activity as well as methods for treating RORgamma mediated diseases with novel RORgamma modulators identified by such methods.10-27-2011
20100285607METHOD FOR DETECTING AND QUANTIFYING ANALYTES ON A SOLID SUPPORT WITH LIPOSOME-ENCAPSULATED FLUORESCENT MOLECULES - The present invention relates to an improved method for detecting and quantifying analytes on a solid support, with liposome-encapsulated fluorescent molecules.11-11-2010
20110104823MEASURING LIPOPROTEIN CONTAINING PARTICLES - This document provides methods and materials involved in assessing samples (e.g., serum samples) for lipoprotein containing particles. For example, methods and materials involved in using anti-apoprotein antibodies (e.g., fluorescently labeled anti-apoprotein antibodies) to label lipoprotein containing particles that can be detected or measured using flow cytometry are provided.05-05-2011
20110256639ASSESSMENT OF PROTEIN DEGRADATION BY MEASUREMENT OF ISOMERISED NEO-EPITOPE CONTAINING FRAGMENTS - A method of immunoassay for fragments of a protein such as type II collagen in a biological sample detects fragments having a first epitope containing an isomerised amino acid residue and a second epitope generated by cleavage of the protein by the use of respective antibodies binding each of the two epitopes.10-20-2011
20110256638DOWNWARD OR VERTICAL FLOW DIAGNOSTIC DEVICE AND ASSAY - A downward or vertical flow-through rapid diagnostic device and assay are provided. The device comprises a test area and reagent storage area, which are linked via a channel. The test area further comprises a reaction zone and an absorbent zone. A capture reagent is immobilized on the reaction zone to detect a target analyte in the fluid test sample. The fluid test sample flows downward or vertically through the reaction zone and into the absorbent zone, with the capture reagent and target analyte forming a two-membered complex that is concentrated in the reaction zone. The reagent storage area comprises a breakable cartridge positioned directly and vertically above the test area and a channel. A reagent used in the assay is housed in the breakable cartridge. Once liberated, the reagent passes through the channel and flows to test area for depositing on the reaction zone. The storage of predetermined amounts of reagents in the diagnostic device reduces the number of manual operations required to produce a result.10-20-2011
20110136254 ALZHEIMER'S DIAGNOSIS - Evaluation of VLP-I levels in combination with at least one of amyloid-β peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.06-09-2011
20110136256METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay.06-09-2011
20110136261METHOD OF ASSAYING COMPLEX AND KIT TO BE USED THEREFOR - In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analogue thereof and substance B or an analogue thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.06-09-2011
20110136260SNAPIN AND METHODS FOR REGULATION OF MICROTUBULE ASSEMBLY AND DENDRITE GROWTH AND BRANCHING - Fragments of snapin important for interaction with cypin and thus regulating microtubule assembly are provided. Also provided are methods of use of said fragments and kits to facilitate said methods.06-09-2011
20110136257Agglutination Based Sample Testing Device - A sample testing device for testing for the presence of a component of interest in a liquid sample comprises: (a) at least one capillary pathway which has an upstream end and a downstream end and which incorporates a reagent system capable of causing agglutination with said component to be detected (the test capillary); (b) preferably, but optionally, at least one capillary pathway having an upstream end and a downstream end (the control capillary); (c) a sampling region to which the liquid sample is applied and from which the sample is able to enter the upstream ends of the test capillary(s) and if present the control capillary(s); (d) a power source; (c) detection arrangements electrically associated with said power source for detecting the presence of liquid at a downstream region of said testing capillary(s) and if present the control capillary(s); (f) display means operated by said power source for indicating the result of the test; and (g) signal processing means associated with the power source, detection arrangement and display means for evaluating the result of the test and providing said result on the display means. The device may be used for a pregnancy test, more particularly for determining the presence of hCG in urine.06-09-2011
20110086436METHOD FOR DETECTING ANTIGEN, AND APPARATUS FOR DETECTING ANTIGEN USING THE SAME, AND MICROFLUIDIC CHIP USING THE SAME - A method for detecting an antigen, an apparatus for detecting an antigen using the same, and a microfluidic chip using the same are disclosed. The method for detecting an antigen, includes: binding a first antibody and nano-beads to generate antibody nano-beads; binding the generated antibody nano-beads and an antigen to generate antigen-antibody nano-beads; forming at least one of an electric field and a magnetic field on the generated antigen-antibody nano-beads to bind the generated antigen-antibody nano-beads and a second antibody; and detecting the antigen-antibody nano-beads bound to the second antibody. Thus, when nano-beads affected by an electromagnetic field exist within the electromagnetic field that temporally and spatially changes, the nano-beads move according to non-uniformity of the electromagnetic field. In particular, an active mixing can be performed by using the electromagnetic field which is spatially non-uniform and changes temporally, a reaction time can be reduced. In addition, a flow can be controlled to make nano-beads move to a capture antibody, thus detecting an antigen with a small amount of a test sample within a short time.04-14-2011
20100323455DIAGNOSTIC ASSAY FOR HUMAN MATRIX GLA-PROTEIN AND ITS USE AS A BIOMARKER - The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.12-23-2010
20100323456Endothelin Receptors in Morphine Withdrawal - The present invention relates to compositions and methods for managing opioid tolerance and reducing opioid withdrawal. More specifically, the present invention provides for endothelin, endothelin receptors, and endothelin receptor antagonists and agonists as a means for managing G-protein activity in the context of opioid tolerance and withdrawal.12-23-2010
20100330698DETECTION OF TARGET COMPONENTS WITH THE HELP OF INDICATOR PARTICLES - The invention relates to a system and a method for the detection of target components (12-30-2010
20100330696Method of diagnosing endometriosis in human subjects - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to EPP2 (SEQ ID NO:9) polypeptide or a peptide comprising an epitope of EPP2 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.12-30-2010
20110256636METHODS AND REAGENTS FOR DIAGNOSING RHEUMATOID ARTHRTIS - Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.10-20-2011
20100167417LONG WAVELENGTH THIOL-REACTIVE FLUOROPHORES - Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus.07-01-2010
20100167416Novel Boronate Complex and Its Use in a Glucose Sensor - A sensor comprises respective acceptor and donor compounds immobilised in or on a matrix including a glucose-binding boronate and a cationic species, whereby the spacing between the acceptor and donor compounds is reduced in the presence of glucose. For example a holographic sensor comprises a glucose-binding boronate and a cationic species held within the sensor.07-01-2010
20110086435DETERMINATION OF DISSOCIATION CONSTANTS USING PIEZOELECTRIC MICROCANTILEVERS - A method for determining the dissociation constant (K04-14-2011
20120034711Digital immunochromatographic test strip for semi-quantitative detection of aflatoxin B1 and preparation method thereof - The present invention belongs to the field of biological detection. Multi-line immunochromatographic test strip for semi-quantitative detection of aflatoxin B02-09-2012
20120034706METHOD FOR ASSESSING INFLAMMATORY CONDITION - Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor.02-09-2012
20110177613Use of periostin as a novel biomarker - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.07-21-2011
20090203150METHODS AND SYSTEMS FOR IDENTIFYING INSULIN MIMETICS - Methods are provided for identifying and selecting candidate molecules that activate glucose transport through binding of the insulin receptor at a site other than the insulin binding site. The methods include analyzing the properties of one or more candidate molecules in terms of the ability to bind the insulin receptor and activate glucose transport. Optionally the methods include, competitive assays in the presence of the glucose receptor, a candidate molecule, and one or more of insulin, alpha PGG and beta PGG.08-13-2009
20120208296DETECTION OF DIFFERENT TARGET COMPONENTS BY CLUSTER FORMATION - The invention relates to a method, a test kit, and an apparatus (08-16-2012
20120208295Methods and compositions for mass spectrometry analysis - Methods and compounds are provided to improve the desorption and ionization of analyte for mass spectrometry analysis. More specifically, it is for Electrospray ionization (ESI) mass spectrometry. The method uses charged affinity molecules that can bind with analyte either temporarily or permanently to improve the desorption and ionization of analyte. The charged affinity molecules can be positively charged or negatively charged.08-16-2012
20090176318BINARY DNA PROBE FOR FLUORESCENT ANALYSIS OF NUCLEIC ACIDS - The invention is directed to binary oligonucleotide probes for nucleic analysis, which probes can be made of DNA or RNA that recognize nucleic acid analytes (both DNA and RNA) with unprecedented high selectivity under mild conditions and are highly sensitive to single nucleotide mismatches (SNP single nucleotide polymorphisms) without PCR amplification. In one group, the binary probes indicate that they have hybridized to a particular nucleic analyte by binding to a molecular beacon that gives off a fluorescent signal. A second group of binary probes bind to a dye such as malachite green, where upon hybridization to analyte the fluorescence of the dye increases dramatically and is easily detected and measured. The new binary probes require only about five minutes at room temperature to generate a detectable signal.07-09-2009
20090176317Soluble B7-H1 - This document features methods of evaluating mammals by assessing expression of B7-H4 in the vasculature.07-09-2009
20090197347IMMUNOASSAY FOR PLASMODIUM FALCIPARUM AND ASSAY DEVICE USED THEREFOR - Disclosed are an immunoassay of 08-06-2009
20120309109METHOD FOR DETERMINING THE BINDING CONSTANT OF HIGH AFFINITY COMPOUNDS - The invention relates to a method for determining the binding constant of a compound of interest to proteins comprising the following steps: a) adding the high affinity compound to a two-chamber system, wherein the two chambers are separated by a semipermeable membrane, which is permeable for the compound of interest, and determining the amount of the high affinity compound of interest in one of the chambers after the distribution equilibrium has been reached, b) adding a sink compound to one of the chambers whereby the sink compound can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the sink compound after the distribution equilibrium has been reached, c) adding an unspecific protein to the other chamber, whereby the unspecific protein can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the unspecific protein in presence of a sink compound after the distribution equilibrium has been reached, and d) determining the binding constant of the test compound with the distribution coefficient of steps b) and c).12-06-2012
20120309110DIAGNOSTIC AGENT FOR URINARY PROTEIN OF CAT - A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 12-06-2012
20120309108MULTI-ANALYTE SYSTEM AND METHOD BASED ON IMPEDIMETRIC MEASUREMENTS - The invention discloses a system for the simultaneous detection and/or quantification of various analytes in a sample or for the simultaneous detection and/or quantification of an analyte in various samples, comprising: a multi-electrode chip (12-06-2012
20120309107Direct Sensing of Molecular Species by Polyfluors on a DNA Backbone - Nucleoside analogs are provided; and fluorescent sensors comprising the nucleoside analogs. The sensors comprise multiple chromophores built on a DNA backbone, in which all the natural DNA bases are replaced by excimeric or exciplex-forming fluorophores, ligands, quenchers and spacers in thousands of combinations. The sensors find use in the detection and identification of target analytes by fluorescence, e.g., detection of metal ions, neutral organic compounds and anions. The sensors find use in the detection and identification of molecular species in the vapor or gaseous phase, or the liquid phase. The sensors find use in qualitative and quantitative screening and detection methods.12-06-2012
20120309106DETECTION OF A TARGET IN A SAMPLE - The invention concerns a system, device, kit and method for detecting the presence, or concentration of a target in a sample. An assay set comprising at least two spaced apart electrodes is used, comprising a recognition moiety, capable of specific binding to the target, which is attached to at least one of the electrodes or the substrate therein between. If the recognition moiety binds the target then a conductive bridge can be formed between the electrodes, based on the complex between the recognition moiety and the target. The conductive bridge is formed by using nucleation-center forming entities attached to the complexes or to the targets from which a conductive substance is substantially grown. Alternatively the conducting bridge forms a conductive polymer between the electrodes.12-06-2012
20110189791Diagnostic Devices - The present invention relates to analytical methods, platforms, and devices for the rapid and efficient immunochromatic determination of one or more components in fluid samples.08-04-2011
20100190265FLUIDICS DEVICE FOR ASSAY - The present invention relates to a device for use in performing assays on standard laboratory solid supports whereon chemical entities are attached. The invention furthermore relates to the use of such a device and a kit comprising such a device. The device according to the present invention is adapted to receive one or more replaceable solid support(s) (40) onto which chemical entities (07-29-2010
20100190264Genetic Variants Increase the Risk of Age-Related Macular Degeneration - Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD, but it was not identified. We identified a strongly associated haplotype in two independent data sets. DNA sequencing of the complement factor II gene (CHI) within this haplotype revealed a coding variant, Y402II, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This identifies Complement factor II as involved in pathogenesis of AMD. This single variant alone is so common that it likely explains 43 percent of AMD in older adults. In addition, we have replicated and refined previous reports implicating a coding change in LOC387715 as the second major AMD susceptibility allele. The effect of rs10490924 appears to be completely independent of the Y402II variant in the CFH gene. The joint effect of these two susceptibility genes is consistent with a multiplicative model, and together, they may explain as much as 65% of the PAR of AMD. In contrast, the effect of rs10490924 appears to be strongly modified by cigarette smoking. Smoking and LOC387715 together may explain as much as 34% of AMD. Our data indicate that variant genotypes at rs10490924 confer a substantially larger AMD risk to cigarette smokers than non-smokers. This observation is supported by traditional case-control modeling, by ordered subset linkage analysis (OSA) incorporating pack-years of cigarette smoking as a covariate, and by family-based association analysis using a more homogeneous set of families as defined by OSA.07-29-2010
20100190267Miniature Chemical Analysis System - An apparatus, according to one aspect, may include a chromatograph and a bulk acoustic resonator. The chromatograph may include a channel that is defined at least partially in a monolithic substrate. The channel may have an inlet to receive a sample and an outlet. A chromatography material may be included in the channel. The bulk acoustic resonator may have a first electrode and a second electrode that has a chemically functionalized surface. The chemically functionalized surface may be included in a chamber that is defined at least partially in the monolithic substrate and that is coupled with the outlet of the channel. Methods of making and using such apparatus, and systems including such apparatus, are also disclosed.07-29-2010
20110189794IMMUNOASSAY WITH EXTENDED DETECTION WINDOW - The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse.08-04-2011
20110189793METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.08-04-2011
20110189792LIQUID-TRANSFER DEVICE PARTICULARLY USEFUL AS A CAPTURING DEVICE IN A BIOLOGICAL ASSAY PROCESS - A capturing device (08-04-2011
20110189789NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO - The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated.08-04-2011
20110263041COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF - In one embodiment of the present invention, a composition is disclosed for measuring a binding affinity between a nucleic acid and a test substance, which contains an organic fluorescent substance capable of binding to an RNA and which emits fluorescence having an intensity greater while the organic fluorescent substance is liberated from an RNA than while the organic fluorescent substance is bound to an RNA. This enables a highly accurate and easy measurement of a binding affinity between a test substance and a nucleic acid, and allows various substances to be examined as a test substance.10-27-2011
20110136259IMMUNOASSAY FOR CROSS-REACTING SUBSTANCES - The present disclosure provides an immunoassay involving a multiplex of antibodies that recognize the same analyte but that have a different cross-reactivity to structurally similar compounds. Data obtained from the immunoassay involving observed analyte concentrations is input into an algorithm to determine the true concentration of the analyte in a sample.06-09-2011
20110136255COMPOSITION AND METHOD FOR PREDICTION OF COMPLICATED DISEASE COURSE IN CROHN'S DISEASE - Methods of identifying Crohn's disease patients who may require early surgery and/or who are susceptible to developing complications during the course of disease. Anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies, both independently and combined, can serve as diagnostic and prognostic indices for Crohn's disease.06-09-2011
20100029013Methods for Detecting Asymmetric Dimethylarginine in a Biological Sample - The present invention provides methods of detecting asymmetric dimethylarginine (ADMA) in a sample, particularly a sample that may contain symmetrical dimethylarginine (SDMA) and/or arginine. The methods generally involve modifying any SDMA and arginine in the sample such that SDMA and arginine are readily distinguishable from ADMA; and detecting ADMA. The invention further provides antibodies specific for ADMA; antibodies specific for modified SDMA; and antibodies specific for modified arginine. The invention further provides kits for practicing the subject methods.02-04-2010
20100022024Method for testing performance of reagents containing microparticles - The present invention provides: a method of testing the performance of reagents containing microparticles by mixing a standard specimen containing two or more kinds of ligands with two or more kinds of microparticles containing receptors capable of specifically binding to the respective ligands and being optically distinguishable, and detecting the optical characteristics of the aggregates thus formed; a kit for detecting a specimen provided with the standard specimen and the microparticles as described above; a method of quantifying a specimen after testing the performance of reagents containing microparticles as described above, mixing a specimen containing two or more kinds of ligands capable of specifically binding to the respective receptors in the microparticles with the microparticles, detecting the optical characteristics of the aggregates thus formed, and then repeating the testing performance of reagents containing microparticles. Thus the present invention provides a performance test of reagents containing microparticles which is suitable for detecting a biological specimen such as a nucleic acid, a quantification method of a specimen which uses the performance testing method thereof and a specimen detection kit including the reagent.01-28-2010
20100022027GENE 763 OF PHYTOPATHOGENIC FUNGUS MAGNAPORTHE GRISEA AND USE THEREOF FOR IDENTIFYING FUNGICIDAL COMPOUNDS - The invention concerns a novel nucleic acid fragment of the genome of rice pathogenic fungus 01-28-2010
20100022028HUMAN OX2 RECEPTORS - Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof.01-28-2010
20100022025METHOD OF DETECTING HUMAN BETA-DEFENSINS - A method of detecting β-defensin in a bodily sample from a subject includes reducing the electrostatic interaction between β-defensin and negatively charged moieties in the bodily sample prior to detecting the β-defensin with an antibody or epitope binding fragment thereof.01-28-2010
20110217790Novel CD3 Epsilon Immunogens And Antibodies - The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides.09-08-2011
20100248390COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS - The present invention relates to compositions and methods for identifying odorant-odorant receptor interactions. In particular, the present invention relates to in silico methods for identifying odorant receptor-odorant interactions based on chemical and physical properties of odorant receptors and odorants.09-30-2010
20090104714VISUAL GLUCOSE SENSOR AND METHODS OF USE THEREOF - A method for determining the presence or amount of one or more ligands or analytes in a sample including contacting the sample with a biosensor having an environmentally-sensitive dye conjugated to a binding member, wherein the biosensor compound exhibits a detectable color change as a result of binding to the ligand or analyte or as a result of a change in concentration of the ligand or analyte in the sample. The presently disclosed biosensors can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples.04-23-2009
20100009464METHOD FOR THE QUANTITATIVE EVALUATION OF SEX HORMONES IN A SERUM SAMPLE - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different sex hormones in a serum sample, which can be used to evaluate different clinical situations. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antibodies used for the detection of representative sex hormones in a serum sample.01-14-2010
20090221098METHODS AND COMPOSITIONS FOR OBTAINING AND USING BIOLOGICALLY ACTIVE MULTI-PROTEIN COMPLEXES - Methods for isolating and using multi-protein complexes that are biologically active are provided. The complexes contain one or more proteins of interest (e.g. a receptor, ion channel, etc.) and associated scaffolding proteins such as phosphatases, kinases and post synaptic density components. Buffers that do not contain denaturing agents and which may be used to isolate the multi-protein complexes are also provided, as are protein arrays containing the biologically active multi-protein complexes. The protein arrays may be used, for example, for high throughput screening assays.09-03-2009
20100227418METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.09-09-2010
20100047922TURBIDIMETRIC IMMUNOASSAY FOR ASSESSING HUMAN CYSTATIN C - There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved.02-25-2010
20080311676IMMUNOASSAYS EXHIBITING REDUCED CROSS-REACTIVITY WITH HYDROPHOBIC DRUG ANALYTE METABOLITES - The present disclosure provides among other things immunoassays exhibiting reduced cross-reactivity with analyte metabolites. Additionally, the present disclosure provides diagnostic immunoassays to determine the concentration or level in a test sample of a hydrophobic drug that metabolizes in vivo or in vitro to form cross-reacting metabolites wherein cross-reactivity with such metabolites of the drug analyte is reduced. In particular, the disclosure provides such immunoassays where the hydrophobic drug is an immunosuppressant drug such as cyclosporine A.12-18-2008
20110045604MOLECULAR AFFINITY CLAMP TECHNOLOGY AND USES THEREOF - The invention provides a molecular affinity clamp. The architecture of the affinity clamp is modular with two biorecognition modules, each capable of binding a target motif. The first biorecognition module has a recognition domain that possesses inherent or natural specificity for the target motif. The second biorecognition module also has a recognition domain that binds the motif. The two biorecognition modules are tethered together either directly, e.g., via a peptide bond between the two modules, or indirectly, e.g., via a linker moiety or linker. The invention further provides a novel affinity ligand which is specifically bound by the molecular affinity clamps of the invention.02-24-2011
20110070662RAMAN-ACTIVE REAGENTS AND THE USE THEREOF - The present invention provides a new class of Raman-active reagents for use in biological and other applications, as well as methods and kits for their use and manufacture. Each reagent includes a Raman-active reporter molecule, a binding molecule, and a surface enhancing particle capable of causing surface enhanced Raman scattering (SERS). The Raman-active reporter molecule and the binding molecule are affixed to the particle to give both a strong SERS signal and to provide biological functionality, i.e. antigen or drug recognition. The Raman-active reagents can function as an alternative to fluorescence-labeled reagents, with advantages in detection including signal stability, sensitivity, and the ability to simultaneously detect several biological materials. The Raman-active reagents also have a wide range of applications, especially in clinical fields (e.g., immunoassays, imaging, and drug screening).03-24-2011
20110070663Method for the enrichment of phosphorylated and/or glycosylated analytes - The present invention relates to a method for the purification and isolation of phosphorylated and glycosylated analytes using titanium dioxide particles.03-24-2011
20110070661RAMAN-ACTIVE REAGENTS AND THE USE THEREOF - The present invention provides a new class of Raman-active reagents for use in biological and other applications, as well as methods and kits for their use and manufacture. Each reagent includes a Raman-active reporter molecule, a binding molecule, and a surface enhancing particle capable of causing surface enhanced Raman scattering (SERS). The Raman-active reporter molecule and the binding molecule are affixed to the particle to give both a strong SERS signal and to provide biological functionality, i.e. antigen or drug recognition. The Raman-active reagents can function as an alternative to fluorescence-labeled reagents, with advantages in detection including signal stability, sensitivity, and the ability to simultaneously detect several biological materials. The Raman-active reagents also have a wide range of applications, especially in clinical fields (e.g., immunoassays, imaging, and drug screening).03-24-2011
20110070657DETECTING IONS AND MEASURING ION CONCENTRATIONS - The present inventions include methods and compositions for detecting the presence of ions and measuring the level or concentration of ions in a sample by nuclear magnetic resonance (NMR) using magnetic particles. In particular, the inventions include the preparation and use of magnetic particles having synthetic ion chelators covalently bound to their surfaces. In the presence of target ions, the surface-modified magnetic particles form clusters, which can be monitored by NMR relaxation measurements. The relaxation times can then be used to detect specific ions and determine their concentration. The described methods, compositions, and devices are useful for a variety of applications including biomedical applications in diagnostics and imaging.03-24-2011
20110070660DETECTION OF POLYMERIC ANALYTES - The present invention relates to methods for detecting polymeric analytes, especially biopolymers, and sensors for detecting the polymeric analytes. The present invention uses magnetic beads in a rotating magnetic field to provide a visual detection of the presence of a polymeric analyte, such as nucleic acids, lipids, polysaccharides, proteins, etc. When a polymeric analyte binds to the magnetic beads, application of a rotating magnetic field to the beads results in unique pinwheel formations. Without the presence of the polymeric analyte, the movement of the magnetic beads induced by the rotating magnetic field differs significantly from the pinwheel formations. The pinwheel, therefore, is used to detect the presence of polymeric analytes.03-24-2011
20110070659SAMPLE PRESENTATION DEVICE - The present invention relates to sample presentation devices useful in performing analytical measurements. These devices have been configured to enable various aspects of liquid handling such as: retention, storage, transport, concentration, positioning, and transfer. Additionally, these devices can enhance the detection and characterization of analytes. The sample presentation devices of the present invention are comprised of one or more substrates having a plurality of zones of differing wettability. Methods of analyzing samples using the sample presentation device of the invention, as well as methods of making the sample presentation devices are disclosed.03-24-2011
20110070658SYSTEMS AND METHODS FOR DETERMINING THE PERCENTAGE OF GLYCATED HEMOGLOBIN - Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.03-24-2011
20110070656Fluorescent Proteins - A fluorescent protein (bFP) having chemiluminescence activity is a complex composed of the apoprotein of a calcium-binding photoprotein, coelenteramid or an analog thereof, and calcium ions or divalent or trivalent ions that can be substituted for the calcium ions. In the complex, the ratio of the number of molecules of the apoprotein to that of the coelenteramid is 1:1 and the ratio of the number of molecules of the apoprotein to that of the divalent or trivalent ions is 1:1 to 1:4. The fluorescent protein is used as a marker because it catalyzes luminescence of coelenterazine and has fluorescence capability. Removal of calcium ions etc. from this fluorescent protein (bFP) having luminescence activity provides a novel fluorescent protein (gFP). Mixing this gFP with the coelenterazine provides a calcium-binding photoprotein, which emit light instantaneously, enabling use as a marker.03-24-2011
20100009463Reagents for the detection of protein phosphorylation in signaling pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.01-14-2010
20090035875Cytochrome C And Leucine-Rich Alpha-2-Glycoprotein-1 Assays, Methods, And Antibodies - The present invention relates generally to assays and methods involving Cytochrome c (Cyt c) and leucine-rich alpha-2-glycoprotein-1 (LRG), and related antibodies. In an embodiment, the invention includes an isolated antibody produced by a hybridoma cell line having ATCC Accession Number PTA-8131, or antibody fragment thereof that specifically binds to leucine-rich alpha-2-glycoprotein-1. In an embodiment, the invention includes a hybridoma cell line producing such an antibody or antibody fragment. In an embodiment, the invention includes a kit including such an antibody. Other embodiments are included herein.02-05-2009
20100129929Tyrosine Phosphorylation Sites - The invention discloses 349 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.05-27-2010
20090203149ENHANCED METHODS FOR GAS AND/OR VAPOR PHASE ANALYSIS OF BIOLOGICAL ASSAYS - Processes for improved efficiencies as it relates to the analysis of small molecules whose concentration in the analysis solution is dependent upon the concentration of a target as determined through a liquid phase biological assays with vapor and/or gas phase analysis are disclosed. The process generally includes the competitive or non-competitive binding of target substances onto carrier particles functioning as substrates in the biological assay. Employing the carrier particles as substrates provides increased surface area for the reaction to occur; increased ease of washing steps; and allows for concentration of the increased surface area into a smaller reaction volume prior to introduction into the vapor and/or gas phase spectrometer such as an ion mobility spectrometer.08-13-2009
20090093066GLYCATED PEPTIDES AND METHODS OF USE - The invention provides glycated peptides and glycated fragments and glycated variants thereof, antibodies and aptamers which bind thereto, compositions and kits comprising the same, related conjugates, and a database comprising data indicating the concentration of glycated peptides present in diabetic and non-diabetic persons. The invention also provides a method of monitoring glycemic control, a method of treating or preventing diabetes, a method of preventing a complication of diabetes, a method of monitoring the status of diabetes, a method of determining the efficacy of a diabetes treatment, as well as methods of detecting diabetes or a predisposition thereto.04-09-2009
20090075394Voltage Sensor Domains of Voltage-Dependent Ion Channel Proteins and Uses Thereof - A composition of matter suitable for use in identifying chemical compounds that bind to voltage-dependent ion channel proteins, the composition comprising a screening protein that comprises an ion channel voltage sensor domain of the ion channel protein immobilized on a solid support.03-19-2009
20110306150ALLERGEN DETECTION METHOD USING IMMUNOCHROMATOGRAPHY - A method is disclosed which rapidly detect allergens with good accuracy by efficiently extracting the allergens from a test sample such as food containing various allergens and eliminating non-specific reactions accompanying the disintegration of colloidal gold conjugated to antibodies by not using a reducing agent. The method uses a developing solution containing at least 10% by weight of FBS in an immunochromatography method which comprises using a colloidal gold-labeled antibody in which a colloidal gold is bound to a monoclonal antibody against denatured and native allergen, a development support wherein a monoclonal antibody against denatured and native allergen recognizing an epitope different from that recognized by the colloidal gold-labeled antibody is fixed, measurement samples of the allergens extracted from the test sample with an anionic surfactant such as SDS and a thiosulfate or an anionic surfactant such as SDS and a non-ionic surfactant such as Tween 20, and the developing solution; developing the developing solution on the development support; and then detecting the allergens based on the presence of the deposition of the colloidal gold.12-15-2011
20110306151WESTERN BLOT BY INCORPORATING AN AFFINITY PURIFICATION ZONE - A mixture of components is flowed through a binding channel region comprising a component-binding moiety, thereby binding at least a portion of a component of interest. The mixture is then flowed through a separation channel region that includes a buffer comprising a detergent, resulting in separated components. Diluent is mixed with the separated components, diluting the detergent, and the separated components are detected. The component of interest is released from the component-binding moiety and flowed through the separation channel region. Diluent is mixed with the released component of interest, diluting the detergent, and the released component of interest is detected.12-15-2011
20110306149OBSERVATION APPARATUS AND OBSERVATION METHOD - An observation apparatus and an observation method capable of changing the stimulation position in accordance with the position and the shape of a cell and of observing the cell immediately after stimulation are provided. The observation apparatus 12-15-2011
20110306148COMPOSITION FOR USE AS AN ASSAY REAGENT - A composition for use as an assay reagent comprises a solid support comprising a member of a signal producing system and a coating of a synthetic copolymer. The synthetic copolymer comprises a first polymerized monomer comprising a pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and a second polymerized monomer comprising a pendant moiety comprising at least 1 carbon atoms and at least 2 heteroatoms. In some embodiments the copolymer comprises a polyethylenic backbone comprising the pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and the pendant moiety comprising at least 1 carbon atom and at least 2 heteroatoms.12-15-2011
20110027910SCREENING - A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular conformation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.02-03-2011
20090087923METHOD OF HIGH SENSITIVE IMMUNOASSAY - An object of the present invention is to provide a method of high sensitive immunoassay using immunoagglutination reaction by antigen-antibody reaction for quantification of thyroid stimulating hormone (TSH). The present invention provides a method of assaying a thyroid stimulating hormone (TSH) comprising assaying agglutination which is generated by contacting TSH with a carrier to which an anti-TSH antibody has been bound, wherein a plurality of types of anti-TSH antibodies that recognize different epitopes of TSH are independently supported on separate carriers, and each carrier on which a TSH antibody has been supported is brought into contact with a TSH-containing analyte with time intervals.04-02-2009
20100015724LYSINE ACETYLATION SITES - The invention discloses 332 novel acetylation sites identified in various cancers, peptides (including AQUA peptides) comprising a acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above.01-21-2010
20110111527MULTIMARKER PANEL FOR DIFFERENTIATION OF DILATED CARDIOMYOPATHY AND AS A BASIS FOR DIFFERENTIAL THERAPY - The present invention relates to a method for diagnosing if a subject suffering from dilated cardiomyopathy is suffering from ischemic or non-ischemic dilated cardiomyopathy. Further, it relates to a method of determining which medication is to be applied in a subject suffering form after dilated cardiomyopathy. The method includes the steps of determining amounts of troponin, GDF-15, and an angiogenic markers selected from the group of PlGF, endoglin, and sFlt-1 in a sample from the subject and comparing the amounts determined With reference amounts. In one embodiment, the method of the invention further comprises also measuring an amount of a natriuretic peptide.05-12-2011
20120231551Methods and Compositions to Detect Nucleic Acids in a Biological Sample - Kits, reaction mixtures and methods for separating a target nucleic acid from a sample by using at least one hairpin capture probe oligonucleotide that has the structure 5′-X.sub.n a′ b′ c′ Y.sub.n-3′, wherein X and Y each comprise nucleic acid sequences that can form a double stranded stem portion, one of X or Y is a capture sequence that is a first member of a specific binding pair and the other of X or Y is a terminal sequence of the hairpin capture probe, and a′ b′ c′ comprises a target-complementary sequence flanked by X and Y to thereby form a loop portion of the hairpin, thus forming a capture hybrid that is separated from other sample components before the target nucleic acid is released from the capture support and hybridized to a detection probe that hybridizes specifically to the same sequence that is at least partially hybridized by the a′ b′ c′ portion of the capture probe, thus forming a detectable detection hybrid to indicate the presence of the target nucleic acid in the sample.09-13-2012
20120301974Clozapine Immunoassay - Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.11-29-2012
20120301973CLOZAPINE IMMUNOASSAY - Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine and N-desmethylclozapine in biological fluids.11-29-2012
20100029012Method for identifying modulators of the NRF2-KEAP1-AREP pathway - A method for identifying modulators of the Keap1-NrG-ARE pathway is described. In particular, an assay is described that identifies molecules that inhibit the binding of a labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Molecules that inhibit the binding are activators of the Keap 1-Nrf2-ARE pathway. Activation of the Keap 1-Nrf2-ARE pathway may result in an increased accumulation of Nrf2 and the subsequent induction of protective enzymes, for example, the phase 2 detoxification enzymes. Activators of the Keap1-NrG-ARE pathway are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.02-04-2010
20090286328USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.11-19-2009
20100330697COMPLEXES OF TRPC DOMAINS AND SESTD1 DOMAINS AND METHODS AND USES INVOLVING THE SAME - The present invention relates to an isolated complex comprising a first protein comprising or consisting of a classical transient receptor potential channel (TRPC) or a functionally active variant thereof and a second protein comprising or consisting of the first spectrin (Spec 1) domain of SEC14 and spectrin domains 1 (SESTD1), a test system comprising the first protein and the second protein as well as means for detecting interaction of the first and the second protein, a method for screening for a TRPC modulator using the system and the use of the test system for the identification of a TRPC modulator.12-30-2010
20090124022ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.05-14-2009
20090098661Method for Determination of Sample Using Agglutination Reaction of Immunological Microparticle, and Kit for the Determination - A method for determining an analyte in a sample, includes the steps of: (a) mixing the analyte and a first specific binding substance, the first specific binding substance being a substance that can specifically bind to the analyte; (b) adding microparticles having a second specific binding substance bound thereto to a mixture obtained in the step (a) and mixing therewith, the second specific binding substance being a substance that can specifically bind to the first specific binding substance; and (c) determining an agglutination reaction of the microparticles in a mixture obtained in the step (b).04-16-2009
20120040476IMMUNOASSAY REAGENT FOR KL-6 ASSAY - The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized.02-16-2012
20120040475SENSING DEVICE FOR DETECTING A TARGET SUBSTANCE - The present invention relates to a sensing device (02-16-2012
20120040474Glycan-Specific Analytical Tools - Provided are lectenz molecules, which are mutated carbohydrate processing enzyme enzymes that are catalytically inactive and that have had their substrate affinity increased by at least 1.2 fold. Further provided are methods for making and methods of using such lectenz. Additional mutated proteins following the lectenz approach are further provided.02-16-2012
20120040473ANALYSIS OF SEVERAL TARGET ANTIGENS IN A LIQUID SAMPLE - A method of individually analyzing with a surface acoustic wave (SAW) sensor apparatus the presence or absence of at least two different target antigens in a liquid sample is described. The method comprises providing and running a single flow cell comprising a SAW sensor chip with at least two, e.g. twelve, SAW sensor elements, each comprising an individual coating immobilizing and exposing a modified antigen that has a weaker affinity for an antibody which is specific for one of the target antigens than the target antigen itself. Such a flow cell and surface acoustic wave (SAW) sensor chip for immunological displacement reactions are also disclosed.02-16-2012
20110091994Methods for Screening Compounds for Treating and/or Preventing an Hepatitis C Virus Infection - The present invention relates to methods for screening compounds for treating and/or preventing an Hepatitis C Virus (HCV) infection.04-21-2011
20090197348PYROCATECHOL VIOLET-METAL PROTEIN ASSAY - A method for protein determination utilizing a pyrocatechol violet-metal complex, a composition used in the protein determination assay, and a kit.08-06-2009
20090053830Blood Test Kit - A blood crossmatching apparatus, kit and methods for testing the compatibility of mammals for blood transfusion. Particulate layers in the apparatus allow nonagglutinated red blood cells to permeate through, while agglutinated red blood cells cannot. The apparatus also has a density solution. The density solution separates white blood cells from red blood cells in the whole blood when centrifuged, without lysing the red blood cells. Thus, the apparatus can be used to test whole blood.02-26-2009
20080233659PROCESS OF SCREENING FOR ALPHA-THALASSEMIA CARRIER USING IMMUNOCHROMATOGRAPHIC STRIP TEST - The invention provides a device and method for the rapid identification of patients suspected of having thalassemia. The invention provides a test strip for the aqueous detection of thalassemia related proteins in whole blood. The test strip includes antibodies specific to the gamma 4, (γ4) protein and provides easy visual discrimination between a positive result and a negative result. The invention can be used in remote or clinical settings.09-25-2008
20090061531DNA BINDING PROTEIN - Methods of screening for compounds which are, for example, capable of modulating amino acid-DNA interaction, modulating DNA replication, modulating cell proliferation, and for identifying compounds which inhibit cellular proliferation caused by cancer, are provided.03-05-2009
20090221096THIN FILM BIOSENSOR AND METHOD AND DEVICE FOR DETECTION OF ANALYTES - Thin-film biosensor chips for detecting a target analyte in a biological sample are disclosed. The chips include a solid substrate, an antireflective optical layer, an attachment layer using a non-polymeric silane, and an Fc-specific binding molecule coupled to the non-polymeric silane. Kits containing the chips and methods of using and making the chips are also disclosed.09-03-2009
20090181468Methods and compositions for treating cellular proliferative diseases - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders.07-16-2009
20090053829ABSORPTION PAD FOR IMMUNOASSAY, STRIP FOR IMMUNOASSAY AND IMMUNOASSAY APPARATUS - Providing an absorption pad which shows remarkable water absorptivity and can shorten a detection time when employed for an immunoassay apparatus. A water absorption pad for the immunoassay apparatus, containing 50% by weight or more of silicon-containing particles wherein a moisture absorptivity is 30% or less at a humidity of 60% or less and a moisture absorptivity is 40% or more at a humidity of 90% or more, a strip for an immunoassay using said absorption pad as a suction part, and an immunoassay apparatus including said strip for the immunoassay.02-26-2009
20120156805Assay For Immunosuppressant Drugs - The invention provides immunoassays for immunosuppressant drugs, wherein the assay is carried out under high salt conditions to achieve improved sensitivity. The invention also provides kits that are useful for performing the methods of the invention.06-21-2012
20120156802SWEPT-FREQUENCY SEMICONDUCTOR LASER COUPLED TO MICROFABRICATED BIOMOLECULAR SENSOR AND METHODS RELATED THERETO - An optoelectronic swept-frequency semiconductor laser coupled to a microfabricated optical biomolecular sensor with integrated resonator and waveguide and methods related thereto are described. Biomolecular sensors with optical resonator microfabricated with integrated waveguide operation can be in a microfluidic flow cell.06-21-2012
20110318847CVD ASSAY - An assay method and kit for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject.12-29-2011
20110318846Aptamer and detection method for C-reactive protein - An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g.12-29-2011
20090098660Method for the Purification of Antibodies - A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described.04-16-2009
20120208297COMPOSITION FOR USE AS AN ASSAY REAGENT - A composition for use as an assay reagent comprises a solid support comprising a member of a signal producing system and a coating of a synthetic copolymer. The synthetic copolymer comprises a first polymerized monomer comprising a pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and a second polymerized monomer comprising a pendant moiety comprising at least 1 carbon atoms and at least 2 heteroatoms. In some embodiments the copolymer comprises a polyethylenic backbone comprising the pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and the pendant moiety comprising at least 1 carbon atom and at least 2 heteroatoms.08-16-2012
20120045849SYSTEM AND METHOD TO MEASURE DISSOCIATION CONSTANTS - A system and method for determining the dissociation constant for a particular ligand is disclosed. In accordance with certain embodiments, the method creates a chemical denaturation curve of a protein in the absence of the ligand. A particular point is selected from this curve, such as the point at which 90% of the protein is unfolded. The molarity of chemical denaturant is determined for this selected point. A one point test is then performed for the protein with a predetermined concentration of the particular ligand. The fraction of protein which is unfolded at this point is then used to determine the dissociation constant for the ligand. This constant is used to quickly determine whether a particular ligard is well suited to be considered a potential drug candidate against that protein target.02-23-2012
20120045848PYRENYLOXYSULFONIC ACID FLUORESCENT AGENTS - The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention.02-23-2012
20120045847ASSAY FOR ANALYTES USING MULTIPLE RECEPTORS - A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample.02-23-2012
20120171780FLUORESCENT POLYMERS AND METHODS FOR SOLID-PHASE EXTRACTION - The apparatus of the present invention comprises a fluorescent polymer contained within a solid-phase extraction (SPE) carrier. The fluorescent polymer is capable of adsorbing an analyte by means of functional monomers. In use of the apparatus, a sample, such as a foodstuff sample, is applied to the fluorescent polymer. If the sample comprises the analyte, adsorption of the analyte onto the fluorescent polymer causes quenching of the fluorescence of the fluorescent polymer. Fluorescence quenching can be detected using a fluorometer or transillumination system. The method can be used to determine whether mycotoxins are present in foodstuff samples.07-05-2012
20120058572ANTIBODY AGAINST PERIOSTIN, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT FOR PREVENTING OR TREATING A DISEASE IN WHICH PERIOSTIN IS INVOLVED - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.03-08-2012
20120003750DETECTION OF ACTUATED CLUSTERS BY SCATTERING - A method for detecting clusters of superparamagnetic particles coated with a bioreactive agent is provided. A suspension of the superparamagnetic particles in a fluid to be analyzed is provided. The particles are allowed to form clusters due to an analyte present within the fluid and a magnetic field rotating at a given frequency is applied to the solution. Light is directed to the fluid and the amplitude of the intensity of scattered light at twice the frequency of the magnetic field is extracted. By determining the amplitude of the measured intensity of scattered light at twice the field depending on the frequency of the magnetic field a frequency-dependent measurement may be achieved. The frequency-dependent measurement may be used to determine the critical frequency of clusters, to distinguish clusters having different sizes or to measure the average value of the susceptibility and the spread of the susceptibility of the particles in the fluid. Furthermore, an apparatus for apparatus for detecting clusters of superparamagnetic particles is provided.01-05-2012
20120003755High Precision Scanning of Encoded Hydrogel Microparticles - Techniques are provided for high precision scanning of hydrogel microparticles. The high precision is achieved by one or more modifications to the microparticle composition, or microfluidics apparatus that align the microparticles in a detection channel, or method of preparing a sample for introduction into the apparatus, or some combination. An apparatus comprises a body structure having formed therein a central channel and multiple focusing channels in fluid communication with the central channel through multiple junctions. A width of the central channel is smaller in a portion downstream of each junction. A particle comprises a hydrogel matrix and a probe molecule. The particle has an aspect ratio greater than about three. A method includes loading into a sample fluid inlet a mixture, wherein a number of particles lies within a range from about 5 to about 10 particles/μl.01-05-2012
20120003753CHEMILUMINESCENT COMPOSITIONS, ENHANCING REAGENTS FOR CHEMILUMINESCENCE AND METHODS FOR THE PREPARATION AND USE THEREOF - A enhancing reagent for enhancing chemiluminescence of 1,2-dioxetane compounds and a method for using the enhancing reagent to enhance chemiluminescence are provided, in which the enhancing reagent contains a multi-alkyl quaternary ammonium salt of Formula I. A chemiluminescent composition with a 1,2-dioxetane compound as a substrate and a kit thereof are further provided, which contain a 1,2-dioxetane compound and a multi-alkyl quaternary ammonium salt of Formula I.01-05-2012
20120003751BIOMARKER FOR THE PREDICTION OF FIRST ADVERSE EVENTS - Subject of the present invention are assays and in vitro methods for the prediction of first coronary and cardiovascular events and biomarkers useful therein.01-05-2012
20120003749NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO 2,4,6-TRINITROPHENYL SKELETON, METHOD FOR DETECTING COMPOUND HAVING 2,4,6-TRINITROPHENYL SKELETON USING THE NUCLEIC ACID MOLECULE, AND USE OF THE NUCLEIC ACID MOLECULE - The present invention relates to a nucleic acid molecule capable of binding to a 2,4,6-trinitrophenyl skeleton, a method for detecting a compound having the 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, use of the nucleic acid molecule for detecting a compound having the 2,4,6-trinitrophenyl skeleton, and a method for detecting a compound having the 2,4,6-trinitrophenyl skeleton.01-05-2012
20120003754METHODS, PRODUCTS AND TREATMENTS FOR DIABETES - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.01-05-2012
20120208298METHOD FOR DETERMINATION OF MACROMOLECULAR MULTIMERS - A method of determining multimers of a macromolecule monomer in a sample containing the macromolecule comprises the steps of (i) determining the total concentration of macromolecule in the sample, (ii) determining by a biosensor-based detection method, especially mass-sensing, the active concentration of macromolecule in the sample, wherein physical characteristics of the macromolecule monomer are used, (iii) comparing the relationship of determined active macromolecule concentration to total macromolecule concentration for the sample with a corresponding relationship for an at least substantially multimer-free macromolecule-containing sample, and (iv) from a resulting difference determining the presence of multimers in the sample. The method may be used in the purification of macromolecules, such as proteins.08-16-2012
20120208294IMMUNODETECTION AND QUANTIFICATION OF PYRAZOLOPYRIMIDINE SEDATIVES - The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.08-16-2012
20120208293NOVEL METHOD FOR TESTING VASCULAR ENDOTHELIAL DAMAGE AND TESTING KIT - An object of the present invention is to provide a method which is capable of carrying out detection and evaluation of the vascular endothelial damage with a high degree of accuracy. According to an aspect of the present invention, there is provided a method for testing vascular endothelial damage with respect to a blood sample collected from living organism comprising the steps of: 1) detecting or determining quantitatively vascular endothelial cell-derived microparticle; and 2) detecting or determining quantitatively tissue factor-containing microparticle. Furthermore, according to another aspect of the present invention, there is provided a testing kit of vascular endothelial damage comprising a first antibody which specifically recognizes the vascular endothelium-derived microparticle, and a second antibody which specifically recognizes the tissue factor-containing microparticle.08-16-2012
20120208291METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) - Disclosed herein are methods and compositions relating to the detection and measuring of kinetic binding interactions.08-16-2012
20090162945INHIBITION OF GASC1 - The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry.06-25-2009
20100221844Caustic stable chromatography ligands - The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, 09-02-2010
20110065208DETERMINATION AND ESTIMATION OF ABSORPTION AND DISTRIBUTION OF SUBSTANCES IN BRAIN TISSUE - A method determines or estimates the absorption and partition of substances into brain tissue and parameters derivable therefrom, such as the permeability of substances through the blood-brain barrier and also, more particularly, the proportion of substances freely available in the brain. The partition coefficient of the corresponding substance between an aqueous phase and the lipid phase is determined with the help of lipid membranes which are preferably contained in a test kit and immobilized on a solid body as a carrier material. The partition coefficient can be subsequently used as a parameter in a QSAR model to determine the blood-brain partition coefficient.03-17-2011
20090215196Sequential Method - A method for determination of an analyte in an original liquid sample by performing an inhibition affinity assay in a microchannel structure of a microfluidic device. The main characteristic feature is the steps of: (i) providing the microfluidic device in a form where the microchannel structure comprises a reaction microcavity which a) an inlet end, and b) contains a solid phase with binding sites (BS) for an analyte or an analyte-related entity, (ii) providing a liquid sample (1) containing the analyte or the analyte-related entity within the microchannel structure at the inlet end of the reaction microcavity, and flowing sample (1) through the reaction microcavity under conditions such that the analyte or the analyte-related entity is captured by BS leaving a portion of BS unoccupied (free BS), (iii) providing a liquid sample (2) which contains an analytically detectable analogue of the analyte or of the analyte-related entity, and flowing sample (2) through said reaction microcavity to capture the analogue by free BS, and (iv) measuring the amount of analyte analogue captured in step (iii) and relating this amount to the amount of analyte in an original sample.08-27-2009
20120208290METHOD FOR ENHANCING MASS OF GOLD NANOPARTICLE THROUGH LIGHT-IRRADIATION, METHOD AND SENSOR FOR DETECTING MOLECULAR BINDING USING THE METHOD FOR ENHANCING MASS - Provided are a sensor for detecting molecular binding by increasing the mass of a gold nanoparticle through light-irradiation and a method thereof. In the method, light-irradiation increases the size of gold nanoparticles without using a reducing agent, to enhance the mass. Accordingly, selectivity may be improved, and the sensitivity of detection may be improved due to a change in various properties of a gold nanoparticle.08-16-2012
20110165698COMPOSITIONS AND METHODS RELATING TO DETECTION OF SOLUBLE E-CADHERIN IN NEURODEGENERATIVE DISEASE - Disclosed herein are compositions and methods for diagnosing, detecting, or monitoring neural disease, conditions, or disorders involving detection of soluble E-cadherin.07-07-2011
20110165699IRINOTECAN IMMUNOASSAY - Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.07-07-2011
20110165697MONOCLONAL ANTIBODIES AGAINST OSTEOPONTIN - The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.07-07-2011
20110165696Method to detect Beryllium by Flourescence - A method of determining beryllium or a beryllium compound thereof in a sample is disclosed by measuring fluorescence. This method discloses improved sample preparation methods, particularly for refractory beryllium materials. The method also discloses methods to improve the detection limit of beryllium including use of optical filters with specific characteristics for selecting the emission wavelengths of the fluorescence signal.07-07-2011
20110165700CLASSES OF COMPOUNDS THAT INTERACT WITH INTEGRINS - A method of inhibiting or effecting the activity of an integrin receptor comprises contacting an integrin with a pyranose of formula I, or a pharmaceutically acceptable salt thereof.07-07-2011
20110165701MONOCLONAL ANTIBODY AND IMMUNOASSAY USING THE SAME - An objective of the present invention is to provide an anti-human IgM monoclonal antibody that is capable of reacting specifically with human IgM and inducing immunoagglutination based on an antigen-antibody reaction with human IgM in solution, and an immunoassay using the said monoclonal antibody. Another objective of the present invention is to provide an agent for suppressing non-specific reactions caused by human IgM that could not be prevented by conventional methods, and an immunoassay in which non-specific reactions caused by human IgM are suppressed.07-07-2011
20120115249Biomarker for Selecting Patients and Related Methods - The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment.05-10-2012
20120115246MICROFLUIDIC DEVICE COMPRISING SENSOR - The invention relates to a microfluidic device for performing detection of a substance in a liquid sample, wherein a cavity (05-10-2012
20120115245ASSAYING SUBSTRATE WITH SURFACE-ENHANCED RAMAN SCATTERING ACTIVITY - A metal substrate obtained by agglomerating 5 nm to 100 nm metal nano-particles (including clusters) having SERS activity on a metal substrate having a lower electrode potential (higher ionization tendency) than the electrode potential of the metal nano-particles, and fixing the metal nano-particles in an optimally agglomerated state that acts as hot sites, when a detection specimen is adsorbed in a non-dried state, and a predetermined laser light is irradiated, the surface enhanced Raman scattered (SERS) light of antigen detection specimen can be detected by surface Raman resonance in an optimally agglomerated state.05-10-2012
20120115244MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS - Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and instructions for CMIA, neopterin comprising an Acr-labeled anti-neopterin Ab as a conjugate and instructions for IA, or Acr-labeled neopterin as a tracer and instructions for IA.05-10-2012
20120064637PREWETTING LATERAL FLOW TEST STRIP - A test strip and method for detecting an analyte present in a sample. The test strip comprising: a buffer addition zone to which a buffer may be added; an absorbent zone proximal to the buffer addition zone; one or more test zones distal to the buffer addition zone, at least one of the test zones including a first analyte binding agent immobilized therein which is capable of binding to the analyte to be detected; a terminal buffer flow zone distal to the one or more test zones, the absorbent zone being positioned relative to the buffer addition zone and having an absorption capacity relative to the other zones of the test strip such that when a volume of buffer within a predetermined buffer volume range for the test strip is added to the buffer addition zone, a distal diffusion front of the buffer diffuses from the buffer addition zone to a distal diffusion point within the terminal buffer flow zone and then diffuses proximal relative to the one or more test zones; and a sample addition zone distal to the terminal buffer flow zone to which a sample may be added.03-15-2012
20120021532Methods of Detecting and Treating Pulmonary Disease and Markers Thereof - The present invention relates to the treatment of pulmonary diseases. More specifically, the invention relates to new methods of detecting and treating chronic obstructive pulmonary disease (COPD). In particular, the invention relates to a method of measuring one or more lipid metabolites in human body fluids as an indicator/biomarker of the progress of chronic obstructive pulmonary disease. The present invention also relates to a method of detecting and/or monitoring chronic obstructive pulmonary disease in a subject, the method comprising measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD. The present invention also relates to a method of assessing the efficacy of a COPD treatment in a subject, the method comprising a step of measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD severity or status.01-26-2012
20110008910METHOD FOR THE IMMOBILIZATION OF A CAPTURE MOLECULE ON A SOLID SUPPORT - This invention is in the field of diagnostic assays, more in particular immunoassays wherein a capture molecule is immobilized on a solid support in order to capture an analyte. The invention relates to a method for the immobilization of a capture molecule on a solid support wherein the capture molecule is covalently attached to a biotin molecule to obtain a biotinylated capture molecule and wherein the biotinylated capture molecule is subsequently contacted with a high affinity binding member to form an capture molecule complex where after the capture molecule complex is contacted with the solid support.01-13-2011
20120058573INNOVATIVE BLOOD PLATELETS BIOMARKER FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention is directed to a method for early, non-invasive, rapid, efficient, reliable and accurate diagnose of Alzheimer's disease. The present invention particularly addresses obtaining blood samples, and stabilizing platelets from healthy persons and patients with probable cognitive impairment and/or Alzheimer's disease; extracting proteins from the platelets; identifying both monomeric and oligomeric tau proteins in the platelets with at least two monoclonal antibodies against the tau proteins, quantifying the amounts of the identified tau proteins, and comparing the amounts and protein profiles of the tau molecular species in the platelets of the healthy person and the patient.03-08-2012
20090239310KOKUMI-IMPARTING AGENT - The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.09-24-2009
20120064638SAMPLE PROCESSING APPARATUS AND SAMPLE PROCESSING METHOD - A sample processing apparatus for performing a process including a plurality of steps on a sample, the sample processing apparatus sequentially processing a plurality of samples, is disclosed. The apparatus comprises a plurality of units corresponding to the respective steps in the process; a transfer section which transfers a sample to the units according to a flow of the steps; and a controller. Specifically, when an operation was not performed successfully, the controller interrupts the process for a sample that had not reached the location where the unsuccessful operation was performed while continuing the process for a sample that had already passed the location, retries the operation that was not performed successfully, and resumes the interrupted process when the retried operation has been performed successfully.03-15-2012
20120064639STABLE ELASTOMERIC NEGATIVE ACOUSTIC CONTRAST PARTICLES AND THEIR USE IN ACOUSTIC RADIATION FIELDS - We describe methods for synthesis and formulations of stable elastomeric negative acoustic contrast particles with controllable compressibility and density. These elastomeric negative acoustic contrast particles have a density/compressibility ratio that is less than that of water and therefore exhibit negative acoustic contrast under acoustic radiation exposure. This negative acoustic contrast allows our elastomeric negative acoustic contrast particles to be acoustically manipulated (e.g. separated) differently from other components (e.g. cells) within an aqueous solution. This disclosure also describes methods for biofunctionalization of the elastomeric negative acoustic contrast particles and as an example their use as platforms for bioassays. Potential applications of these elastomeric negative acoustic contrast particles include sensitive bioassays based on acoustic flow cytometry and other types of techniques that utilize acoustic fields, including ultrasound imaging and ultrasound triggered drug delivery.03-15-2012
20110020951PURIFIED SR-P70 PROTEIN - The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.01-27-2011
20120070912DETECTION METHOD AND QUANTIFICATION METHOD FOR TARGET SUBSTANCE - Provided are a detection method and a quantification method for a detection target, which can detect and quantify the detection target rapidly, inexpensively, simply, and with high accuracy in a variety of environments. A method for detecting the detection target in a specimen includes processes in which there are mixed a first binding substance which binds a first material containing a stimuli-responsive polymer and a first affinity substance which has affinity for the detection target, a second binding substance which binds a hydrophilic second material and a second affinity substance which has affinity for the detection target, and a specimen; the resulting mixture is placed under conditions where the stimuli-responsive polymer agglutinates and the mixture is developed into a developing carrier, or the resulting mixture is developed into a developing carrier and the mixture is placed under conditions where the stimuli-responsive polymer agglutinates; the signal produced by the presence of the first binding substance or the second binding substance in the developing carrier is verified; and the presence of the detection target in the specimen is determined when the signal is different from that when the detection target is absent. The first affinity substance and the second affinity substance can bind to different positions of the detection target.03-22-2012
20120070911Method of Detecting and Quantifying Analytes of Interest in a Liquid and Implementation Device - The invention provides a method of detecting and quantifying analytes present in a solution, which is portable, rapid, inexpensive, selective and ultra-sensitive. For this purpose, the subject of the invention is a method of detecting and quantifying analytes of interest (03-22-2012
20120070910MICROANALYSIS METHODS AND SYSTEMS USING FIELD EFFECT TRANSISTOR - Provided is a microanalysis method and system using a Field Effect Transistor (FET). The microanalysis method includes a channel region having a receptor molecule fixed; forming a nano-particle conjugate in the channel region by supplying a sample for test and the nano-particle conjugate to the FET; growing a probe material on the channel region; and measuring a current flowing through the channel region, wherein the receptor molecule is a material that is selectively bonded to a target molecule in the sample for test.03-22-2012
20120070909LABEL-FREE METHOD FOR DETECTING PRESENCE OR ABSENCE OF NUCLEIC ACIDS - The present invention is directed to a method of detecting presence or absence of a target nucleic acid using negatively charged metallic nanoparticles dissolved in a solution. A nucleic acid probe with a substantially neutral net charge is used for detecting the target nucleic acid. The present invention is also directed to a kit including at least one nucleic acid probe with a substantially neutral net charge and at least one type of negatively charged metallic nanoparticles for carrying out the method.03-22-2012
20120070908IMMUNO CONJUGATE AND PROCESS FOR PREPARATION THEREOF - Present invention deals with a new immuno-reagent comprising hapten (MPAD)-protein-gold for pesticides detection. The conjugate MPAD-protein-gold competes with the analyte of interest for a finite number of binding sites provided by anti-atrazine antibodies coated on nitrocellulose membrane. The newly developed conjugate has a long shelf life with high stability at 4° C. The dynamic concentration range for standard atrazine solutions shows a linear inhibition (decrease in intensity of color) between 10 ppb to 1 ppm atrazine in water samples.03-22-2012
20120156804METHOD FOR DETERMINING PROTEIN-NUCLEIC ACID INTERACTION - The present invention refers to a method of determining protein-nucleic acid interaction. The method comprises mixing a protein with a sample comprising a nucleic acid which is suspected to interact with the protein to form a first mixture. The first mixture can be incubated to allow interaction between the protein and nucleic acid. Metallic nanoparticles are added to the first mixture to obtain a second mixture. An electrolyte is added to the first or second mixture to determine the protein-nucleic acid interaction. The present invention also refers to a kit for determining protein-nucleic acid interaction. The kit comprises a protein capable of interacting with a nucleic acid or a nucleic acid capable of interacting with a protein, and at least one type of metallic nanoparticle.06-21-2012
20120156803BIOLOGICALLY-ACTIVE RADIOLABELED CRY1FA AND RECEPTOR BINDING ASSAY METHODS - Cysteine-specific radiolabeled Cry1Fa protein retains insecticidal activity against insect pests and binds to insect brush border membrane vesicle receptors in a saturable manner. The biologically-active radiolabeled Cry1Fa protein is useful in competitive binding assays with other Cry toxins.06-21-2012
20110008913TUMOR SUPPRESSOR GENE - A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) was also isolated. The colony forming activity of cells exogenously expressing Gros1-L was significantly reduced, while that of cells expressing Gros1 antisense RNA was significantly increased.01-13-2011
20090023227METHOD - The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention.01-22-2009
20090258434FLUORESCENT PROBE FOR PEROXYNITRITE - A compound represented by the following general formula (I):10-15-2009
20100120171CIRCULATING VE-CADHERIN AS A PREDICTIVE MARKER OF SENSITIVITY OR RESISTANCE TO ANTI-TUMORAL TREATMENT AND IMPROVED METHOD FOR THE DETECTION OF SOLUBLE PROTEINS - The application relates to improved means for the detection of soluble protein(s), such as soluble angiogenesis-related protein(s), more particularly circulating VE-cadherin. These means notably comprise the dilution of the fluid sample (e.g., serum or plasma sample), before submitting it to protein detection. Said dilution is advantageously diluted in a surfactant-containing solution. The improved means of the invention enabled to determine that circulating VE-cadherin is a reliable prognostic marker of the sensitivity or resistance to anti-tumoral treatment. It is believed that prior art sVE-cadherin detection means did not enable such determination.05-13-2010
20110091993METHOD FOR QUANTIFICATION OF SOLUBLE LR11 - Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.04-21-2011
20110091992CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT - The present invention provides crystalline forms of a human IgG Fc variant comprising one or more amino acid residues that provides for enhanced effector function, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them. The present invention also provides human IgG Gc variants with reduced binding to at least one FcγR.04-21-2011
20110091991Protein Biomarkers for Alzheimer's Disease Detection - Protein biomarkers are selected for diagnosing Alzheimer's disease. Samples of Alzheimer's disease are used to find the biomarkers. It is done through methods including 2-dimentional differential in-gel electrophoresis (2D-DIGE), isotope-coded protein labeling (ICPL) and western blotting. Through examining density differences of the selected biomarkers, Alzheimer's disease can be early diagnosed or prevented.04-21-2011
20110091997IMMUNOSUPPRESSANT DRUG EXTRACTION REAGENT FOR IMMUNOASSAYS - An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays.04-21-2011
20110091996ORGANIC NON-SUGAR COMPOUNDS FOR PROTECTION OF BIOLOGICALLY ACTIVE MOLECULES AND CONJUGATE LABELS AND METHODS OF USE THEREOF - Provided are methods comprising the use of non-sugar organic compatible solutes for protection and preservation of the activity of biologically active molecules and conjugate labels. The methods are particularly adaptable for use in conjunction with immunoassays, such as for example, immunochromatographic test assays and may be incorporated into any test methodology wherein a dry test strip is used as a carrier for depositing, mobilizeable and/or immobilized biologically active molecules and/or conjugate labels.04-21-2011
20120107955METABOLITE BIOMARKERS FOR THE DETECTION OF ESOPHAGEAL CANCER USING MS - Results of studies of nucleosides in biofluid specimens from patients with esophageal adenocarcinoma and related disorders have identified five biomarkers of the conditions: 1-methyladenosine, N05-03-2012
20110065209Integrated Sample Preparation and Analyte Detection - A system for sample preparation and analyte detection includes a cartridge, with a fluidic channel, a waveguide, and a capture spot. The system further includes a force field generator, an imaging system, and a fluid, which includes a sample potentially containing a target analyte, first type particles, which include binding moieties specific for the target analyte and are responsive to a force field, and second type particles, which include binding moieties specific for the target analyte and are capable of generating a signal. When the sample contains the target analyte, specific binding interactions between the target analyte and binding moieties link first and second type particles via the target analyte to form multiple-particle complex capturable at a capture spot. The force field allows manipulation of the particles and multiple-particle complex such that the detected signal from the second type particles is indicative of the target analyte within the sample.03-17-2011
20110065211DEVICE AND METHODS FOR DETECTING ANALYTES IN SALIVA - The invention provides a device for detecting drugs of abuse or other compounds in saliva. The invention thus provides a device for detecting the presence of one or more analytes in a saliva sample, comprising: (a) One or more pre-treatment regions for specifically or non-specifically removing at least a part of the fraction of the saliva sample interfering with detection of the one or more analytes; and (b) A detection region comprising a biosensor surface, the surface comprising: molecules capable of specifically binding the one or more analytes; or the one or more analytes and/or analyte analogues.03-17-2011
20110065207COMBINATORIAL MULTIDOMAIN MESOPOROUS CHIPS AND A METHOD FOR FRACTIONATION, STABILIZATION, AND STORAGE OF BIOMOLECULES - A new fractionation device shows desirable features for exploratory screening and biomarker discovery. The constituent MSCs may be tailored for desired pore sizes and surface properties and for the sequestration and enrichment of extremely low abundant protein and peptides in desired ranges of the mass/charge spectrum. The MSCs are effective in yielding reproducible extracts from complex biological samples as small as 10 μl in a time as short as 30 minutes. They are inexpensive to manufacture, and allow for scaled up production to attain the simultaneous processing of a large number of samples. The MSCs are multiplexed, label-free diagnostic tools with the potential of biological recognition moiety modification for enhanced specificity. The MSCs may store, protect and stabilize biological fluids, enabling the simplified and cost-effective collection and transportation of clinical samples. The MSC-based device may serve as a diagnostic tool to complement histopathology, imaging, and other conventional clinical techniques. The MSCs mediated identification of disease-specific protein signatures may help in the selection of personalized therapeutic combinations, in the real-time assessment of therapeutic efficacy and toxicity, and in the rational modulation of therapy based on the changes in the protein networks associated with the prognosis and the drug resistance of the disease.03-17-2011
20110065204ASSESSING RISK OF CARDIAC INTERVENTION BASED ON GDF-15 - The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and/or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.03-17-2011
20110065210Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes - The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.03-17-2011
20110065205METHOD FOR DETERMINING PROGNOSIS OF ACUTE CENTRAL NERVOUS SYSTEM DISORDER - The present invention has its main object of providing a method for determining prognosis scientifically by searching an early marker for predicting neurological prognosis in order to grasp the disease state of a patient with an acute central nervous system disorder in the early stage and enabling an appropriate treatment to be performed. The method for determining the prognosis is provided in which the expression level of SH3BGRL3 in the biological fluid of the patient within 48 hours after resuscitation from cardiopulmonary arrest is measured, and the prognosis of the disorder classified into a good prognosis group and a poor prognosis group depending on the expression level or the presence or absence of the expression based on the Glasgow Outcome Scale (GOS) is predicted.03-17-2011
20110065212GRAFT POLYMER-CONTAINING SUBSTRATE, METHOD FOR PRODUCING THE SAME, TARGET SUBSTANCE-DETECTING ELEMENT, AND TARGET SUBSTANCE DETECTION KIT - There is provided a graft polymer-containing substrate that reduces nonspecific adsorption of impurities onto a substrate surface and specifically captures a target substance. There is provided a graft polymer-containing substrate with a graft polymer formed on the surface thereof, characterized in that the graft polymer includes monomer units represented by the following general formulas (1) and (2):03-17-2011
20120252138Methods and Related Devices for Continuous Sensing Utilizing Magnetic Beads - Provided is a fluidic device including a main channel, wherein a first inlet fluidly connects to an upstream end of the main channel and introduces magnetic beads into a first side of the main channel. A second inlet is fluidly connected to the upstream end of the main channel and introduces a sample stream into a second side of the main channel. A magnet disposed adjacent to the second side of the main channel pulls the magnetic beads towards a sidewall of the second side, and thus into the sample stream. The beads continue through an extended incubation channel before entering a return channel. The return channel includes a detection region. Also provided is a multi-layer micro-fluidic assay device. An assay method that utilizes a microfluidic assay device is provided as well.10-04-2012
20120252137Fluorescence Polarization Assay For Bacterial Endotoxin - The present invention comprises methods of detecting and quantifying bacterial endotoxin by using a tracer or a fluorescently labeled polymyxin wherein fluorescent tags include bodipy, NHS-fluorescein, FITC, 5-carboxyfluorescein, boron dipyrromethene, or tetramethylrhodamine. The polymyxins utilized include polymyxin B10-04-2012
20110104822Determination of Distribution - A method for determining the occurrence of an analyte subpopulation of heteroforms of a substance (=S) in a liquid sample. The method comprises as its main characteristic features the step of: (i) providing a flow path which a) comprises an outlet part and an inlet part, b) comprises a capture zone (CZ) containing a solid phase exhibiting an immobilized analyte specific binder (B) [=affinity counterpart to the substance] which is capable of affinity binding to S with an affinity that differs for the various heteroforms of S, and c) permits capillary suction from the outlet part for driving a liquid flow through CZ, (ii) flowing said liquid sample containing S in the downstream direction through CZ while S is captured by said binder B in CZ, (iii) determining the distribution of S along the flow direction in CZ by measuring the relative amount of S in at least one subzonei of CZ, and (iv) determining the occurrence of the analyte subpopulation based on the distribution determined in step (iii).05-05-2011
20110104821ABeta-OLIGOMER MEASUREMENT METHOD - Provided is a measurement method of an Aβ oligomer by the ELISA method, particularly, a method of selectively measuring an Aβ oligomer with a comparatively high molecular weight.05-05-2011
20110104818CARBAMYLATED PROTEINS AND RISK OF CARDIOVASCULAR DISEASE - Methods for characterizing a test subject's, particularly a human test subject's, risk of having cardiovascular disease or developing cardiovascular disease are provided. Also provided are methods for characterizing a test subject's risk of experiencing a complication of cardiovascular disease near term. The methods comprise determining levels of one or more carbamylated biomarkers in a bodily fluid of the test subject and/or comparing these levels with a reference value. In certain embodiments, the carbamylated biomarkers are carbamylated albumin, carbamylated fibrinogen, carbamylated immunoglobulin and carbamylated apolipoprotein A. In other embodiments, particularly where the test subject does not have clinical evidence of renal disease, the carbamylated biomarker is free and/or total peptide-bound homocitrulline.05-05-2011
20110104820Tyrosine, Serine, And Threonine Phosphorylation Sites - The invention discloses 94 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies that specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.05-05-2011
20110104819Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children - The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. Children of this age group are also prone to nasopharyngeal colonization with the same bacteria, and urine samples taken from colonized, but otherwise healthy, children were shown to exhibit an unduly high incidence of test results that were false positive for the presence of disease.05-05-2011
20120122234FLUIDIC INDICATOR DEVICE - Disclosed is a fluidic assay device for assaying at least one property of a liquid sample comprising: a liquid sample application region; at least one test flow path in liquid flow communication with the sample application region; a reference flow path in liquid flow communication with the sample application region; and a junction region, at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid; wherein a liquid flowing along the reference flow path, upon reaching the junction region, has the effect of preventing the flow of liquid along the test flow path. The invention relates to a fluidic device for the passage of a liquid and an assay device suitable for measurement of the amount and/or presence of an analyte in, or property of, a fluid sample.05-17-2012
20120122244Method Of Identifying Compounds That Inhibit Fertilization - A method of identifying compounds that inhibit fertilization is provided. The method can include selecting compounds that bind to equatorin protein. Two types of equatorin protein, a long form and a short form, can be present in the testis. The amino acid sequence of mouse equatorin from positions 101 to 146 including the 138th O-glycosylated threonine residue contains an epitope recognized by anti-equatorin antibody MN9 that has an effect of inhibiting fertilization. In addition, the MN9 antibody also binds to human sperm. Compounds that bind to the epitope can inhibit fertilization. Both forms of mouse equatorin can be used as well as human equatorin to identify compounds that inhibit fertilization.05-17-2012
20100093106Amine-Reactive Biosensor - Described are methods, articles of manufacture, and kits for coupling an analyte-binding molecule to the surface of a biosensor through formation of amide bonds. One amide bond is formed between a first carboxyl group on a polymer and a first reflecting surface comprising an aminoalkyl moiety. A second amide bond is formed between a second carboxyl group on the polymer and an amine group on an analyte-binding molecule to be coupled. The present invention thus provides for covalent attachment of the analyte-binding molecule to the biosensor, thus providing advantages over non-covalent attachment methods of the prior art. These advantages include the ability to couple without using bio tin (which, in some instances can alter functional properties of a molecule) the ability to improve the fidelity with which a binding or dissociation reaction that takes place on the surface of the biosensor represents a solution phase reaction, and the ability to regenerate the sensor by stripping ligands from the covalently bound analyte-binding molecule.04-15-2010
20120315706LIPOPROTEIN ANALYSIS BY DIFFERENTIAL CHARGED-PARTICLE MOBILITY - The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.12-13-2012
20120122242METHOD FOR ASSESSING ARTERIOSCLEROSIS AND DIABETIC NEPHROPATHY - A method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is.05-17-2012
20120122241IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS - A method for identifying or monitoring SLE in an individual is provided. The method includes quantitating complement component C405-17-2012
20120122240BIOASSAYS USING PLASMONIC SCATTERING FROM NOBLE METAL NANOSTRUCTURES - The present invention relates to detecting and/or measuring scattering effects due to the aggregating metallic nanostructures or the interaction of plasmonic emissions from approaching metallic nanoparticles. The scattering effects may be measured at different angles, different wavelengths, changes in absorption and/or changes in polarization relative to changes in the distances between nanoparticles.05-17-2012
20120122238VMP-Like Sequences of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.05-17-2012
20120122237HOMOGENEOUS NONCOMPETITIVE DETECTION OF POST TRANSLATIONAL MODIFICATIONS FOR USE IN HIGH THROUGHPUT ASSAYS - A non-competitive immunoassay method for detection of post-translationally modified (PTM) proteins is disclosed. The method will enable the direct detection of PTM proteins in solution or on solid phase with a single reagent addition step, and with improved selectivity for specific PTM sites on target proteins. The key to the method is the use of a secondary binding molecule that specifically recognizes the immune complex between the primary antibody and the antigen.05-17-2012
20120122236METHOD AND SYSTEM UTILIZING LATERAL FLOW IMMUNOASSAY TEST DEVICE WITH INTEGRATED QUALITY ASSURANCE LABEL - The present invention provides a method and system for performing analyte analysis with improved reliability of test results through use of quality assurance labels for accuracy and robust results.05-17-2012
20120122235Devices and Methods for Detection of Biomolecular Interactions - Devices, systems, and methods are provided for the detection of biomolecular interactions. The interactions between one or more target DNA strands, one or more receptor DNA strands, and one or more probe DNA strands, if necessary, are used to detect the one or more target DNA strands. The one or more target DNA strands or the one or more probe DNA strands may be coupled to a magnetic bead, and the one or more receptor strands may be coupled to the Hall device.05-17-2012
20120122245ALLOYED METAL COLLOID - Provided is a metal colloid having higher visibility and higher sensitivity than a gold colloid and a Au-core Pt-shell composite colloid and suitable as a labeling agent for use in a test such as an immunoassay. An alloyed Au/Pt composite colloid formed by mixing a gold salt and a platinum salt with at least one reducing agent selected from the group consisting of an amino acid and a derivative thereof, an oligopeptide and a derivative thereof, and an amino sugar in the presence of an alkali, thereby reducing the gold salt and platinum salt.05-17-2012
20120122233METHOD FOR RISK STRATIFICATION IN STABLE CORONARY ARTERY DISEASE - An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.05-17-2012
20110111523METHOD FOR ASSESSING OOCYTE MATURATION - The present invention provides methods and kits for assessing the state of oocyte maturation in a female mammal based on the level of PAPP-A found in the female's bodily fluid sample.05-12-2011
20090130775METHOD FOR CLINICAL STAGING OF ULCERATIVE COLITIS OR INTERSTITIAL PNEUMONIA AND REAGENT KIT FOR THE SAME - The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body.05-21-2009
20090130774Elisa assays using prion-specific peptide reagents - Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described for use in detecting PrPsc in biological samples. In particular, ELISA assays are described.05-21-2009
20110183438Method for Sensing a Substance to be Detected in a Sample - A single-electron transistor comprising at least a substrate, a source electrode and a drain electrode formed on top of the substrate opposing to each other, and a channel arranged between the source electrode is disclosed wherein the channel is composed of ultra fine fibers. By having such a constitution, a sensor can have excellent sensitivity.07-28-2011
20110183437METHODS OF IDENTIFYING COMBINATIONS OF ANTIBODIES WITH AN IMPROVED ANTI-TUMOR ACTIVITY AND COMPOSITIONS AND METHODS USING THE ANTIBODIES - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.07-28-2011
20110183436DIAGNOSTIC METHODS FOR CONGESTIVE HEART FAILURE - The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).07-28-2011
20110183435Biodegradable Photoluminescent Polymers - The present invention describes a novel elastomeric biodegradable photoluminescent polymer (BPLP). The BPLPs of the present invention possess great processability and tunable fluorescence emission characteristics and are cell-compatible and biodegradable. The BPLPs of the present invention can serve as both implant materials and bioimaging probes.07-28-2011
20110183434DIAGNOSTIC METHODS AND KITS USING FIBROBLAST GROWTH FACTOR-23 - The present invention describes the ability to identify chronic kidney disease (CKD) mortality risk in asymptomatic patients. For example, a patient having a normal glomerular filtration rate would be considered likely to have an increased mortality risk for chronic kidney disease upon the detection of an FGF-23 amino acid sequence that is above a normal level, but below CKD Stage 1 levels. Consequently, therapeutic strategies may be implements to prevent morbidity and mortality following chronic kidney disease progression. Such therapeutic strategies can involve phosphate reduction strategies (i.e., for example, reduced dietary intake of phosphorus and/or administration of phosphate binding compound). Further, kits are described providing instruction to determine a specific mortality risk based upon measured FGF-23 levels and estimated glomerular filtration rates.07-28-2011
20120164755Selective Ion Binding Nanomaterials - Nanoparticles with a patterned ligand coat can bind ions selectively. The ligand patterning can arise via self-assembly when two chemically dissimilar (e.g., in size and/or hydrophilicity) ligands are used together. One of the ligands can include one or more moieties capable of interacting with an ion, such as ether oxygens, hydroxyl groups, amine nitrogens, or other groups having a lone pair of electrons. Ion binding can be both selective and reversible.06-28-2012
20120164751Rapid Test Apparatus - Provided herein are methods and devices for rapid testing of solid, semi-solid, or liquid specimens, such a stool, blood, urine, saliva, or swab specimens of the cervix, urethra, nostril, throat, and for environmental testing.06-28-2012
20120164754KIT AND METHOD OF DETERMINING NUCLEOTIDE SEQUENCE OF TARGET NUCLEIC ACID - A kit for determining a nucleotide sequence of a target nucleic acid, and a method of determining a nucleotide sequence of a target nucleic acid using the kit are disclosed.06-28-2012
20120164753MONOLITHIC FBAR-CMOS STRUCTURE SUCH AS FOR MASS SENSING - An apparatus comprises a thin-film bulk acoustic resonator such as including an acoustic mirror, a piezoelectric region acoustically coupled to the acoustic mirror, and first and second conductors electrically coupled to the piezoelectric region. In an example, an integrated circuit substrate can include an interface circuit connected to the first and second conductors of the resonator, the integrated circuit substrate configured to mechanically support the resonator. An example can include an array of such resonators co-integrated with the interface circuit and configured to detect a mass change associated with one or more of a specified protein binding, a specified antibody-antigen coupling, a specified hybridization of a DNA oligomer, or an adsorption of specified gas molecules.06-28-2012
20120164752IMMUNOASSAY METHOD AND REAGENT THEREFOR - [Problems] An object of the present invention is to provide a novel method which can expand the measurement range in an immunoassay method.06-28-2012
20120129270VESICULAR SYSTEM AND USES THEREOF - Disclosed is a vesicular system comprising a surface with a vesicle immobilized thereon. The immobilized vesicle has a circumferential membrane of an amphiphilic polymer. The vesicle is coupled to a surface by means of a molecule with a non-polar moiety. The non-polar moiety comprises a main chain of 3 to about 30 carbon atoms and 0 to about 12 heteroatoms selected from Si, O, S, and Se. The molecule with the non-polar moiety is coupled to the surface via a covalent or non-covalent bond. A portion of the non-polar moiety is integrated in the circumferential membrane.05-24-2012
20100210034METHODS OF DETERMINING PATIENT RESPONSE BY MEASUREMENT OF HER-3 - The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.08-19-2010
20100210035HUMAN PROTEINS RESPONSIBLE FOR NEDD8 ACTIVATION AND CONJUGATION - The invention relates to covalent modification of proteins through their conjugation with other proteins. More particularly, the invention relates to the modulation of such conjugation involving the protein NEDD8. The invention provides compositions and methods for detecting and/or modulating the activation and/or conjugation of NEDD8, as well as compositions and methods for discovering molecules which are useful in detecting and/or modulating the activation and/or conjugation of NEDD8. The present invention arises from the purification and characterization of novel NEDD8 activating and conjugating enzymes.08-19-2010
20100210033PORTABLE DEVICE FOR DETECTING FOOD ALLERGENS - The invention relates to a portable device and method for detecting allergenic substances.08-19-2010
20100210036PPAR ACTIVE COMPOUNDS - Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.08-19-2010
20120214256METHOD OF ANALYSIS OF GENETIC MARKERS - A method of analyzing genetic markers includes binding a set of probes to a segment of single stranded nucleic acids. The segment of single stranded nucleic acids includes a repeat region formed of at least two of a repeat unit. The repeat unit can include at least two nucleic acids. The set of probes includes a first probe complementary to the repeat unit. The method can further include directing the segment through a nanopore device and measuring a signal through the nanopore device. The signal can be indicative of the number of repeat units.08-23-2012
20120214257Reagent Kit for Determining an Analyte in a Sample by Agglutination - A reagent kit for determining an analyte in a sample by agglutination includes a first reagent containing a first specific binding substance that is a substance that can specifically bind to the analyte; and a second reagent containing microparticles having a second specific binding substance bound thereto, the second specific binding substance being a monoclonal antibody against the first specific binding substance.08-23-2012
20120214255METHODS AND COMPOSITIONS FOR ASSAYING A SAMPLE FOR AN AGGREGANT - This invention relates to an aggregation sensor useful for the detection and analysis of aggregants in a sample, and methods, articles and compositions relating to such a sensor. The sensor comprises first and second optically active units, where energy may be transferred from an excited state of the first optically active unit to the second optically active unit. The second optically active unit is present in a lesser amount, but its relative concentration is increased upon aggregation, increasing its absorption of energy from the first optically active units. This increase in energy transfer can be detected in variety of formats to produce an aggregation sensing system for various aggregants, including for quantitation. Other variations of the inventions are described further herein.08-23-2012
20120220054DEVICE FOR DETECTION OF TARGET MOLECULES AND USES THEREOF - Devices and methods for the detection of target molecules are disclosed. Devices and methods for detecting food-borne target molecules are also disclosed.08-30-2012
20120220052SURVIVAL PROGNOSTIC ASSAY - Assay kit and Assay for determination of likely survival of a subject Assay kits for determining the total amount of free-light chains (FLC) in a sample are provided. Also provided are a general health screen method comprising detecting an amount of free light chains (FLC) in a sample from a subject, wherein a lower amount of FLC is associated with increased survival and/or better general health of the subject, and a higher level of FLC indicates the possible presence of an undetected medical problem.08-30-2012
20120220050METHOD OF PURIFYING 8-ISOPROSTANE - A method of purifying 8-isoprostane is provided that includes a step of contacting a liquid sample containing 8-isoprostane with an ion exchange support having a quaternary ammonium salt immobilized thereon such that 8-isoprostane in the liquid sample is retained on the ion exchange support and a step of eluting 8-isoprostane from the ion exchange support using a first eluent containing a water-soluble organic solvent and water as main components.08-30-2012
20090246884Reagent for Assaying Antiphospholipid Antibody and Reagent for Assaying Anti-Treponema Pallidum Antibody - It is an object of the present invention to provide a reagent for assaying anti-phospholipid antibodies, which is excellent in long-term storage stability and enables an accurate diagnosis of syphilitic infection, and a reagent for assaying anti-10-01-2009
20120135538AGENT AND METHOD FOR IDENTIFYING LYSINE CROTONYLATION IN PROTEINS - A method and related agent for detecting novel post-translational modification. This novel post-translational modification is in the form of crotonylation of lysine residues in proteins. The method includes the steps of (a) preparing a mixture of polypeptides from a protein sample; (b) separating the polypeptides by molecular weight; (c) contacting the separated polypeptides with a binding affinity reagent which binds specifically to a polypeptide containing a crotonyllysine residue; and (d) detecting presence of a binding complex between the affinity reagent and one or more of the polypeptides. An example of the binding agent is an antibody, which may be prepared from animal serums, or is a monoclonal antibody or single-chain variable fragment.05-31-2012
20120135542METHODS AND MATERIALS FOR DIAGNOSING LIGHT CHAIN AMYLOIDOSIS - This document relates to methods and materials involved in diagnosing light chain amyloidosis. For example, methods and materials for using exosomes to diagnose a mammal (e.g., a human) as having immunoglobulin light chain amyloidosis are provided.05-31-2012
20120135541MULTI-DIRECTIONAL MICROFLUIDIC DEVICES COMPRISING A PAN-CAPTURE BINDING REGION AND METHODS OF USING THE SAME - Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.05-31-2012
20120135540Methods and compositions of nucleic acid ligands for detection of clinical analytes related to human health - Specific DNA sequences for binding various clinically relevant analytes from the human body are described. Each of these sequences or their linear, two- and three-dimensional linked sequences can function in varying assay and sensor formats with varying degrees of success. Linkage of the whole or partial DNA sequences (putative binding sites) can be used to enhance specificity and affinity towards complex targets, thereby improving assay selectivity and sensitivity in many instances. In addition, a FRET-based quantitative method is described for normalizing analyte data by assessing urine creatinine and urea levels. Finally, a method is described for removing creatinine or urea by size-exclusion chromatography prior to a FRET-based aptamer assay to avoid the denaturing effects of these compounds.05-31-2012
20120135539Split DNA Enzyme for Visual Single Nucleotide Polymorphism Typing - A probe that changes solution color in the presence of only one of the two DNA sequences, which differ by a single nucleotide, is reported. The probe consists of two oligodeoxyribonucleotides, which form a hydrogen peroxidase-like DNA enzyme when hybridized to the abutting fragments of the complementary analyte. The active peroxidase catalyses oxidation of colorless substrates to the colored products. The probe allows visual detection of a mutation in Alzheimer's disease-related DNA.05-31-2012
20120220055Method for Detecting Cardiac Ischemia via Changes in B-Natriuretic Peptide Levels - The present invention relates to a method of detecting cardiac ischemia by measuring the levels of BNP or NTproBNP. Increases in BNP or NTproBNP levels in an individual are indicative of cardiac ischemia.08-30-2012
20120220053GRAPHENE-ENCAPSULATED NANOPARTICLE-BASED BIOSENSOR FOR THE SELECTIVE DETECTION OF BIOMARKERS - A field effect transistor (FET) with a source electrode and a drain electrode distanced apart from each other on a semi-conductor substrate, and a gate electrode consisting of a uniform layer of reduced graphene oxide encapsulated semiconductor nanoparticles (rGO-NPs), wherein the gate electrode is disposed between and contacts both the source and drain electrodes. Methods of making and assay methods using the FETs are also disclosed, including methods in which the rGO-NPs are functionalized with binding partners for biomarkers.08-30-2012
20120220048MAGNETIC MARKER PARTICLE AND METHOD FOR PRODUCING THE SAME - There is provided a magnetic marker particle. The magnetic marker particle comprises a magnetic particle and a polymer deposited on the surface of the magnetic particle, wherein the deposited polymer comprises a combination of a carboxyl group and a polyethylene glycol chain or a combination of a carboxyl group and a sulfo group.08-30-2012
20100173425High Capacity Solid Phase - A high capacity solid phase for bioaffinity assays and other solid phase applications prepared by coating a solid support with an analyte-specific biomolecule in the presence of a zwitterionic additive is described. Structures prepared according to the invention provide high capacity solid phases with enhanced binding properties, which are advantageous for any solid phase based assay.07-08-2010
20100173428Protein Phosphorylation By Basophillic Serine/Threonine Kinases - The invention discloses 461 novel phosphorylation sites identified in basophilic Ser/Thr kinase signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.07-08-2010
20100173429METHODS USING NOVEL CHEMILUMINESCENT LABELS - Methods using chemiluminescent label compounds and chemiluminescent labeled conjugates are provided. The compounds comprise an acridan ring bearing an exocyclic ketene dithioacetal group and further contain a labeling substituent which permits attachment to compounds of interest. The novel chemiluminescent compounds and labeled conjugates are convenient to prepare, are highly stable, and generate chemiluminescence rapidly on demand. The compounds and conjugates are useful in assays of an analyte in a sample and in assays employing labeled specific binding pairs.07-08-2010
20100173426BIOMAKER IDENTIFYING THE REACTIVATION OF STAT3 AFTER SRC INHIBITION - A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject.07-08-2010
20100173427LEVETIRACETAM IMMUNOASSAYS - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.07-08-2010
20120252140FLUORESCENT SUBSTANCE-CONTAINING SILICA NANOPARTICLES AND BIOSUBSTANCE LABELING AGENT - Disclosed are fluorescent substance-containing silica nanoparticles containing a fluorescent substance therein featured in that the surface of the silica nanoparticles is coated with a material having a bulk refractive index of from 1.60 to 4.00. The invention can provide fluorescent substance-containing silica nanoparticles excellent in long term storage stability and a biosubstance labeling agent employing the same.10-04-2012
20120077286HIGHLY SENSITIVE IMMUNOASSAY SYSTEMS FOR DETECTING MULTIPLE ALLERGENS - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.03-29-2012
20120077285LAYERING FOR SEPARATING PARTICLES - The present invention relates to a method for purifying biomolecules or for analyzing whether an aqueous phase contains biomolecules by means of magnetic separation. The invention further relates to uses, to devices, and to kits that relate to the method according to the invention.03-29-2012
20120077284Binding Surfaces for Affinity Assays - Non-saturated or non-saturated and orientated binding surfaces for an affinity assay are provided, as are methods and compositions for their preparation. The non-saturated or non-saturated and orientated binding surfaces may further comprise paramagnetic microparticles. The methods include methods for making ligand::support coupler-based complexes by a process optionally employing a low input ratio of ligand to support coupler, by dilution, and by methods employing a dispersion and/or coating step using a block copolymer. Specific examples employing biotin-BSA and biotin-ovalbumin binding surfaces are provided, as well as strepavidin-coated microparticles and microparticles coated with capture moieties such as biotinylated immunoglobulins or fragments thereof. Other examples couple a ligand to the solid surface. Further provided are dispersed microparticles and methods for making them. Use of the methods and compositions in connection with a wide variety of analytes and capture moieties is provided, particularly for use in immunoassays.03-29-2012
20110201128BLOOD MARKERS OF TRANSPLANTED INTESTINE REJECTION - The present invention relates to a method for detecting bowel transplant rejection.08-18-2011
20120220051Immunogenicity Assay - Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.08-30-2012
20100047925SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting multiple targets in a biological sample are provided. The methods includes contacting the sample with a first probe; physically binding the first probe to a first target; observing a first signal from the first probe; applying a chemical agent to modify the first signal; contacting the sample with a second probe; physically binding the second probe to a second target; and observing a second signal from the second probe. The methods disclosed herein also provide for multiple iterations of binding, observing, signal modification for deriving information about multiple targets in a single sample. An associated kit and device are also provided.02-25-2010
20100047924STABLE NANOREPORTERS - The present invention relates to compositions and methods for detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to improved, stable nanoreporter probes that are capable of binding to and identifying target molecules based on the probes' uniquely detectable signal. Methods for identifying target-specific sequences for inclusion in the probes are also provided, as are methods of making and using such probes. Polynucleotide sequences of certain nanoreporter components are also provided. The probes can be used in diagnostic, prognostic, quality control and screening applications.02-25-2010
20100047923TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of 02-25-2010
20080293161Detection of Carbohydrate Biomarkers - The present invention generally relates to detection of carbohydrate biomarkers in nipple aspirate fluid samples. One aspect of the invention is a method for assaying a nipple aspirate fluid for the presence of TF or Tn carbohydrate biomarker. The assay generally employs an immobilized capture agent specific for TF or Tn and can be further coupled to either direct or indirect detection of bound TF or Tn carbohydrate biomarker through the use of a labeled binding agent.11-27-2008
20100273274POLYNUCLEOTIDES ENCODING ACETYLCHOLINE-GATED CHLORIDE CHANNEL SUBUNITS OF CAENORHABDITIS ELEGANS - The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that modulate the acetylcholine-gated chloride channels are provided.10-28-2010
20120178184T CELL PROTEINS AND NUCLEOTIDES ENCODING THE SAME - The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.07-12-2012
20120178183Mass Dots: Nanoparticle Isotope Tags - Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection.07-12-2012
20120178182MICROFLUIDIC DEVICE AND ANALYTE DETECTION METHOD USING THE SAME - Provided are a micro-fluidic device having multiple reaction chambers to simultaneously detect a plurality of different analytes, and an analyte detection method using the same. The micro-fluidic device includes multiple reaction chambers containing a plurality of capture materials to be combined with different analytes, multiple channels connecting the multiple reaction chambers, and valves provided within the multiple channels to control fluid flowing through the channels.07-12-2012
20120178186BINDING ASSAY WITH MULTIPLE MAGNETICALLY LABELLED TRACER BINDING AGENTS - The present invention relates to a cartridge (07-12-2012
20120178185IMMUNODIFFUSION ASSAY FOR INFLUENZA VIRUS - A method for performing an immunodiffusion assay comprising at least the following steps of:07-12-2012
20100009465METHOD FOR THE ANALYSIS OF CIRCULATING ANTIBODIES - There is provided a method for the analysis of circulating antibodies comprising the steps: 01-14-2010
20100009462Timp-2 as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of TIMP-2 in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes.01-14-2010
20100009461Npcil1 (Npc3) And Methods Of Identifying Ligands Thereof - The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.01-14-2010
20120122243MEANS AND METHOD AND MEANS FOR DIAGNOSING PROSTATE CARCINOMAS - The present invention relates to a method, preferably an ex vivo method, for diagnosing prostate carcinomas and/or predisposition thereof comprising determining at least one metabolite in a test sample of a subject suspected to suffer from prostate carcinomas or to have a predisposition therefor and comparing said at least one metabolite to a reference, whereby prostate carcinomas or a predisposition therefor is to be diagnosed. Moreover, the present invention encompasses a collection of metabolites, a data collection comprising characteristic values of metabolites and a storage medium comprising said data collection. Furthermore, the present invention also relates to a system comprising means for comparing characteristic values of metabolites of a sample operatively linked to a data storage medium. Further encompassed by the present invention are diagnostic means comprising at least one metabolite and the use of said at least one metabolite for the manufacture of diagnostic means for or for diagnosing prostate carcinomas. Finally, the present invention pertains to a method for identifying prostate carcinoma-related metabolites.05-17-2012
20120122239HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide or human NT-pro B-type natriuretic peptide fragment in a test sample.05-17-2012
20120225494DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE - The present invention relates to DNA ligands capable of binding to aflatoxin and zearalenone. The invention relates also to methods for determining the presence and concentration of aflatoxin and zearalenone in samples such as agricultural and food products, and to methods for removing or reducing the level of aflatoxin and zearalenone in samples such as agricultural and food products. The invention further relates to methods for identifying DNA ligands capable of binding to aflatoxin and zearalenone. The invention further relates to new DNA sequences.09-06-2012
20100285609SENSOR - This invention relates to a method for detecting an analyte in a sample, comprising the steps of exposing the sample to a transducer which is capable of transducing a change in energy to an electrical signal, the transducer having at least one tethered reagent on or proximal thereto, the at least one tethered reagent having a binding site which is capable of binding the analyte; introducing a labelled reagent into the sample, wherein the labelled reagent contains a binding site for the analyte or the tethered reagent and a label which is capable of absorbing electromagneticradiation generated by a radiation source to generate energy; allowing the labelled reagent to bind to the analyte or tethered reagent in a first period in which the transducer is oriented such that the labelled reagent is caused to settle, at least in part, on the transducer; subsequently, in a second period, causing the labelled reagent to become unsettled; irradiating the sample with electromagnetic radiation during the first and second periods, transducing the energy generated into an electrical signal; detecting the electrical signal. A device for performing the method is also provided.11-11-2010
20100285605Neurofibrillary labels - Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of “blocking ligands” to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.11-11-2010
20090061532FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION WITH NANOPARTICLES FOR IN VITRO AND IN VIVO APPLICATIONS - A combination of nanoparticles is disclosed comprised of amine functionalized polyethylene glycol in which one particle with a fluorescent donor dye having one wavelength excitation maximum and at least one additional particle with a second fluorescent dye having a second, higher wavelength excitation maximum, the particles having the same or different biomolecule targeting moieties bound to their external surfaces.03-05-2009
20100291708METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION - Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β11-18-2010
20100291707Multiplexed Scanometric Assay for Target Molecules - The present invention is directed to compositions and methods of use of a functionalized nanoparticle having a catalytic metal deposit.11-18-2010
20100291705ANTIGEN EXPOSING MICELLE AND UNORDERED AGGREGATE - An antigen exposing micelle or unordered aggregate comprising at least one carrier, at least one epitope and at least one anchoring molecule, wherein said anchoring molecule comprises at least one anchoring part, intended to anchor the antigen exposing micelle to a surface.11-18-2010
20120220049ASSAY METHOD AND DEVICE - The present invention relates to a method and a device for detecting the presence of an analyte. More particularly, the present invention relates to the method and device for detecting the presence of immunoglobulins directed at polymorphic alloantigens such as HLA antigens and/or other products of the major histocompatibility complex (MHC).08-30-2012
20120225492Starch Binding Domain and Use Thereof - The present invention provides a method for identifying starch binding sites of starch binding domain in CBM family. The CBM family is consisting of CBM20, CBM21, CBM25, CBM26, CBM34, and CBM41. The method further comprises predicting starch binding sites of starch binding domain in CBM family using the identified starch binding sites of starch binding domain with same topology.09-06-2012
20120083048METHOD FOR DETECTING LIGAND USING FRET BIOSENSOR - The present application relates to a method for detecting ligand using a biosensor applied the FRET(fluorescence resonance energy transfer) phenomenon. More particularly, the method may be used for simply detecting a ligand in a sample by measuring the FRET of a biosensor under the conditions in which a specific critical temperature is maintained. The method may use a phenomenon in which a ligand-binding protein in a biosensor shows reversible unfolding at a temperature higher than the specific critical temperature and the level of the unfolding changes depending on the concentration of a ligand. The method can be widely applied to a variety of kinds of FRET biosensors using the ligand-binding protein.04-05-2012
20120083047OVULATION PREDICTOR TEST - The present invention is related to a diagnostic test kit for detecting luteinizing hormone (LH) in a biological sample at a concentration relative to a threshold concentration of LH. The device can include a release medium formed of a first material and including a labeled conjugate with a detectable label and a first binding member reactive with a first epitope of LH and a capture medium formed of a second, different material, in fluid communication with the release medium. The capture medium includes a result site having immobilized thereon a capture component capable of directly or indirectly binding LH that is bound to the labeled conjugate. The device is calibrated such that color development at the result site occurs only when the LH concentration of the liquid sample is greater than the threshold concentration.04-05-2012
20120258553ANALYTE MEASUREMENT APPARATUS AND METHOD - An apparatus for measuring a target molecule in a sample is disclosed. The apparatus comprises a moiety comprising a magnetic label (10-11-2012
20120258552HOMOGENEOUS MEASUREMENT METHOD AND MEASURING REAGENT - Provided is a homogenous measurement method using insoluble carrier particles that suppresses the matrix effect originating from the sample and also suppresses differences in measurement accuracy among different models of automated analyzers. Also provided is a measuring reagent for use in an automated analyzer. Inclusion of a silicone-based defoaming agent in the reagent reduces the matrix effect originating from the sample and reduces variability of measurement accuracy among different automated analyzers having differing specifications.10-11-2012
20120258551STABILIZATION OF BIO-SENSORS FOR IN VIVO APPLICATIONS - The present invention relates to the use of preparations for stabilizing isolated proteins. In particular, the use of such a preparation for stabilizing receptors in biochemical sensors is disclosed. The invention in addition relates to biochemical sensors containing such preparations.10-11-2012
20120190129TEST DEVICE, REACTION APPARATUS AND REACTIVE TEST METHOD - A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times.07-26-2012
20120264233METHOD OF ANALYSIS WITH IMPROVED MIXING - The invention is a method for characterizing an interaction in a liquid environment, between at least one species in solution and a target immobilized on a surface of a flow cell. The method comprises the following steps: (a) activating the surface of the flow cell and immobilizing the target thereon; (b) providing, in a flow of liquid, at least one of the species; (c) passing the flow of liquid comprising at least one of the species through the surface of the flow cell which contains the immobilized target; and (d) detecting a result of an interaction between the at least one species and the target using surface plasmon resonance (SPR) technique. The improvement of the method comprises in at least one of steps (a) or (b), inline mixing at least two liquid solutions to generate a mixed solution before it is passed through the surface of the flow cell.10-18-2012
20120264232ANTIGEN DETECTION SYSTEM AND METHODS OF USE - A system and method for testing for the presence of antigens in food stuffs permits a user to test food products for the presence of antigens for a given food allergy that the user may have. The system comprises two main components, a base station and a test well. The user places a sample of food into the test well. A macerator homogenizes the food in the test well. Antibodies to a particular antigen are bound to an antigen detector in the test well. The base station includes a cartridge dock which powers the macerator and the antigen detector. Antigen-antibody binding provides a change detectable by the detector, which signals the base station of the presence of a threshold degree of antigen-antibody binding and alerts the user of the presence of the antigen, such as by a visual or audible indicator.10-18-2012
20120264231ASSAY FOR ORAI CALCIUM CHANNEL REGULATORS - The methods and systems described herein are based, in part, on the discovery that STIM modulates calcium release from store-operated channels through a direct interaction with the ORAI channel. Based on this discovery, methods and systems are described herein for identifying an agent that modulates calcium flux through the ORAI channel and/or regulates intracellular calcium via the ORAI channel. The methods and systems can also be used to detect an interaction between STIM and a functional ORAI channel.10-18-2012
20090017558APOLIPOPROTEIN E STABLE FOLDING INTERMEDIATE AND METHODS OF USE THEREOF - The present invention provides isolated apolipoprotein E (apoE) stable folding intermediates. The invention further provides methods for identifying compounds that alter the structure or level or activity of an apoE stable folding intermediate, as well as methods of inhibiting the formation or activity of stable folding intermediates of apoE. The invention further provides methods for reducing the level and/or activity of an apoE stable folding intermediate, and methods for treating disorders relating to apoE4 in a subject.01-15-2009
20110124126DETECTION OF AN ANALYTE IN AQUEOUS MEDIA - Test kit for the detection of an analyte in an aqueous solution, including chromatographic test strips for a hapten-antihapten complex and first and second standardized vessels for receiving and positioning test strips, which include first and second hapten-coupled receptors against the analyte dried onto the interior wall for the formation of the hapten-antihapten complex, where a portion of the standardized vessels further include a known amount of analyte embedded in a glass-like layer of trehalose, which are dried onto the interior wall of the control vessel so that they dissolve during reaction of the sample with the hapten-coupled receptors. Through this standardization, analytes in unknown samples may be safely detected by immunochromatography within minutes through a hapten-antihapten complex.05-26-2011
20110124125PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to 05-26-2011
20110124124ENHANCED DETECTION SENSITIVITY WITH PIEZOELECTRIC MICROCANTILEVER SENSORS - A method for enhancing the detection sensitivity of a piezoelectric microcantilever sensor. The method may involve providing a piezoelectric microcantilever and inducing a change in the Young's modulus during detection of a species of interest. The change in the Young's modulus may be induced or enhanced by the application of a DC bias electric field to the piezoelectric layer that enhances non-180° polarization domain switching of the piezoelectric layer. The change in the Young's modulus may also result from binding of the species of interest to the piezoelectric microcantilever sensor or a combination of binding and application of a DC bias electric field Significantly enhanced detection sensitivity results from the changed Young's modulus of the piezoelectric layer.05-26-2011
20110124123METHOD FOR EXAMINING WT1-RELATED DISEASE - The invention provides a method for testing a WT1-related disease, such as leukemia, a solid cancer, or an atypia, for diagnosing the disease, evaluating the course of cure and the prognosis of the disease more simply with high reliability, the method comprises measuring the amount of antibody against WT1 in a sample and using the measurement value and the time course of the value as a clinical marker for the testing.05-26-2011
20110124122BIOMARKERS AND ASSAYS FOR MYOCARDIAL INFARCTION - Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included.05-26-2011
20110124121METHODS FOR PREDICTING WEIGHT LOSS SUCCESS - Methods and kits for predicting weight loss success are provided. The methods generally include the steps of selecting a patient or other person undergoing or considering undergoing a weight loss therapy, obtaining a measurement of one or more hormone responses of the person to caloric intake, and subsequently predicting success of a weight loss therapy based on the hormone response.05-26-2011
20110124119Methods For Assessing Modified LDL Immune Complexes in Subjects Having or at Risk of Coronary Artery Disease - The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.05-26-2011
20110124118MICROFLUIDIC STRUCTURE FOR DETECTING BIOMOLECULE AND MICROFLUIDIC DEVICE COMPRISING THE SAME - Disclosed are a micro-fluidic structure for detecting biomolecules and a micro-fluidic device having the same. More particularly, a target material including at least two cis-diols is detected by a first material containing a boronate moiety and a second material containing another boronate moiety while generating electrical signals.05-26-2011
20100240149ELECTRONIC ANALYTE ASSAYING DEVICE - The invention is an electronically processed single-step test device for detecting the presence of a preselected analyte in a fluid. The device includes a hollow rectangular outer casing, disposed within co-joined upper and lower sections of the casing are assay material, an electronic processing system, and a LCD display. The LCD display is observable through a viewing window. The assay material is a sorptive material including a fluid sample application region in the form of a sample wick in fluid communication with a test strip. The test strip includes an analyte capture region adjacent to a light shield. The electronic processing system includes red and green LEDs which are alternately pulsed or energized over predetermined periods of time to determine if fluid test results show a marker or markers in the capture region indicative of the presence of a preselected analyte in the fluid. If so, Yes+ is displayed on the LCD. If not, No− is displayed on the LCD.09-23-2010
20130171739MICROCHIP SOLUTION SENDING SYSTEM - [Technical Problem]07-04-2013
20100022029HOMOCYSTEINE IMMUNOASSAY - In immunoassays such as homocysteine immunoassays, it is known that the measured values can be dispersed due to the influence of inhibiting substances present in a biological sample on the immunoreaction. The present invention provides among other things a method whereby the influence of the immunoreaction inhibiting substances is easily and efficiently suppressed or eliminated, and also provides a kit used for such a method. The influence of the immunoreaction inhibiting substances is suppressed or eliminated when the analyte (e.g., homocysteine) contained in the biological sample is reacted with the antibody in the presence of extrinsic polyanion.01-28-2010
20100330699APPARATUS AND METHOD FOR THE DETECTION OF LIQUIDS OR SUBSTANCES FROM LIQUIDS, AND USE OF SAID APPARATUS - The embodiments relate to an apparatus and a method for detecting liquids or substances from liquids in spatially separate reaction zones. The embodiments further relate to the use of the apparatus in a plug-in module or a chip card which can be used for rapid immunological tests, for example, with the help of a reading device. The liquids or substances from liquids are detected by means of a sensor array which includes at least two sensors and on which at least one diaphragm is arranged. Individual sensors are spatially separated from each other on a plane by means of walls. The diaphragm can be filled with liquid that is to be analyzed. Sealed reaction chambers are created when pressure is applied to the diaphragm. Pores in the diaphragm are completely closed in the zone of the walls while the pores are merely reduced in size and liquid can continue to be exchanged in zones directly above the sensors. No liquid can be exchanged between adjacent reaction chambers as long as the pressure is applied to and compresses the diaphragm. In the sealed reaction chambers, reactions can take place independently of reactions in adjacent reaction chamber. Reaction products or substances in the liquid can be measured with smaller measurement errors in sealed reaction chamber than when the liquid flows across the entire diaphragm.12-30-2010
20120264230 HOME OR POINT-OF-CARE ALLERGY TESTING - An allergy testing method based on a highly sensitive testing of a small blood sample is provided. The method includes collecting a blood sample from a subject, the blood sample being limited to a volume taken from a skin-prick; and, testing serum from the blood sample without dilution for an allergic response of the subject to one or more allergens, the testing having a high detection sensitivity ranging from about 1010-18-2012
20100129931Anti-Methylation-Controlled J Protein Antibodies and Uses Thereof - This application includes, in part, methods of preparing antibodies that specifically bind to tnethylation-controlling J (MCJ) polypeptide. In some aspects, the application also includes, hybridoma cell lines that produce antibodies that specifically MCJ polypeptide; antibodies and antigen-binding fragments thereof produced with the methods of the application,—and methods of using antibodies and antigen-binding fragments that specifically bind MCJ polypeptide for diagnosis and treatment of cancer.05-27-2010
20120322165HIGHLY SENSITIVE IMMUNOCHROMATOGRAPHY METHOD AND IMMUNOCHROMATOGRAPHY KIT - The present invention is to provide an immunochromatography method which is capable of performing a detection with high-sensitivity or reduced false-positives by suppressing the occurrence of false-positive when a signal is amplified. An immunochromatography method includes in a state of forming a complex from a test substance and a labeling substance containing a metal modified with a first binding substance for the test substance, developing the complex on an insoluble carrier in presence of a protease hydrolyzate of protein; capturing the test substance and the labeling substance in a detection site on the insoluble carrier containing a substance which has a binding property to a second binding substance for the test substance or the first binding substance for the test substance; and detecting the test substance by amplifying the labeling substance captured.12-20-2012
20110039354Method of Characterizing and Quantifying Calcifying Nanoparticles - A method of characterizing calcifying nanoparticles (CNPs) can include creating a test sample comprising CNPs isolated from a biological source, a buffer solution, a plurality of calibration beads, and a fluorescent marker specifically linked to the CNPs; evaluating the test sample using a flow cytometer; and analyzing results from the flow cytometer to determine a characterizing feature of the calcifying nanoparticles. The characterizing feature of the calcifying nanoparticles can be the number of CNPs, concentration of CNPs, size of CNPs, level of CNP aggregation, size and light dispersion characteristics of CNPs, fluorescence intensity of the CNPs when labeled with a specific antibody, or a combinations thereof The method can also include evaluating an isotype control comprising CNPs isolated from the biological source, the buffer solution, a plurality of calibration beads, and a fluorescent marker that is not linked to the CNPs.02-17-2011
20110039353METHOD FOR DIRECT DETECTION OF ISCHEMIA-MODIFIED ALBUMIN USING A PARTNER FOR BINDING TO AN ALDEHYDE DERIVATIVE RESULTING FROM THE PEROXIDATION OF LIPIDS IN BOUND FORM - The present invention relates to the use of at least one partner for binding to an aldehyde derivative resulting from the peroxidation of lipids in protein-bound form, for instance to 4-hydroxy-2-nonenal, to 4-hydroxy-2-hexenal or to malondialdehyde, for the detection of ischemia-modified albumin (IMA) in a biological sample.02-17-2011
20110039352METHODS TO MEASURE DISSOCIATION RATES FOR LIGANDS THAT FORM REVERSIBLE COVALENT BONDS - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.02-17-2011
20120322164NANOWIRE ARRAY STRUCTURES FOR SENSING, SOLAR CELL AND OTHER APPLICATIONS - Nanowire array structures based on periodic or aperiodic nanowires are provided in various configurations for sensing and interacting with light and substances to provide various functions such as sensors for detecting DNAs and others and solar cells for converting light into electricity.12-20-2012
20120322166FLUORESCENCE DETECTING APPARATUS, SAMPLE CELL FOR DETECTING FLUORESCENCE, AND FLUORESCENCE DETECTING METHOD - Excitation light from a light source is caused to enter a finely apertured thin metal film, having fine apertures with diameters less than or equal to the wavelength of the excitation light, formed on a surface of a substrate different from a light incident surface thereof, through the substrate, to cause near field light to be generated at the fine apertures. Fluorescent labels included in a sample liquid supplied to contact the thin metal film are caused to emit light by the near field light and by surface plasmon which are induced in the finely apertured thin metal film by the near field light. Fluorescence emitted by the fluorescent labels is detected with a detector. Fluorescent particles having a plurality of fluorescent pigments enveloped in a transmitting material that transmits both the excitation light and the fluorescence are employed as the fluorescent labels.12-20-2012
20100203650BIOMOLECULE BINDING LIGANDS - The invention provides biomolecule binding ligands, collections of biomolecule binding ligands, and their use in the purification of biological mixtures and in the identification of ligands having an affinity for a substance. The ligand is a compound of formula (III) or a compound of formula (IV): wherein for compounds of formula (I) one of R08-12-2010
20120270337METHOD FOR MAKING AND USING A DIAGNOSTIC ELEMENT - The invention relates to a method for making a diagnostic element. The method comprises providing a shaped channel comprising at least one holding port and an inlet passage and outlet passage on either side of the holding port; flowing in a diagnostic gel into the inlet passage of the shaped channel; and encapsulating the diagnostic gel in the at least one holding port to form a diagnostic element. The invention also provides a method for using a diagnostic element, wherein the method comprises flowing sample through the diagnostic gel to provide an analyte diagnostic gel; analyzing the analyte diagnostic gel.10-25-2012
20110217791METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.09-08-2011
20110212542LABELS FOR ELECTRONIC DETECTION OF INDIVIDUAL MOLECULES AND METHODS FOR THEIR DETECTION - The invention provides labels for electronic detection of individual molecules. The labels are comprised of elements with different electrical properties that affect the electric current flowing through a nanoelectrode. The labels are of polymeric or filamentous structure where the elements are arranged linearly along their length. The arrangement of the elements is predetermined and combinatorial, so that a high diversity of labels can be generated in a manner that resembles barcoding on a nanoscale level. Methods for the synthesis of said barcode labels and for the binding of the barcode labels to individual molecules, their movement past a nanoelectrode, and their detection are also provided.09-01-2011
20110212541COMPOSITIONS AND METHODS TO PROTECT CELLS BY BLOCKING ENTRY OF PATHOGEN PROTEINS - Pathogenic effector proteins include one or more virulence motifs of amino acid consensus sequence BXZ, where B=RK or H; X=any amino acid or is absent; Z=L, M, I, W, Y or F) which bind to target polar lipids on a host (plant or animal) cell as a prerequisite for translocation of the pathogenic effector proteins into the cell. Translocation is prevented by binding blocking compounds to one or more motifs of the effector protein or to the lipid ligands of the host cell. The blocking compounds include synthetic or naturally occurring polypeptides which bind the polar lipids or the motifs, various polar lipids, the hydrophilic head-groups of polar lipids, etc. Suitable blocking compounds can be identified by assays demonstrating binding to the motifs or to the target polar lipids.09-01-2011
20100248392Method of Immunoassaying Specimen Using Aggregation Reaction of Microparticles and Assay Kit - A method of assaying a sample with the use of the aggregation reaction of immunological microparticles and an assay kit. The assay is conducted by using microparticles wherein the same or an analog of the analyte and a substance that specifically binds to a substance that can specifically bind to the analyte are both bound to an insoluble carrier. Thus, it becomes possible to conveniently carry out the assay even in the case where the analyte has only a small number of specific binding sites, without especially adding a competitive substance carrying hapten bonded thereto to the reaction system so as to induce simultaneous competition of the target substance and the competitive substance.09-30-2010
20110236996METHOD FOR MEASURING CYSTATIN C IN HUMAN BODY FLUID - There is provided a particle-enhanced immunoassay method for cystatin C in a human body fluid, which has higher specificity and is easily automatable at low cost as compared with conventional assay methods that use large amounts of polyclonal antibodies having low specificity or monoclonal antibodies having high specificity but having poor agglutinability.09-29-2011
20110236995METHOD FOR DETERMINING PROSTATE CANCER - The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)), and benign prostatic hyperplasia is determined in the case of 30% or less.09-29-2011
20110236993PANCREATIC CANCER MARKERS - The present invention relates to pancreatic cancer markers. In particular, the present invention provides methods and compositions for the identification of protein glycosylation patterns associated with pancreatic cancer.09-29-2011
20110236992METHOD OF DETECTING A SPECIFIC NUCLEOPHILE AND SURFACE ACOUSTIC WAVE SENSOR FOR DETECTING THE SPECIFIC NUCLEOPHILE - Provided herein is a method of detecting the presence of a specific nucleophile, which uses a material Y degraded by nucleophilic substitution of reacting with a specific nucleophile X, and a material Z selectively binding to a material Y′ produced by the degradation. According to the method, the nucleophile X can be easily analyzed according to the bonding between the materials Y′ and Z.09-29-2011
20100022026METHODS, KITS, REAGENTS AND DEVICES FOR DETECTING MESOTHELIN AND/OR MEGAKARYOCYTE POTENTIATING FACTOR IN PERITONEAL FLUIDS - Certain embodiments disclosed herein are directed to methods and kits for detecting and quantifying in patient peritoneal fluid, such as spent peritoneal dialysis buffer, peptides having amino acid sequences related to megakaryocyte potentiating factor. The methods and kits can be used to monitor the biological status of the mesothelial lining of the peritoneal cavity in a patient, to predict development of a pathology of the mesothelium in an otherwise asymptomatic patient, and/or to assess the risk and suitability of a therapeutic method. In particular, the method can be used to assess negative effects of peritoneal dialysis on the biological integrity of the peritoneum, and thus to determine the time point when peritoneal dialysis treatment should be discontinued in favor of hemodialysis in a patient with kidney dysfunction, in order to avoid the development of peritoneal hypertrophy and other progressive mesothelial disorders such as encapsulating peritoneal sclerosis.01-28-2010
20100233824MICROFLUIDIC METHODS AND SYSTEMS FOR USE IN DETECTING ANALYTES - A microfluidic reactor arrangement (09-16-2010
20110263043Scanning Analyzer for Single Molecule Detection and Methods of Use - The invention encompasses analyzers and analyzer systems that include a single molecule analyzer, methods of using the analyzer and analyzer systems to analyze samples, either for single molecules or for molecular complexes. The single molecule uses electromagnetic radiation that is translated through the sample to detect the presence or absence of a single molecule. The single molecule analyzer provided herein is useful for diagnostics because the analyzer detects single molecules with zero carryover between samples.10-27-2011
20120088312VINCRISTINE IMMUNOASSAY - Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids.04-12-2012
20120088311Immuno-Detection of a Cancerous State in a Subject - The present invention is based on the finding that antibodies raised against a fragment of PAR1-released peptide may be used to detect in a bodily fluid sample from a subject a marker associated with cancer state, if said subject has cancer. Thus, the present invention provides the methods and packages for conducting one or more of the following: determining a cancerous state in a subject, the method comprises determining binding of an antibody raised against a protease-activated receptor 1 (PAR1) released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, wherein binding of said antibody to said marker being indicative of a cancerous state; determining severity of a cancerous state in a subject comprising determining level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, and comparing the level of binding with the level of prior determined standards that correlate level of antibody binding to PAR1 released peptide with severity of cancerous state; and determining the effectiveness of a therapeutic treatment of a subject with an anti-cancer agent to the subject comprising determining the level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject in two or more successive time points, one or more time points are during the therapeutic treatment, wherein a difference in the level being indicative of effectiveness of therapeutic treatment.04-12-2012
20100216254DRUG MONITORING ASSAY - A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.08-26-2010
20120329173METHOD AND FOR THE DETECTION OF BIOLOGICAL MOLECULES USING A TWO PARTICLE COMPLEX - Methods, compositions and kits for detecting analytes of interest in a sample using electrogenerated chemiluminescence are provided. Compositions comprising at least one solid support that entraps or contains an electrogenerated chemiluminescent moiety also provided.12-27-2012
20120329176INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.12-27-2012
20120329175Detection of Degradation Products of Feline NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices.12-27-2012
20120329172ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES - The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.12-27-2012
20120329174LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.12-27-2012
20120100638Method and Test Strip for Detection of Residues - A method, test strip and method of manufacturing a test strip useful for detecting one or more analytes, such as an antibiotic, in a test sample such as a milk sample. The test strip and method include a labeled specific binder and test capture agent for the specific binder that increases test sensitivity to the analyte for which the specific binder has affinity while decreasing test sensitivity to an analyte for which a multianalyte binder has affinity.04-26-2012
20120100637GENETIC MARKERS OF SCHIZOPHRENIA ENDOPHENOTYPES - This document provides methods and materials related to genetic markers of schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD), (collectively referred to herein as “schizophrenia spectrum disorders” or SSDs). For example, methods for using such genetic markers to identify an SSD (e.g., SZ) endophenotype are provided.04-26-2012
20120100636APPARATUS AND METHOD FOR MEASURING BINDING KINETICS WITH A RESONATING SENSOR - A subject material in a fluid sample is detected using a resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material. Prior to exposing the resonating sensor to the fluid sample, operation of the resonating sensor is initiated, producing a sensor output signal representing a resonance characteristic of the resonating sensor. Optionally, a reference resonator that lacks binding sites for the analyte is used to produce a reference output signal. Introduction of a fluid sample to the resonating sensor is automatically detected based on a characteristic change in the sensor output signal or a reference output signal. In response to the detecting of the introduction of the fluid sample, automated measurement of the binding kinetics are measured.04-26-2012
20120100635RISK ASSESSMENT FOR ANTIBOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN - The present invention relates to a diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic.04-26-2012
20120100634ASSAY SYSTEM FOR DETERMINING BINDING OF HYDROPHOBIC DRUGS - The invention comprises a method for the determination of the binding coefficient of a hydrophobic chemical compound comprising: g. Providing an assay plate with a plurality of rows and columns of test vessels; h. Providing the majority of the test vessels in said assay plate with a polymer, wherein in each row the amount of polymer coating per test vessel is increased; i. Filling each test vessel with a solution of binding partner to which the binding coefficient should be assayed, wherein in each column the amount of binding partner is increased; j. Adding the hydrophobic compound and incubate the plate; k. Determining the concentration of said compound in said polymer or in the solution; l. Calculating the protein binding coefficient of the compound.04-26-2012
20120100633CLICK CHEMISTRY ON HETEROGENEOUS CATALYSTS - The present invention relates to new methods and reagents for coupling molecules by a Click reaction using a heterogeneous catalyst system. Further, the present invention refers to novel devices for carrying out Click reactions04-26-2012
20120100632MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF - The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.04-26-2012
20120100631BIOSENSOR DEVICE FOR SENSING AMPHIPATHIC ANALYTES - The current invention relates to sensing elements and devices comprising at least one amphipathic lipid-binding protein or fatty acid binding protein, wherein the binding proteins are associated with a luminescent reporter group. The binding proteins and luminescent reporter groups are encapsulated within a hydrogel matrix that comprises at least one co-monomer, wherein the co-monomer is present at a concentration that decreases or inhibits micelle formation of the amphipathic lipid. Binding of the amphipathic lipid or fatty acid to the appropriate binding protein can produce at least one detectable change in the property of the luminescent reporter group.04-26-2012
20120288960METHOD FOR MEASURING CONCENTRATION OF ANTIGEN CONTAINED IN TEST SOLUTION - A biogenic substance concentration measuring apparatus includes an optical measuring apparatus for measuring optical properties of a first substrate and a second substrate by using a cell for biogenic substance concentration measurement that includes: the first substrate on which a plurality of first metallic nanorods, each of which is modified with a substance that bonds specifically to a test substance, are immobilized such that the long axes thereof are aligned in the same direction; and the second substrate on which a plurality of second metallic nanorods, each of which is modified with a blocking substance, are immobilized such that the long axes thereof are aligned perpendicularly to the long axes of the first metallic nanorods on the first substrate, and calculates a biogenic substance concentration with high accuracy from the optical properties.11-15-2012
20120288961CAPILLARITY-BASED DEVICES FOR PERFORMING CHEMICAL PROCESSES AND ASSOCIATED SYSTEMS AND METHODS - The present technology is directed to capillarity-based devices for performing chemical processes and associated system and methods. In one embodiment, for example, a device can include a base configured to receive one or more fluids, a porous wick carried by the base portion, and a flow-metering element along the porous wick to modify a rate or volume of fluid flow along the porous wick. The porous wick can comprise a first pathway, a second pathway, and an intersection at which the first pathway and the second pathway converge. Input ends of the first and second pathways can be wettably distinct. Upon wetting of the input ends, fluid is configured to travel by capillary action along each pathway. The device may also include volume-metering features configured to automatically and independently control or modify a volume of fluid flow along one or more pathways of the porous wick.11-15-2012
20100167420Micro Mechanical Methods and Systems for Performing Assays - The present invention provides a micro mechanical system for performing assays for determining the presence of one or more selected analytes in a sample. The device comprises of a base and a disposable strip with at least one reaction well and at least one moveable member capable of moving fluids and parts through the fluids in a defined reaction well. Reagents in the reaction chambers and or the moveable members, react with the sample to yield a physically detectable change. The moveable parts are capable of executing motions that either mix, move reaction components, exchange or systematically deliver reagents to targets in the cartridge. Sensors in the base are configured to detect and or quantify the presence of a sample in the reaction well and of analytes in the sample. The signal is converted to an output on a visual display window on the external part of the base.07-01-2010
20100167418STABILIZED LOW AFFINITY CONFORMATION OF INTEGRINS FOR DRUG DISCOVERY - The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.07-01-2010
20130011933METHOD OF DIAGNOSING BLADDER CANCER - Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.01-10-2013
20130011934BIOPOLYMER SEQUENCING BY HYBRIDIZATION OF PROBES TO FORM TERNARY COMPLEXES AND VARIABLE RANGE ALIGNMENT - Methods for sequencing a biopolymer by forming local ternary complexes along the length of the double-stranded biopolymer target molecule using one or more probes and obtaining information about the location of the probe(s) using a detector. These methods offer particular advantage when implemented with nanopore (including micropore) detection systems.01-10-2013
20130011935METHOD OF MEASURING CHARACTERISTICS OF SPECIMEN AND SENSING DEVICE FOR USE WITH THE SAME - A method of measuring characteristics of a specimen, the measuring method including the steps of bonding the specimen to a host molecule on a sensing device, emitting an electromagnetic wave of a particular frequency to the sensing device to which the specimen is bonded, measuring a frequency characteristic of the transmitted or reflected light, and measuring the characteristics of the specimen based on a change of the frequency characteristic, wherein an absorbance of the host molecule per unit quantity at the particular frequency is smaller than that of the specimen.01-10-2013
20130011932REAGENT COMPOSITION FOR IMMUNOCHROMATOGRAPHY - [Object] To provide a reagent composition, or a sample thinner, for immunochromatography which are more effective in suppressing nonspecific reactions than the conventional counterparts, which use an immunochromatography device to detect a target substance; also to provide a high performance and highly sensitive immunochromatography device and a detective kit capable of prompt and simple detection work.01-10-2013
20100129934Glycated Insulin as a Biomarker for Diagnosis and Monitoring of Diabetes - One of the major pathophysiological consequences of long term elevation of plasma glucose in diabetes is an increase in the non-enzymatic glycation of proteins. Contrary to expectations the present inventors have determined that individuals with well controlled short duration diabetes have particularly high concentrations of glycated insulin which decrease with increased disease severity and duration of diabetes. Further, a small proportion of apparently normal healthy individuals exhibit high glycated insulin levels in line with expected incidence of diabetes in the population. Methods of predicting the onset of diabetes and for monitoring the progression of diabetes by measuring the concentration of Glycated Insulin and the progression of diabetes are disclosed.05-27-2010
20100129933METHOD FOR DETECTING THE BINDING BETWEEN MDM2 AND THE PROTEASOME - This invention provides both nucleic acid and amino acid sequences encoding for isolated protein-HDM2 binding sites as well as for isolated protein-proteasome binding sites (the ED(X)Y sequences). In a further aspect this invention also provides related nucleic acids, amino acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with the binding between HDM2 and the proteasome, as well as pharmaceutical compositions comprising said test compound, in particular as anti-cancer agent, even more particular for treating cell proliferative disorders in a subject.05-27-2010
20100129932Determination of Isoerythropoietins - A method for the determination of the occurrence of an analyte subpopulation of isoEPOs in a biological fluid comprising the steps of: i) providing a liquid sample deriving from the biological fluid and containing isoEPOs that are characteristic (=analyte isoEPOs) for said analyte subpopulation together with isoEPOs of other subpopulations, ii) separating the isoEPOs of said liquid sample into two or more fractions so that at least one of these fractions contains analyte isoEPOs which are enriched relative to other isoEPOs, by A) contacting the liquid sample with an isoEPO reactant under conditions allowing affinity complex formation between isoEPOs of the liquid sample and the affinity reactant, and B) fractionating and collecting the isoEPOs of the liquid sample into said two or more fractions, relating the occurrence of analyte isoEPOs in said at least one fraction to the occurrence of said analyte subpopulation in the biological fluid. A flow matrix containing an application zone and downstream thereof a separation zone in which there is an immobilized isoEPO reactant.05-27-2010
20120149131PROCALCITONIN FOR THE PROGNOSIS OF ADVERSE EVENTS - The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event.06-14-2012
20120149130POLYPEPTIDES FOR THE IN VITRO ASSESSMENT OF THE SENSITISING POTENTIAL OF A TEST COMPOUND - The invention relates to novel polypeptides and to the use thereof for the in vitro assessment of the sensitising potential of a test compound, to a method for the in vitro assessment of the sensitising potential of a test compound, to an in vitro method for selecting a compound suitable for reducing the sensitisation, as well as to kits for implementing such methods.06-14-2012
20120149128ASSAYS AND ASSAY DEVICES - Methods and apparatus for conducting analyte assays, including multiplexed assays are described. Such methods include assays adapted for low volume assay devices in which assays can be performed using undiluted biological liquid samples by exchanging binding medium with detection medium, using layered labels, and/or using droplet based mixing in an assay device.06-14-2012
20130017623Fluid sample collecting and analyzing apparatus and method - A spongy swab (01-17-2013
20130017622METHOD AND SYSTEM FOR ANALYTE MONITORING USING SURFACE PLASMONS WITH A REFRESHABLE SURFACEAANM Rahn; John RichardAACI SammamishAAST WAAACO USAAGP Rahn; John Richard Sammamish WA US - The present technology provides an illustrative method for analyte monitoring using surface plasmons with a refreshable surface. The method includes placing a solution to be monitored in contact with a working surface of a surface plasmon resonance (SPR) generation system. The working surface includes a metal surface disposed on a glass surface, and the metal surface includes a first binding substance that provides binding sites for an analyte. The method further includes applying light to the metal surface at a plurality of angles over a period of time, measuring a reflectance of the light at each of the plurality of angles to determine an SPR angle, and monitoring changes to the SPR angle over the period of time. The working surface of the SPR generation system is refreshed by depositing a new layer of the first binding substance on the working surface of the SPR generation system.01-17-2013
20130017624METHOD FOR DETERMINATION OF BINDING STOICHIOMETRYAANM Karlsson; RobertAACI UppsalaAACO SEAAGP Karlsson; Robert Uppsala SE - A method is provided for determining binding stoichiometry for the interaction between a first molecule and a second molecule forming a complex between them. Either (i) a solution having a fixed initial active concentration of the first molecule is titrated with solutions of varying active concentrations of the second molecule, and the free active concentrations of the second molecule are measured; or (ii) a solution with fixed initial concentrations of the first molecule and the second molecule is incubated, and the free active concentrations of both molecules are measured. In the first case, the binding stoichiometry can be determined from the initial concentration values of both molecules and the free concentration value(s) of the second molecule at saturation; and in the second case from the initial concentration values of both molecules and the free concentration values of both molecules. Active concentration measurements are typically performed by an interaction analysis sensor, using a calibration-free analytical format at least for the determination of active initial concentrations.01-17-2013
20110159608GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION - The application relates to methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.06-30-2011
20110159607BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF - The invention relates to the identification of a biomarker whose abundance in biological samples is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.06-30-2011
20130023061METHOD FOR STABILIZING GLYCEROPHOSPHOLIPIDS AND REAGENTS USING SAME - Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system.01-24-2013
20130023060MICROFLUIDIC ELEMENT WITH MULTI-FUNCTIONAL MEASURING CHAMBER FOR THE ANALYSIS OF A FLUID SAMPLE - A test element, analytical system and method for optical analysis of fluid samples is provided. The test element has a substrate and a microfluidic channel structure, which is enclosed by the substrate and a cover layer. The channel structure has a measuring chamber with an inlet opening. The test element has a first level, which faces the cover layer, and a second level, which interconnects with the first level such that the first level is positioned between the cover layer and the second level. A part of the measuring chamber extending through the first level forms a measuring zone connecting with a part of the measuring chamber that extends partially into the second level, forming a mixing zone. Optical analysis of fluid samples is carried out by light guided through the first level parallel to the cover layer, such that the light traverses the measuring zone along an optical axis.01-24-2013
20130023059METHOD FOR IMMOBILIZING STREPTAVIDIN ON A SELF-ASSEMBLED MONOLAYER - Provided are a method for increasing an amount of streptavidin to be immobilized on the self-assembled monolayer and a sensor which comprises streptavidin immobilized with the method. The method of the current technology is characterized by that one molecule of an amino acid is interposed between the self-assembled monolayer and the molecule of streptavidin.01-24-2013
20130023058METHOD AND APPARATUS FOR SELECTING A PRODUCT - A method of selecting a product suited to an individual. The method includes: identifying a product category from a predefined set of product categories, each product category being associated with a set of products; on the basis of said selected product category, selecting a genetic testing cartridge type from a set of available cartridge types, each cartridge type being configured to perform a genotype profiling test on a polynucleotide sample; collecting a polynucleotide sample from the individual; performing a genotype profiling test on said polynucleotide sample using a genetic testing cartridge of the selected genetic testing cartridge type; and using the result of said test to select a product from within the identified product category.01-24-2013
20130171740REAGENT COMPOSITION FOR NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY, METHOD FOR MEASUREMENT BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY, AND KIT FOR MEASUREMENT BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY - A reagent composition for nucleic acid chromatography or immunochromatography which includes a water-soluble polymer having a weight average molecular weight of 8,000 or more, a salt of a divalent or trivalent metal, a nonionic surfactant, and an aprotic water-soluble organic compound. The reagent composition is capable of determining an analyte accurately and rapidly even when it has a low concentration in a measurement by nucleic acid chromatography or immunochromatography, by reducing the binding of components other than the analyte through a non-specific reaction and enhancing the dispersion capability of the analyte to improve the developability on a chromatography carrier and to promote a specific reaction.07-04-2013
20080241959Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification - The present invention relates to new macrolide compounds represented by the general structure I,10-02-2008
20100087010METHOD FOR MEASURING IMMUNOCHROMATO TEST PIECE - After dropping a sample onto an immunochromatographic test strip 04-08-2010
20080227218TARGET SUBSTANCE DETECTION METHOD AND TARGET SUBSTANCE DETECTION KIT - A target substance detection method for detecting a target substance in a specimen, comprises the steps of contacting with a specimen a target substance detecting element comprised of a base, a metal structure and a first capturing body for capturing a target substance; contacting with the target substance detecting element a labeling material comprised of a labeling substance and a second capturing body for capturing a target substance; and acquiring an absorption spectrum (A) of the target substance detecting element contacted with the specimen and the labeling material, wherein the employed labeling substance is a substance that a slope of a tangent of an absorption spectrum (C) of the labeling substance at a peak wavelength (λ09-18-2008
20110263042ASSAY METHOD FOR ANTIBODIES AGAINST CYCLIC CITRULLINATED PEPTIDE - The present invention relates to method for assaying anti-cyclic citrullinated peptide antibodies in a clinical sample, said method comprising contacting said sample with at least one homogeneous reagent comprising at least one specific binder for anti-CCP antibodies, whereby to form a solution or suspension of an anti-CCP-binding partner complex in a homogeneous sample mixture and detecting the presence or level of said anti-CCP-binding partner complex in a homogeneous liquid-phase. The invention also relates to a method for the assessment of the existence of; risk of; potential for; or propensity to RA in a subject.10-27-2011
20080220536Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates - The present invention relates to the use of “tethering” to identify compounds that modulate enzymatic activity.09-11-2008
20130143332SPFS SENSOR EQUIPPED WITH MECHANISM PURIFYING NON-SPECIFICALLY ADSORPTIVE CONTAMINANTS - [Object] It is an object of the invention to provide a sensor area which can suppress a decrease in assay signal and an increase in assay blank in an SPFS measurement.06-06-2013
20120252139Novel Process - A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to: 10-04-2012
20120252136MARKER SOLUTION TO BE APPLIED BY MEANS OF AN INKJET PRINTER - The invention relates to a marker solution which is to be applied by means of an inkjet printer and contains (i) at least one organic solvent that has a greater steam pressure than water at 20° C. and a water content of less than 50 percent (v/v), (ii) predefined first synthetically produced nucleic acids, and (iii) a nucleic acid-complexing, organic auxiliary agent as components.10-04-2012
20130137187SYNTHETIC ACTIVE PEPTIDE FRAGMENTS - The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of 05-30-2013
20110269247MEASUREMENT KIT AND AN IMMUNOCHROMATOGRAPHY METHOD - It is an object of the present invention to provide a measurement kit for developing a first developing solution and a second developing solution from different directions to suppress background noise, and an immunochromatography kit. The present invention provides a measurement kit, which comprises a first developing member for supplying a first developing solution and a second developing member for supplying a second developing solution, wherein the developing direction of the first developing solution is allowed to intersect with the developing direction of the second developing solution, so that development is carried out by developing the first and second developing solutions in different developing directions, and a water absorbent portion is established on the downstream of each of the developing directions.11-03-2011
20110269244LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN - The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.11-03-2011
20130177996Device and Method for Testing Biological Samples - Devices and methods for testing a biological sample for an analyte of interest are provided that make use of a reaction chamber for receiving a reaction mixture, a housing positioned below the reaction chamber for receiving a test cassette, and a door that is positioned in the top portion of the housing. The door includes a ramp that extends downwardly into the housing such that biasing the ramp upwards opens the door into the cavity of the reaction chamber and places the reaction chamber in fluid communication with the insertion area to thereby allow the reaction mixture to flow onto a test cassette and allow for the determination of an amount of an analyte of interest.07-11-2013
20130095574METHOD FOR PRODUCING MICROPARTICLES - Silicon microcarriers suitable for fluorescent assays as a well as a method of producing such microcarriers are provided. The method includes the steps of providing a SOI wafer having a bottom layer of monocristalline silicone, an insulator layer and a bottom layer of monocristalline silicon, delineating microparticles, etching away the insulator layer and then depositing an oxide layer on the wafer still holding the microparticles before finally lifting-off the microparticles.04-18-2013
20130095575Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples - A methods are provided for the flow cytometry profiling of microvesicles, including exosomes.04-18-2013
20130115714WESTERN BLOT ANALYTICAL TECHNIQUE - In accordance with an embodiment of the present invention, there is provided a method of performing the western blot analytical technique, wherein the method comprises carrying out the following steps in the following order: a), pre-staining the proteins within a sample; b). separating the proteins using gel electrophoresis; c). analysing the separated proteins to determine the total protein load and/or at least one housekeeping protein load; d). transferring the proteins onto at least one membrane; e). probing the separated proteins to detect a target protein; and f). analysing the probed proteins to determine the target protein's molecular weight and/or load.05-09-2013
20130115713QUANTUM DOT-BASED OPTICAL SENSORS FOR RAPID DETECTION AND QUANTITATIVE ANALYSIS OF BIOMOLECULES AND BIOLOGICAL MATERIALS - The invention generally relates to detection and analysis of biological materials. In particular; the invention relates to quantum dot-based optical, sensors and methods for rapid detection and quantitative analysis of various biomolecules and biological materials, such as nucleic acids, proteins, cells, etc.05-09-2013
20130115717ANALYZING CHEMICAL AND BIOLOGICAL SUBSTANCES USING NANO-STRUCTURE BASED SPECTRAL SENSING - An integrated chromatography-immunoassay system for integrated chromatography-immunoassay system includes a chromatographic unit that receives labeled nano-structured probes comprising nano particles and antibodies attached to the nano particles, and a test membrane comprising coating antigens. The chromatographic unit allows the labeled nano-structured probes to diffuse there through and into the test membrane, wherein the antibodies on the nano particles are bound to the coating antigens. A laser device emits a laser light to illuminate the labeled nano-structured probes having the antibodies bound to the coating antigens on the test membrane. A spectral analyzer obtains a Raman spectrum from light scattered from the labeled nano-structured probes having the antibodies bound to the coating antigens on the test membrane, and to identify a spectral signature in the Raman spectrum associated with the antibody-antigen pair, which enables detection and identification of the antibody.05-09-2013
20130115716METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD - A method for determining A.beta. turnover in blood includes the use of a labeled amino acid to assess the turnover rate.05-09-2013
20130115715METHOD OF SENSOR MEASUREMENT - The present invention provides a method of determining the amount of an optical probe species binding to or releasing from an optical sensor surface characterized in that the determination comprises the steps of determining at least one physical measurand (x05-09-2013
20130102090OPTICAL ANALYTE SENSOR - A waveguide sensor capable of direct, real-time detection and monitoring of analytes in the vicinity of the waveguide surface without requiring the tagging or labeling of the analyte, is described. Analytic and numerical calculations have predicted that by locally detecting either changes in the evanescent field or changes in the light coupled out of the waveguide as a result of the presence of the analyte, high detection sensitivity will be able to be achieved.04-25-2013
20130115718Carrier Carrying Identifying Information for Identifying an Identification Subject and Use Thereof - Disclosed are a carrier that carries identifying information having favorable identification performance and a use thereof. The carrier carries identifying information for identifying an identification subject, and comprises one or more pieces of DNA having a thymine-rich base sequence and having, as the identifying information, an identifying base sequence pre-associated with the identification subject.05-09-2013
20130130403Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.05-23-2013
20130130404SIGNAL AMPLIFICATION IN LATERAL FLOW AND RELATED IMMUNOASSAYS - The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.05-23-2013
20130130402FLUORESCENT COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING THE COMPOUNDS AND COMPOSITIONS - Low pKa fluorescent compounds, compositions that include the compounds, bioconjugates made from the compounds, and methods for making and using the compounds and bioconjugates.05-23-2013
20130203181DETERMINATION OF INTERACTIONS BETWEEN A SUBSTANCE OR A SUBSTANCE MIXTURE AND A TARGET - A method includes incubating at least a first and a second sample of the substance or of the substance mixture with the target immobilized on a solid carrier. Incubation is in each case effected in a sample container. The first and the second sample are incubated with different amounts of the target, whereas all sample containers include the same amount of buffer solution during incubation. After incubation, the solid carrier is separated from the buffer solutions together with the target immobilized thereon as well as, if applicable, substance bound thereon. The concentration of the substance or of the substance mixture is then measured in the respective supernatant.08-08-2013
20130203182METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS - A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting a plurality of allergens to be tested for in the sample, c) determining for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed.08-08-2013
20130203183ASSAY DEVICE - An assay device for performing an assay on a liquid sample using a detection conjugate capable of binding to an antigen and containing a label. The device includes a substrate surface having a sample addition zone, a reaction zone and an absorbing zone, the zones being connected by at least one fluid passage, wherein the device has a first functionality verifying feature located between the sample addition zone and the reaction zone, and a second functionality verifying feature located within the absorbing zone. Both functionality verifying features are capable of undergoing a detectable change when contacted by the sample, in which the assay device further includes at least one alignment verification zone. There is further provided a kit of parts and a method of conducting an assay.08-08-2013
20130203184METHOD FOR DETECTION OF CLEAVAGE PRODUCT OF SOLUBLE AMYLOID-B PRECURSOR PROTEIN 770B FOR DIAGNOSIS OF DISEASES ASSOCIATED WITH ACCUMULATION OF AMYLOID-B PEPTIDE - The present invention provides a method of detecting soluble amyloid β precursor protein 770β derived from vascular endothelial cell, comprising the following steps: 08-08-2013
20130203185METHOD FOR IMMOBILIZING A PROTEIN ON SELF-ASSEMBLED MONOLAYER - One molecule of the amino acid selected from the five kinds of amino acids consisting of cysteine, lysine, histidine, phenylalanine, and glycine is interposed between a self-assembled monolayer and a molecule of a protein. A method for immobilizing an protein on a self-assembled monolayer includes the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the protein to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecular of the amino acid and the amino group of the protein.08-08-2013
20110212544Method and Reagent Kit for Immunological Measurement - A method for measuring an analyte in a sample, includes the steps of (a) mixing a sample containing the analyte, a complex comprising a plurality of molecules of a substance that specifically binds to the analyte, and microparticles each having the analyte or an analog of the analyte bound to an insoluble support; and (b) measuring an agglutination reaction of the microparticles in a mixture obtained in the step (a). In the method, for example, an antibody is used in the form of a complex of a plurality of molecules of the antibody, rather than in the form of a single molecule of the antibody. Therefore, the sensitivity to the measurement is increased, and the measurement in a lower concentration range becomes possible. A reagent kit for measuring is also disclosed.09-01-2011
20080199972Spectroscopic Method For the Detection of Analytes - The present invention relates to methods for the detection of one or more analytes, in particular pathogens, viruses, prions, bacteria, parasites, pharmaceuticals, antibiotics, cytostatics, psychoactive substances, narcotics, analgesics, cardiac drugs, metabolites, coagulation inhibitors, hormones, interleukins and cytokines, performance-enhancing drugs, drugs, toxins, noxious substances, pesticides, insecticides, wood preservatives, herbicides, fungicides, explosives, vitamins and flavors by providing a conjugate of the analyte and an europium cryptate fluorophore or respectively a terbium cryptate fluorophore together with an antibody which is specific for the analyte and an antibody which is specific for the europium cryptate fluorophore or respectively the terbium cryptate fluorophore and by spectroscopically determining the fluorescence quenching which occurs when the analyte is added. Furthermore the present invention relates to conjugates of the analyte and the europium cryptate fluorophore or respectively terbium cryptate fluorophore as well as to a kit for the detection of analytes.08-21-2008
20110223686PROTEIN PRODUCTION METHOD, FUSION PROTEIN, AND ANTISERUM - Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by 09-15-2011
20110223683AFFINITY SELECTOR BASED RECOGNITION AND QUANTIFICATION SYSTEM AND METHOD FOR MULTIPLE ANALYTES IN A SINGLE ANALYSIS - A multi-dimensional method for simultaneously analyzing multiple analytes within a sample solution, comprising adding affinity selectors to a sample solution containing analytes to be measured, the affinity selectors having an affinity for one or more of the analytes within the sample solution; allowing immune complexes to form between the affinity selectors and the analytes; partially or totally resolving the formed immune complexes from non-analyte substances within the sample solution; dissociating the resolved immune complexes; separating the analytes and the affinity selectors of the dissociated immune complexes from one another by capturing the analytes through a surface adsorption process; transferring the captured analytes to a detection means; and resolving the analytes with the detection means in accordance with their mass-to-charge ratios.09-15-2011
20110229982METHOD FOR BINDING A PROTEIN CONSISTING OF PROTEIN A OR CONSISTING OF AT LEAST ONE DOMAIN OF THE A TO E DOMAINS OF THE PROTEIN A TO THE SUBSTRATE - The object of the present invention is to provide a method for immobilizing the SpA protein on the surface of a substrate with high density without causing dimerization.09-22-2011
20110236994MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.09-29-2011
20130149792CANCER PROGNOSIS ASSAY - The invention provides a method of prognosis of a subject with a cancer, identifying a subject having a greater risk of having an undiagnosed cancer and/or identifying a subject at greater risk of developing a cancer the method comprising detecting an amount of free light chains (FLC) in a sample from a subject, wherein a higher amount of FLC is associated with decreased survival due to a cancer and/or increased risk of the subject having an undiagnosed cancer and/or having an increased risk of developing a cancer.06-13-2013
20130149793ANTI-FDP MONOCLONAL ANTIBODY, FDP MEASUREMENT REAGENT AND REAGENT KIT USING SAME, AND FDP MEASUREMENT METHOD - The present invention relates to an anti-FDP monoclonal antibody selected from the first, second and third monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent and reagent kit for the measurement of FDP and a method for measurement of FDP using the anti-FDP monoclonal antibodies.06-13-2013
20100285610Lateral Flow Test Kit and Method for Detecting an Analyte - A method and device for detecting analytes in a test sample. Embodiments include methods for quantitatively detecting analytes within a range of concentrations. In an embodiment the method includes a lateral flow test strip with multiple test areas for capturing a labeled receptor to provide a detectable signal.11-11-2010
20100285608CONFORMATIONAL ENTROPY IN MOLECULAR RECOGNITION - The present invention provides methods for the determination of the degree of molecular recognition of a protein with a ligand, including a first protein with a second protein. The methods may comprise determining the squared generalized order parameter (hereinafter, O) for at least one intramolecular bond of the first protein. The protein is then formed into a complex with a ligand. The value or values of O2 for the said at least one bond of the protein is then determined while the protein and the ligand are in the complex. The O value or values determined for the protein while the protein and the ligand are in a complex are compared or related to the O value or values determined for the uncomplexed protein.11-11-2010
20100285606DENSITY-BASED METHODS FOR SEPARATION OF MATERIALS, MONITORING OF SOLID SUPPORTED REACTIONS AND MEASURING DENSITIES OF SMALL LIQUID VOLUMES AND SOLIDS - The ability to levitate, to separate, and to detect changes in density using diamagnetic particles suspended in solutions containing paramagnetic cations using an inhomogeneous magnetic field is described. The major advantages of this separation device are that: i) it is a simple apparatus that does not require electric power (a set of permanent magnets and gravity are sufficient for the diamagnetic separation and collection system to work); ii) it is compatible with simple optical detection (provided that transparent materials are used to fabricate the containers/channels where separation occurs; iii) it is simple to collect the separated particles for further processing; iv) it does not require magnetic labeling of the particles/materials; and v) it is small, portable. The method and kits provided provide for separation and collection of materials of different densities, diagnostics for detection of analytes of interest, monitoring of solid-supported chemical reactions and determination of densities of solid and liquid mixtures.11-11-2010
20120258550REGULATION OF AUTOPHAGY PATHWAY PHOSPHORYLATION AND USES THEREOF - The invention relates to polypeptides and proteins known to function in the autophagy pathway that have novel phosphorylation sites. The invention also relates to antibodies specific to these polypeptides and proteins that are phosphorylated or not phosphorylated at novel phosphorylated sites. The invention also relates to methods of producing these antibodies and use of these antibodies in the treatment of diseases related to autophagocytosis.10-11-2012
20120258549External cavity laser biosensor arrangements - A label-free biosensor detection arrangement incorporating an external cavity laser (ECL) includes a tunable lasing element (e.g. an antireflection coated laser diode or semiconductor optical amplifier) and a narrow bandwidth resonant reflectance filter as the wavelength-selective element for the tunable lasing element. A sample is deposited on the surface of the resonant reflectance filter containing a biological material. The wavelength emitted by the external cavity laser is continuously tunable by binding interactions between the biological material and the resonant reflectance filter or adsorption of the biological material present in the sample on resonant reflectance filter. The narrow bandwidth resonance reflectance filter can take the form of photonic crystal (PC), a Bragg stack, or a Brag fiber reflection filter.10-11-2012
20130137192IMMUNOCHROMATOGRAPHY REAGENT COMPOSITION, AND MEASUREMENT METHOD USING SAME - When an immunochromatography reagent composition containing a nonionic surfactant, an N,N-bis(2-hydroxyethyl)glycine buffer, and casein is used as a specimen treatment solution or developing solution in detecting a detection object in a specimen according to an immunochromatographic method, an immunochromatography reagent composition which suppresses a non-specific reaction; does not cause aggregation of antibody-immobilized colloidal gold; and has a high developing rate, in comparison with conventional technology which detects a detection object by using an immunochromatographic device; and a high-performance and highly-sensitivity immunochromatographic method and a detection kit capable of rapid, simple and easy virus detection, which use the immunochromatography reagent composition are provided.05-30-2013
20100035364Diagnostic Test for Renal Injury - A method is provided of diagnosing and monitoring acute renal injury leading to acute renal failure in a human or mammalian subject by determining the ratio of the concentration of neutrophil gelatinase-associated lipocalin (NGAL) in urine to that in plasma or serum.02-11-2010
20100317128METHOD FOR DETERMINATION OF TARGET SUBSTANCE - A method for highly sensitive determination of a target substance by means of an aptamer includes: causing an aptamer capable of specific binding with a target substance to bind competitively with said target substance and a nucleic acid strand having a base sequence complementary to at least a portion of said target substance, detecting at least either of the physical change and the chemical change that results from said aptamer binding with said nucleic acid strand, and determining said target substance based on the result of detection.12-16-2010
20100317127DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.12-16-2010
20100317126AGGLUTINATION ASSAY METHOD IN POROUS MEDIUM LAYER - An agglutination assay method for quantitatively determination of an analyte in an aqueous liquid sample using particles bearing an anti-analyte. The agglutination is conducted in the porous medium layer of the analysis element. A speedy quantitative analysis of the analyte can be conveniently attained with high sensitivity. When the particle-labeled anti-analyte is contained in the porous medium layer, the anti-analyte can be stored with higher stability in the dry state. A dry analysis element for enabling such analysis method is also provided.12-16-2010
20130157380MULTIASSAY IMMUNOCHROMATOGRAPHIC CHIP - A multiassay immunochromatographic chip comprises: a viscous bottom lining (06-20-2013
20130157381SAMPLE TESTING APPARATUS AND METHOD - Apparatus for performing an assay to detect the presence of an analyte in a test sample. A housing defines a slot for receiving a sample collector, and a capsule contains a buffer liquid, the capsule being sealed by an openable lid, and being connected to the housing such that insertion of a sample collector into the slot causes the lid to open releasing the buffer liquid into the slot. The housing further defines an incubation chamber containing or configured to receive a reagent, and an aperture permitting liquid communication between said slot and the incubation chamber. The apparatus comprises one or more test elements, a substantially liquid tight sealing member separating the incubation chamber and the test element(s), and an activation mechanism operable to open said liquid tight sealing member thereby bringing at least a portion of the or each test element into liquid communication with said incubation chamber.06-20-2013
20120282710LIGAND BINDING DOMAINS OF NUCLEAR RECEPTORS IN CONTROLLABLE FORM AND METHODS INVOLVING THE SAME - The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.11-08-2012
20120282709METHOD AND DEVICE FOR DNA SEQUENCE ANALYSIS USING MULTIPLE PNA - Provided are a DNA sequence analysis method of high precision providing improved optical limits by detecting wavelengths of lights emitted from labels in the state where a DNA is electrically tethered and completely stretch, and a nanodevice chip for automating the method. Also provided are a DNA sequence analysis method capable of removing binding errors through complementarily binding between a plurality of peptide nucleic acids (PNAs) labeled with labels emitting lights of different wavelengths and a target DNA to be sequenced, and resolving the limit in optical spatial resolution.11-08-2012
20120282708Method and Apparatus for Conducting an Assay - The present invention relates to methods and apparatus for conducting an assay. In particular, the present invention relates to a rotatable platform which can be used for conducting an assay, in particular multi-step assays. The present invention provides a rotatable platform adapted to immobilise a first binding partner in one or more discrete areas on a surface of said platform, or to selectively immobilise a second binding partner in one or more discrete areas on a surface of said platform. The invention also relates to methods, apparatus, a kit and the use of the rotatable platform for conducting an assay. In particular, the invention has been developed primarily for use in sequencing nucleic acid by pyrosequencing, however the invention is not limited to this field.11-08-2012
20130157378ATTENUATING DYE FOR INTERROGATING MULTIPLE SURFACES, AND METHOD THEREOF - A device including a shallow chamber for analyzing a plurality of target analytes in a body fluid using the signal generated by fluorescent detector molecules each specific for a target analyte, an attenuating dye for attenuating the signal emitted by fluorescent detector molecules specifically bound to the surfaces of the chamber other than an optically clear surface, and method for determining the signal generated by each of the plurality of analytes.06-20-2013
20130157379DIAGNOSTIC DETECTION DEVICES AND METHODS - Described herein are methods and devices for detecting the presence of an analyte in a liquid sample. In some embodiments, methods and devices for the detection of an antigen in a body fluid using a plurality of species-specific antibodies are provided. A sandwich complex may be formed using primary antibodies derived from two different species.06-20-2013
20130183772APPARATUS, METHOD AND ARTICLE TO PERFORM ASSAYS USING ASSAY STRIPS - An assay system includes an optical imager to acquire high resolution images of assay strips (e.g., lateral flow immunochromatographic test strips) and performs image processing to identify individual assay strips and determine results for each assay strip, by quantifies the presence or absence of test signal line(s) and control signal line(s). Assay strips may be in a holder or carrier contained in a specimen container also holding a specimen. The assay system automatically logs all results and data to a database that stores a high resolution image of the original immunochromatographic assay, the values of test line(s) and control line(s), and the test result. A user interface directs an end user through operation.07-18-2013
20130183770METHODS FOR ANALYSIS OF FREE AND AUTOANTIBODY-BOUND BIOMARKERS AND ASSOCIATED COMPOSITIONS, DEVICES, AND SYSTEMS - The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample.07-18-2013
20130183771NOVEL LUMINESCENT LANTHANIDE CHELATES WITH ENHANCED EXCITATION PROPERTIES - The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III)07-18-2013
20130122606METHOD AND DEVICE FOR CHEMICAL AND/OR BIOLOGICAL ANALYSIS - A method of chemical and/or biological analysis including: providing a container delimited by a wall including an inner surface on which there is deposited an active component intended to make possible a chemical and/or biological reaction with a solution disposed in the container; filling the container with a liquid solution containing an analyte which is to be detected; and in applying to the liquid a succession of movements of aspirating/discharging a volume in the container at a suitable frequency to bring about resonance of the liquid so as to deform the free surface thereof and to result in a preferential distribution of the fluid along the inner surface of the wall of the container.05-16-2013
20130122605Methods for Ionophorically Screening Pore Forming Bacterial Protein Toxins and Receptors - A method for determining the amount of live pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample. A kit for determining the amount of live pore forming bacterial toxin protein present in the sample is also provided.05-16-2013
20110294228DETECTION DEVICES AND METHODS - The present invention relates to devices and methods for rapid and easy to use quantitative detection of one or more analytes in, for example, food, food ingredients, drinking water or pharmaceuticals. Analytes that can be detected by the devices and methods herein include, for example, adulterants, toxins, allergens, pathogens, pesticides, pharmaceuticals, pharmaceutical intermediates, biopolymers and biotechnology products.12-01-2011
20110312105DETECTION SYSTEM AND METHOD FOR HIGH SENSITIVITY FLUORESCENT ASSAYS - This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (≦5 mm) and a high molecular weight polymer (≧1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked Ficoll molecule having a plurality of binding molecules and a plurality of fluorescent labels.12-22-2011
20110312104IMMUNOASSAY METHOD - Provided is an immunoassay method that can reduce the effort of establishing an immunoassay system due to not needing two or more antibodies, and that is applicable to not only high molecular weight antigens but also to low molecular weight antigens such as hapten. The method is for releasing, from a surface of a base plate, immunoglobulin G antibody bound to the surface via protein A. The method includes the following steps (A) and (B): (A) a step of preparing the base plate having the surface to which immunoglobulin G antibody produced by a producer cell line of deposit No. FERM BP-10459 is bound via protein A; and (B) a step of providing a solution (from pH 6 to pH 8.9; preferably, from pH 7.4 to pH 8.9) containing human serum albumin onto the surface so as to release the immunoglobulin G antibody from the protein A.12-22-2011
20110312103SAMPLE DETECTION SENSOR AND SAMPLE DETECTION METHOD - The present invention uses a detecting plate having a transparent substrate on which a single-crystal Si thin film layer, a transparent thin film layer, and a sample capturing layer for capturing a sample are provided. The present invention comprises a light directing mechanism for directing light through said transparent substrate of the detecting plate, and a light detection mechanism for detecting reflected light of the incident light from the detecting plate. The present invention is configured so that a change in absorbance occurs at the sample capturing layer or in the vicinity thereof, when said sample is captured on said sample capturing layer. The wavelengths of said incident light are determined in a range of wavelengths within which said change in absorbance occurs. In this way, the sample is detected by means of measuring a significant change in intensity of the reflected light which is generated when the sample is captured on the sample capturing layer.12-22-2011
20130189797OPTICAL BIOSENSOR REFERENCING METHOD - A referencing method for an optical biosensor system using a single sensing region is provided. The method involves limiting the ligand immobilized in a single sensing region to only a portion thereof. In one embodiment, this is accomplished by selectively deactivating a portion of the sensing surface to prevent immobilization of ligand to that portion. As a result, a reference response can be recorded in the same sensing region as a molecular interaction response. Thus, the bulk refractive index can be accurately accounted for in measuring the kinetics of a molecular interaction.07-25-2013
20130189794Optical Assay Device with Pneumatic Sample Actuation - This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to test devices, e.g., cartridges, methods and systems, wherein the test devices have an entry port configured to receive a test sample into a holding chamber; a first conduit having at least one lateral flow test strip; and a displacement device, such as a pneumatic pump, configured to move a portion of said test sample from said holding chamber into said first conduit. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care.07-25-2013
20130189796Assay Device Having Uniform Flow Around Corners - An assay device includes: a liquid sample zone; a reagent zone downstream and in fluid communication with the sample zone containing a reagent material; a detection zone in fluid communication with the reagent zone having capture elements bound thereto; and a wicking zone in fluid communication with the capture zone having a capacity to receive liquid sample flowing from the detection zone. The sample receiving zone, the reagent zone, the detection zone and the wicking zone define a fluid flow path and at least a part of the fluid flow path has a substrate and projections which extend substantially vertically from the substrate, wherein the projections have a height, cross-section and a distance between one another that defines a space between the projections capable of generating capillary flow parallel to the substrate surface. In addition, the fluid flow path having projections includes a corner section which changes the direction of the flow path. The projections in or around the corner section are modified to maintain the configuration of the flow front of the sample flowing through the flow path after the corner is substantially the same configuration as before the corner.07-25-2013
20130189798LUMINESCENCE METHOD OF DETECTING AN ANALYTE IN A LIQUID SAMPLE AND ANALYSIS SYSTEM - The present disclosure relates to a luminescence method of detecting an analyte in a liquid sample comprising marking the analyte with a marker capable of effecting luminescence upon application of excitation energy, wherein reference data descriptive of the luminescence decay is stored in an electronic memory; applying the excitation energy for causing the luminescence; time-resolved measuring of the luminescence over a period of time for acquisition of a measurement signal; reading the reference data from the electronic memory; comparing the measurement signal with the luminescence decay described by the reference data; generating an output signal indicative of the presence of the analyte in the liquid sample using the measurement signal; in case of a mismatch of the measurement signal and the luminescence decay described by the reference data, generating an error signal.07-25-2013
20090275145METAL-ENHANCED FLUORESCENCE FOR POLARIZATION-BASED AFFINITY ASSAYS - A method and kit for determining the quantity of an analyte include providing a functionalized substrate and a reagent. The functionalized substrate includes metallic nanoparticles and a plurality of substantively identical bioactive target molecules affixed to a substrate. The bioactive target molecule binds to a particular analyte. The reagent includes identical detection molecules. Each detection molecule includes a fluorophore, and binds to a particular analyte or competes with a particular analyte for binding to the target molecule. The functionalized substrate is contacted to a test sample and the reagent. The functionalized substrate and a covering solution are exposed to polarized electromagnetic waves that excite the fluorophore. A quantity of the particular analyte in the test sample is determined based on measuring polarization anisotropy of fluorescent emissions from the substrate and the covering solution.11-05-2009
20120015450Method for Detecting Prozone Phenomenon, Analysis Method, Device for Detecting Prozone Phenomenon, and Analysis Device - Provided is a prozone phenomenon detecting method, by which generation of a prozone phenomenon can be detected even when a conventional specimen analysis tool is used, and examinations using an immunochromatography method and the like can be performed efficiently. In the method, a specimen analysis tool containing substances that specifically bind to a target component contained in a sample is used. The specimen analysis tool is obtained by arranging a sample supplying portion, a reagent portion, and a detection portion on the porous base material from upstream to downstream in a sample moving direction in this order. The reagent portion contains a labeled substance that specifically binds to the target component. The detection portion contains an immobilized substance that specifically binds to the target component. The target component is detected by detecting a complex of the target component, the labeled substance, and the immobilized substance through detection of a label of the labeled substance in the detection portion. The method includes at least one of the following processes A and B: the process A: a process in which detection results obtained in the detection portion are plotted along the sample moving direction, and generation of a prozone phenomenon is detected on the basis of a position of a peak in plots thus obtained; and the process B: a process in which the label is detected at two or more different time points in the detection portion, and generation of a prozone phenomenon is detected on the basis of a magnitude relationship between two or more detection results thus obtained.01-19-2012
20120015449METHOD AND DEVICE FOR DETERMINING A FOREIGN SUBSTANCE CONTENT IN A MATRIX - A method and a device are provided for determining a content of at least one foreign substance in a matrix of a solid or liquid food. At least one reagent area for providing at least one reagent has a receptacle for a replaceable reagent container for replaceably connecting a sample container including at least the matrix; a transfer line is provided between the reagent area and the reaction area, by which the at least one reagent can be fed to the reaction area; a sensor area is provided for demonstrating the foreign substance released from the matrix; a carrier gas line is provided between the reaction area and the sensor area, by which the released foreign substance can be fed to the sensor area; and an output line is provided through which the dissolved foreign substance can be fed outward from the sensor area.01-19-2012
20120015448ASSAY DEVICE WITH SHARED ZONES - Disclosed is an assay device for determining the presence and/or extent of one or more analytes in liquid sample containing a) first and second assays each comprising a flow-path having a detection zone for immobilising a labelled binding reagent, wherein detection of a labelled binding reagent at one or both detection zones is indicative of the presence and/or extent of one or more analytes; b) a shared reference zone; c) one or more light sources to illuminate the detection zones and the reference zone; d) one or more photodetectors to detect light from the detection zones and the reference zone, which photodetector/s generate a signal, the magnitude of which signal is related to the amount of light detected; and e) signal processing means for processing signals from the photodetector/s.01-19-2012
20120021534MARKERS FOR BRAIN DAMAGE - Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.01-26-2012
20120021533SENSITIVE METHOD TO ANALYSE FREE PEG-MALEIMIDE - The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal.01-26-2012
20120021531Assay Reader, Device and Method of Measuring HCG - Disclosed is a method for determining a quantitative estimate of the length of time since conception in a female mammalian subject, the method comprising: a)providing a liquid sample suspected of containing hCG; b)measuring, by means of an assay or assay device, an analyte measurement signal, whose value is dependent upon the level of hCG; c)comparing the measured signal value to an analyte threshold, wherein said analyte threshold corresponds to a time since conception; d)providing an quantitative estimate of the length of time since conception based upon the comparison in step (c).01-26-2012
20120021530HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS - Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.01-26-2012
20120028371METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.02-02-2012
20120028370REAGENT FOR ASSAYING D-DIMER AND KIT OF REAGENT FOR ASSAYING D-DIMER - The present invention provides a reagent for assaying D-dimer which includes carriers sensitized to first and second monoclonal antibodies which react with D-dimer, but have different reactivity to D-dimer in which the first monoclonal antibody reacts with high- and low-molecular fractions of D-dimer, the second monoclonal antibody reacts with the high-molecular fraction, but reactivity of the second monoclonal antibody with the low-molecular fraction is different from that of the first monoclonal antibody and a kit of reagent for assaying D-dimer.02-02-2012
20120028369QUANTIFYING LOCAL INFLAMMATORY ACTIVITY AND ITS USE TO PREDICT DISEASE PROGRESSION AND TAILOR TREATMENTS - This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid.02-02-2012
20130196450METHOD FOR COATING NANOPARTICLES - The invention relates to methods for coating nanoparticles with a limited amount of a binding partner and nanoparticles obtainable by the methods disclosed. In particular, the invention is of interest, when coating with only a limited amount of protein is desirable.08-01-2013
20130196448SURFACE PLASMON RESONANCE SENSOR - An SPR sensor comprising a thin conducting layer comprising at least one conductive element formed on a surface of a transparent substrate, a light source that illuminates an interface between the conducting layer and the substrate, a photosensitive surface that generates signals from light reflected from the interface, a flow cell formed with at least one flow channel having a lumen defined by a wall formed from an elastic material and from a region of the conducting layer, and at least one hollow fluid-providing flow control apparatus having a lumen and an orifice communicating with its lumen. Fluid flow is enabled between the flow channel and the lumen of the flow control apparatus by forcing an end of the flow control apparatus through the elastic material so that the orifice communicates with the flow channel lumen.08-01-2013
20130196449ELECTRICALLY DRIVEN DEVICES FOR SURFACE ENHANCED RAMAN SPECTROSCOPY - An electrically driven device for surface enhanced Raman spectroscopy includes a substrate, a Raman signal-amplifying structure positioned on the substrate, and an analyte receptor attached to a structure chosen from i) the Raman signal-amplifying structure, or ii) the substrate near the Raman signal-amplifying structure, or iii) combinations of i and ii. The analyte receptor has a selective binding affinity for an analyte. Conductive elements are positioned relative to one another and to the analyte receptor such that the conductive elements together produce an electric field in the vicinity of the analyte receptor when a voltage bias is applied between the conductive elements.08-01-2013
20120295366DIAGNOSTIC SYSTEM - The invention relates to a device for contactless control of magnetic beads on a microfluidic card by means of external magnetic fields, without having to use complicated mechanics or hydraulics. Based on a modulation of the gradient of a magnetic field, magnetic beads are lifted in a first step in a contactless way out of different reaction chambers of the microfluidic card. By means of a translation movement or a variation or modulation of the gradient of a magnetic field, horizontal transport of the magnetic beads over a mechanical barrier of the microfluidic card is facilitated in a second step. It is possible in a third step to use a further modulation of the gradient of the magnetic field to lower the magnetic beads into a desired further fluid zone.11-22-2012
20120295369METHOD FOR DETERMINATION OF AGGREGATES - A method of determining aggregates of a macromolecule monomer in a fluid containing the macromolecule, comprises the steps of: 11-22-2012
20120045850SILICA NANOPARTICLE EMBEDDING QUANTUM DOTS, PREPARATION METHOD THEREOF AND BIOSUBSTANCE LABELING AGENT BY USE THEREOF - Disclosed is a quantum dot-embedded silica nanoparticle having plural quantum dots embedded within the silica nanoparticle, wherein the number of quantum dots existing in a concentric area within 10% of a radius from a center of the silica nanoparticle accounts for 10 to 70% of the number of total quantum dots embedded in the silica nanoparticle.02-23-2012
20120088315DEVICE HAVING SELF-ASSEMBLED-MONOLAYER - A device for bio-sensing applications is disclosed, comprising a substrate such as a semiconductor chip having Cu electrodes thereon, and a self assembled monolayer bonded to at least one of the Cu electrodes, wherein molecules of the self-assembled monolayer comprise a head group which bonds to Cu, a carbon-comprising chain comprising a chain of at least 12 C atoms, and a terminal group which is hydrophilic and for binding a bio-receptor. The terminal group is hydrophilic to allow binding to the bio-receptor, and inclusion of the carbon-comprising chain, limits or avoids corrosion of the copper. Also disclosed is a method of providing such a device, activating the terminal group and coupling a bio-receptor to the activated terminal group. Disclosure further extends to use of such a device for bio-sensing applications.04-12-2012
20120088314ASSAY FOR MONITORING ACTIVITY OF FRIZZLED RECEPTORS - The present invention relates to cell free assays for measuring receptor activity, especially for measuring a constitutive or a non-constitutive activity of frizzled receptors and uses thereof. The present invention further concerns a method for measuring a constitutive or non-constitutive activity of a frizzled receptor and a method for obtaining an active frizzled receptor ligand.04-12-2012
20120094396METHODS AND COMPOSITION FOR MEASURING THE AMOUNT OF VITAMIN D DERIVATIVES - Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.04-19-2012
20120094395Methods for identifying a subject who has developed an anti-antibody response - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.04-19-2012
20130210165Luminescent Lanthanide Chelates Having Three Chromophores and Their Use - The present application discloses a luminescent lanthanide chelate of formula (I)08-15-2013
20130210166Low-Cost Electrode Chip Variants and Methods for Multi Analyte Analysis and Referencing Based on Cathodic Electroluminescence - The invention relates to electrode chip (EChip) cartridge devices which are used in hot electron -induced electro-chemiluminescence (HECL) and electroluminescence (EL) methods and instrumentation based on the electrical excitation of label molecules with subsequent measurement of the luminescence in order to quantitate analyte concentrations in bioaffinity assays, especially outside of central laboratories, but also in rapid screening tests.08-15-2013
20130210168ASSAY FOR DETECTING FREE LIGHT CHAINS BY CAPILLARY ZONE ELECTROPHORESIS - The invention provides a method detecting free light chains (FLCs) comprising: (i)providing a sample from a subject; (ii)mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii)passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv)detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.08-15-2013
20130210167IMMUNOASSAY FOR PYRROLIDINOPHENONES - The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones.08-15-2013